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ABSTRACT

"TUMOR-TARGETING APTAMERS FOR THE TREATMENT
OF PROSTATE CANCER"

Enid W. Choi, B.S.
December 2011

Prostate cancer is the most common type diagnosed among men in the United States.
Random oligodeoxynucleotide (ODN) libraries are used to generate DNA aptamers by
systematic evolution of ligands by exponential enrichment (SELEX). We explored the
utility of guanine-rich libraries, and found that some had cancer-selective antiproliferative
activity that generally correlated with G-quadruplex formation, nuclease resistance, and
enhanced cellular uptake. We identified several proteins by mass spectrometry that bind
to GC and cytosine ODNs. We compared the GT library with the classic random library
for SELEX of whole prostate cancer cells and identified a new aptamer from the GT
library with enhanced nuclease resistance and antiproliferative activity. We present
evidence that ASI411, a known G-rich anticancer aptamer, inhibits prostate tumor
initiating cells. This body of work supports the hypothesis that G-rich ODNs are well
suited to the development of new aptamers in the treatment of cancer.
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CHAPTERl

INTRODUCTION TO NOVEL CONCEPTS IN ONCOLOGY RESEARCH:
APTAMERS AND TUMOR INITIATING CELLS

BACKGROUND

Prostate cancer and the need for new therapies
Cancer is responsible for one out of every four deaths and ranks as the second
leading cause of death in the United States (1). More than 11 million people were
estimated to be living with a history of cancer as of 2005 (the most recent statistic) (6.,J.).
In 2008, The National Institute of Health estimated the cost of cancer to the nation at over
$228 billion for the year (6.,1). Although the five year survival rate for cancers of all types
has improved from 50% (1975-1977) to 66% (1996-2004), the persistently high impact of
cancer on the American population, including patients, their families, and the economy,
make further endeavors in cancer prevention, detection, and treatment a necessity in this
country. In addition, according to the World Health Organization, cancer rates in the
world are on the rise. Reasons underlying this statistic include a longer-lived - and thus
increasingly aged - population and changes in lifestyle, such as Westernization of the diet
and increased rates of smoking, in areas with previously low cancer incidence. It is clear
that cancer is a serious problem that affects a large portion of the world's population and
will continue to do so for years to come.

Prostate cancer is the most common non-cutaneous cancer type diagnosed among
men in the Western world. After lung cancer, it is the second leading cause of male
cancer-related death in the United States (J). In 2010, approximately 217 thousand men
were diagnosed with prostate cancer and 32 thousand died from this cancer (the
approximate capacity of 68 jumbo jets). African American men are particularly
vulnerable to prostate cancer with a death rate more than double that of white men (J).
The reasons behind this discrepancy are incompletely understood at this time, but merit
further investigation. The yearly cost of treating prostate cancer has been estimated at
$2.3 billion, making it the most expensive cancer to treat among men (followed by lung
and then colorectal) (1). Prostate cancer patients who undergo androgen ablation
generally experience initial regression of their disease which may last for several years.
However, with time, most patients will go on to develop castration-resistant prostate
cancer (CRPC) that must then be treated with chemotherapy. The current first line
chemotherapy for such patients is largely ineffective, improving overall survival by only
a few months (1,1). In the last year, four new drugs have been approved as second line
chemotherapy for CRPC (one for palliation of bony metastases), but again the increase in
survival is a few months at best (§). Additionally, chemotherapy drugs are generally
poorly selective, causing serious side effects due to damage to non-cancer cells. The
average age at diagnosis for men with prostate cancer is 70 years of age (J). Therefore,
developing more specific therapies is especially important for geriatric patients who often
cannot tolerate highly toxic regimens.
Although early stage prostate cancer typically has a high survival rate, there
remains a clear need for better treatments. Surgical prostatectomy involves significant
2

risk of major side effects like impotence and incontinence. These adversely impact
quality of life, highlighting the need for new medical technologies that lessen the risk to
patients. Moreover, advanced prostate cancer is generally insensitive to chemotherapy
and has a particularly poor prognosis, so novel agents are sorely needed.

Oligonucleotides as medicines

Small pieces of synthetic nucleic acid (oligonucleotides or nucleic acid oligomers)
are now commonly used in a number of different ways as tools for laboratory research.
Interest is also growing in the possible applications of oligonucleotides as medically
useful agents. Strategies utilizing oligonucleotides (both in the laboratory and in the
clinic) are many:
•

Antigene - a synthetic DNA oligomer targets a portion of the genomic double-helix
DNA to form a triple helix and block transcription of that region (7-9).

•

Antisen,se - a DNA oligomer is designed to be complementary to mRNA encoding a
specific protein. Base-pairing between the oligomer and the mRNA results in a
double-stranded molecule which is degraded by the cell, blocking translation of the
protein of interest (lQ,ll).

•

RNA interference - the oligomer is a double-stranded RNA that is processed
intracellularly to single-stranded molecules. The RNA-induced silencing complex
(RISC) pathway is activated, causing degradation of a specific endogenous mRNA
species (1).

•

Transcription decoy - a double-stranded DNA oligomer mimics the target of a
specific transcription factor, but does not result in production of protein. The decoy
3

thus decreases the expression of the endogenous sequence eU).
•

Immunostimulating - DNA oligomers containing the CpG (i.e. cytosine-guanine)
motif act as agonists of Toll-like receptor 9 (TLR9), causing activation of dendritic
cells and B cells (H,U).

•

Aptamer - a single-stranded DNA or RNA oligomer folds into a sequence-determined
three dimensional shape that binds specifically to a molecular target and (generally)
inhibits its function (16-20).
Though the field of nucleic acid oligomers as clinically useful medications has

immense potential, the major hurdle of nucleic acid oligomer therapeutics of all types is
whether or not the drug actually reaches its intended human cellular target. Optimally,
any such therapy would be given in a systemic fashion and thus must have enough
molecular stability to withstand degradation while traveling through the patient's
circulation. Unfortunately, oligonucleotides by nature are particularly vulnerable to
degradation by serum nucleases such that the half-life of most oligonucleotides after
systemic administration is on the order of minutes. Another limitation of oligonucleotides
with intracellular targets (including all those that act via RNA interference) is the low
degree of intrinsic cellular uptake. Many bacteria utilize uptake of extrinsic DNA
fragments as an important method to maintain genetic variability within the species, and
have evolved cellular mechanisms for competency. In contrast, eukaryotic cells have
protective mechanisms against competency, which in nature act to defend the cell against
viral infection.
Several methods have been attempted to address these two major challenges
(stability and uptake) in the clinical use of nucleic acid oligomers. One strategy is by
4

enhancing resistance to degradation by modifying the nucleotides that make up the
oligomer, such as substitution of an amine of fluorine group at the 2' position of the
ribose ring. The phosphodiester linkage of the oligomer backbone may also be modified
by replacing a non-binding oxygen with a sulfur atom to form a phosphorothioate bond.
While these changes do achieve the intended effect of increasing the molecular stability
of the oligomer, they may have detrimental effects such as decreased activity or increased
toxicity. In terms of the poor delivery of oligonucleotides to the intracellular
compartment, researchers have employed various vehicles such as liposomes, polymer
vesicles, genetically engineered viruses, and nanoparticles (21-28). These methods work
very well in vitro, and are invaluable tools in laboratories worldwide, but translation into
practical clinical use is limited at this time.
In summary, although a number of methods designed to enhance oligomer
stability and/or cellular uptake exist, they all generally decrease the ability of the
molecule to act at its intended target and/or increase the toxicity of the agent.

G-rich oligodeoxynucleotides and guanine quadruplexes

It is well-established that oligodeoxynucleotides (ODNs) enriched in guanine
bases (guanine-rich oligodeoxynucleotides, or GROs) have distinct properties. Via
hydrogen bonding, the guanines facilitate the formation of folded three-dimensional
structures, namely the G-quadruplex (29). This structure is by nature highly stable, with a
melting point well above physiologic temperatures and a high degree of intrinsic
resistance to both serum and intracellular digestive enzymes that is much greater than
typical single- or double-stranded oligomers (days vs. hours). In addition, GROs have
5

been reported as having enhanced cellular uptake in a number of different settings, even
without any of the chemical modifications or convoluted delivery systems that classic
oligomer therapy requires

(l~,30).

The specific mechanism behind the increased uptake

of GROs is unclear despite decades of research, but may be at least in part secondary to
the molecular stability of the higher order structure.

Aptamers: a new class of cancer drug
Of the different types of nucleic acid oligomer therapeutics, our laboratory is
focused on the study of aptamers. Aptamer therapeutics are particularly pertinent to the
field of medical oncology. Currently available chemotherapy drugs can be generally
divided into two categories: small molecules or monoclonal antibodies. Small molecules
are typically toxic chemicals, and were the first type of pharmaceutical used to treat
cancer. Examples include cyclophosphamide, a nitrogen mustard, and cisplatin, a
platinum derivative. Both these and other drugs nonspecifically kill cells by causing DNA
damage, and like most small molecule therapeutics, have considerable toxicity to nonmalignant cells. This non-specificity is responsible for the classic chemotherapy side
effects, including hair loss, gastrointestinal upset, and bone marrow suppression. Therapy
is based on the rationale that cancer cells are more vulnerable to DNA damage than
healthy cells.
Monoclonal antibodies are much larger than small molecules, being comprised of
four large protein chains. Antibody therapy operates on the premise that tumor-specific
antigens exist which can be used to distinguish cancer versus normal cells (e.g.,
trastuzumab, which binds the signaling molecule HER2/neu that is overexpressed in
6

many breast cancers, or to target processes that are critically important for tumor growth
(e.g. bevacizumab, an anti-VEGF antibody that inhibits angiogenesis). Antibodies are a

much more recent addition to the chemotherapy pharmacopeia, with the first anticancer
antibody approved in 1997 for the treatment of non-Hodgkin lymphoma

Cll). The major

advantage of anticancer monoclonal antibodies is the high degree of specificity with
which they bind their antigen target, making them as selective as the antigen against
which they were raised.
Each of the two classes described thus far has its own intrinsic advantages and
disadvantages in terms of clinical use. Aptamers, made of synthetic DNA or RNA that
bind to specific targets, comprise an entirely new class of cancer drug. An aptamer's
function lies beyond the traditional paradigm of DNA and RNA acting as passive
blueprints for proteins or binding in a Watson-Crick sequence-dependent manner as
required for RNA interference therapies. Instead, the basis for aptamer binding is the
molecule's specific three-dimensional shape. Just as proteins have a specific structure
determined primarily by the amino acid sequence, aptamers often contain secondary
structure motifs (e.g. hairpins, G-quartets) determined by the sequence oftheir nucleotide
bases. The mechanism of action for aptamers is, in essence, like that of monoclonal
antibodies.
In terms of size, aptamers fall between traditional small molecules and large
antibody proteins, and they have advantages of both of these classic drug types. Aptamers
are specific for their molecular targets and less likely to cause toxic side effects than
small molecules. Functionally, in terms of target-binding, aptamers are on par with
monoclonal antibodies, yet aptamers have additional desirable characteristics including
7

ease of manufacture,

molecular stability (i.e.

longer shelf life),

and

lower

immunogenicity. In addition to frank therapeutic effects, aptamers may also be utilized as
vectors for targeted drug delivery or for imaging. The same intrinsic characteristics that
make aptamers appealing as pharmaceuticals also allow them to be easily employed for
these ancillary purposes; attaching a highly specific aptamer to a drug or radionuclide
that lacks cancer cell specificity would result in targeted delivery of the non-specific
molecule. Aptamers lend themselves easily to these types of chemical modifications.
Compared to most other nucleic acid therapies, aptamers do not necessarily require
cellular uptake in order to function and need not be limited by transmembrane transport.
Aptamers are also being explored for non-oncologic purposes. Essentially any
application that currently uses monoclonal antibodies could be performed with a less
expensive, more stable, and similarly target-specific aptamer. This includes many
research assays such as Western blotting, flow cytometry, immunohistochemistry, and
ELISA. Several aptamers are also in different stages of human clinical trial, particularly
for anticoagulation (12,20). The first aptamer to be approved for clinical use is
pegaptanib, an intraorbital injection for the treatment of wet macular degeneration, which
targets vascular endothelial growth factor (VEGF). It was approved by the Food and
Drug Administration in 2004 (32).

SELEX (systematic evolution of ligands by exponential enrichment)
Aptamers may be engineered through a process called SELEX (Figure 1), an
iterative procedure of approximately 10-20 cycles. The SELEX technology uses intrinsic
binding affinity to isolate candidate aptamer sequences that bind to a target of interest
8

-Remove unbound oligos
-Capture bound oligos
-Amplify by PCR
-Isolate single-strand oligos
Repeat
up to 20x

-Sequence
-Test

Figure 1: Schematic of SELEX workflow. An oligonucleotide
library containing a mixed population of billions of sequences is
applied to a specific target. Sequences that bind are retained and
amplified by peR. The new pool enriched in target-binding
sequences is reapplied to the target, and the cycles repeated
until aptamer sequences become prominent.
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(typically a purified protein) from an oligonucleotide library of millions of individual
species. Briefly, a library of single-stranded DNA or RNA molecules of different random
sequences flanked by known primer-binding regions is applied to the target. For a library
of 26 unknown bases between the primer-binding regions, the number of possible
different species is on the order of 10 15 (26 positions, with each position having equal
likelihood of being A, C, T, or G; 426 = 4.5

X

10 15 possible sequences (Chapter 2)). Some

sequences will bind to the target. The unbound sequences are removed, and those
remaining are detached and amplified by PCR. The PCR product, now enriched in targetbinding sequences, is purified and then reapplied to fresh target for the next round of
SELEX. As these steps are repeated, the sequences that bind with greatest affinity will
become increasingly prominent, and candidate aptamers can be identified.
Aptamers generated by SELEX have the same problems with molecular stability
(i.e. resistance to degradation) and cellular uptake as other therapeutic nucleic acid
oligomers. In addition to the previously discussed standard oligomer modifications to
enhance stability, SELEX may address this issue "upstream" with the use of chemically
modified or L-configuration nucleotide bases in the starting libraries and PCR reactions
such that the selected aptamers have intrinsic stability and do not require downstream
modifications that may adversely affect their activity or safety profile.

In this project, two upstream SELEX variations to improve molecular stability
and cellular uptake are described and will be discussed fully in Chapter 4. The first is the
utilization of a starting oligomer library that is G-rich. We propose that such a library will
contain fewer sequences, with a higher proportion of molecules that can form Gquadruplexes. The library will thus have more molecules with the naturally enhanced
10

stability and uptake associated with this tertiary structure. This hypothesis is strengthened
by the observation that many aptamers produced by SELEX using the standard (non-Grich) starting library have been reported to be able to form G-quadruplexes. Our second
variation is to perform whole-cell SELEX; but, instead of simply selecting sequences that
bind to the cells, we select for those that have been internalized by the cell. Rather than
attempting to target a particular mechanism to transport the oligomer across the cell
membrane, we propose to let the cell determine which sequences are able to do so. This
method could handily address the issue of poor cellular uptake of oligomers, allowing us
to generate efficiently internalized aptamers that would be ideal for drug delivery of
molecules such as siRNAs for which transport across the cellular membrane is an
effective-dose-limiting hurdle.

"AS1411" is the first anticancer aptamer in human trials

Dr. Paula J. Bates (the mentor for this proposal) and her colleagues have already
discovered aptamers that selectively kill cancer cells (33-37). One of these, a G-rich
oligodeoxynucleotide (ODN) called AS 1411 (previously known as AGRO 100), is the
first anticancer aptamer to enter human clinical trials (ll.). AS 1411 was initially
discovered following a chance observation that a particular DNA sequence had
significant antiproliferative activity against the DU145 prostate cancer cell line. F,urther
studies on AS 1411 proved that it binds to nucleolin, a protein that is highly expressed on
the surface of cancer cells but not normal cells. Dr. Bates' work thus not only led to a
new anticancer drug, but also a new class of anticancer molecules and a new anticancer
target.
11
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---------------

Phase I and Phase II clinical trials of AS1411 have shown promising results that
are remarkable for the lack of major side effects (11,38). AS1411 has been tested against
metastatic renal cell carcinoma (MRCC) and acute myelocytic leukemia, and may
ultimately prove useful in treating other metastatic cancers such as prostate. Of twelve
MRCC patients in the Phase I trial, one had a complete response, one had a partial
response (70% tumor shrinkage) and seven more had disease stabilization ranging from 2
to 15 months. This aptamer clinical trial is the first of its type, indicating an almost
wholly unexplored niche for new, more specific anticancer aptamers.
The clinical response to AS 1411 is very unusual in that a single treatment may
have no immediate effect, but over several months may cause complete tumor regression
with no additional treatment. Due to this curious effect, one hypothesis of this project is
that AS 1411 and other aptamers may act by targeting cancer stem cells.

Tissue stem cells, cancer stem cells, and tumor initiating cells
Tissue stem cells (also known as "adult stem cells" or "somatic stem cells") are
capable of both differentiation and long-term self-renewal. They are now believed to exist
in most if not all organs of the human body, remaining quiescent until signaled to divide
for tissue maintenance or repair. Though elusive, the definitive identification of tissue
stem cells is slowly being pinpointed in many different systems such as the bone marrow,
skin, gastrointestinal tract, bronchial epithelium, and prostate gland (39-42). These stem
cells are also responsible for common hyperproliferative disease states such as
hyperkeratosis and benign prostatic hyperplasia (BPH). In the prostate, the malignant
version of such over proliferation is prostate cancer.
12

It has long been recognized that cancers have diversity within their cell

populations (e.g. stromal, immune cells), but until recent years, the extreme diversity of
the cancer cell population itself within a single malignancy has been largely overlooked.
Many recent publications report a rare subgroup, dubbed cancer stem cells (CSCs), which
appear to divide and differentiate to make a tumor just as benign stem cells do to make a
healthy tissue (43-46). CSCs were first detailed in the context of acute myelocytic
leukemia (AML) (47,48). Cells were isolated from human patients based on cell surface
marker profiles and injected into mice. These cells proliferated and repopulated in the
mice into AML pathologically identical to the disease in the original human patients.
Other cells without this surface marker profile were wholly unable to cause cancer in the
mice. Since this first report, CSC populations have been characterized in breast, brain,
prostate, ovary, colon, and other solid tumors. In these organs, it may be only this small
population (generally between 0.01 and 5% of the total cancer cells) that is able to
establish and perpetuate a tumor.
Current anticancer therapies focus on rapid shrinkage of tumor volume, and
indeed this is the primary objective of most cancer research models. However, the
majority of cancer patients who enter remission will eventually suffer a relapse of their
disease. The concept of CSCs could explain this sad phenomenon. If CSCs comprise only
a tiny percentage of the total tumor, divide slowly, are resistant to chemotherapy, and are
responsible for the perpetuation of the tumor, then even those cancer therapies that cause
dramatic clinical responses may leave the CSCs unscathed (49). The surviving CSCs
would reestablish the disease in time. On the other hand, a therapy that selectively targets
CSCs may initially appear to have no effect on tumor growth, but over time the tumor
13

would shrink and finally disappear. (Figure 2) This is precisely the effect shown by
AS 1411. Furthermore, most of the morbidity and mortality associated with cancer is due
to distant metastases. If only CSCs are able to form a metastasis, then anti-CSC therapies
could potentially be used as prophylaxis for cancer spread.
The nascent field of CSC research is fraught with conflicting reports as the
methodology slowly becomes established. One confounding element is the inconsistency
of the very definition of "cancer stem cell." In 2006 the American Association of Cancer
Research convened a CSC workshop to discuss guidelines for this rapidly growing area
of study. At that time a CSC was defined as "a cell within a tumor that possess[es] the
capacity to self-renew and to cause the heterogeneous lineages of cancer cells that
comprise the tumor" (50). Despite this guideline, many researchers use the term CSC for
subgroups of cancer cells that can reproducibly grow a tumor; the feature of self-renewal
is often not addressed. For this situation, the term tumor initiating cell (TIC) is preferable,
and this term will be used throughout this body of work.
Different research groups propose varying and overlapping properties for TICs:
TICs alone are sufficient for the formation of cancer, there are different types of TICs
which may have varying tumor-forming capacities, TICs might make up the bulk of the
tumor rather than comprising a rare subpopulation, and many cells (both benign and
malignant) have to potential to become a TIC. Whether or not a true self-renewing CSC
compartment exists, within a given malignancy there is a high degree of cellular
heterogeneity that has been largely ignored in the development of new cancer therapies.
Certain subpopulations of cells are known to be markedly more invasive, proliferative,
and/or stem-like (i.e. having stem cell markers and features). Therefore, despite the
14

Drugs that
eliminate cancer
stem cells

Drugs that do
not target
cancer stem
cells

Tumor responds
slowly, with
disappearance

Tumor initially
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CSCs survive
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+
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~
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REGRESSION
due to
absence
ofCSCs

Figure 2: Cancer stem cells (green) and clinical implications.
Treatments that spare cancer stem cells may initially have a
dramatic clinical response, but given time the intact stem cell
compartment will repopulate the tumor. Conversely, treatments
that destroy the cancer stem cell subpopulation may appear to
have limited initial effect, but with time the tumor spontaneously
regresses.
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controversy surrounding the study and terminology of CSCs, TICs, and different cancer
cell subtypes, the basic concept of a subpopulation of cancer cells that is particularly
responsible for tumorigenicity is becoming widely accepted and must be addressed in
cancer drug development.

Aptamers and cancer stem cells

Upon further consideration, aptamers and CSCs have many additional aligning
features that make the study of their relationship even more compelling:
•

CSCs are largely quiescent, making them less vulnerable to chemotherapies that
target rapidly proliferating cells (51-53). Unlike most chemotherapy drugs, aptamers
do not require cycling cells for activity.

•

CSCs have been shown to express multi-drug resistance efflux pumps that nonspecifically remove small molecules from the cell

(g,54,~.

Aptamers are not small

molecules and would likely be unaffected by these pumps.
•

CSCs may have highly activated DNA damage responses, making ionizing radiation
therapy and many anticancer drugs less effective (43,52). Aptamers do not appear to
damage DNA as part of their mechanism of action.

•

CSCs may prove to be difficult to access, either embedded deep within a tumor or
within a protected stem cell "niche" (43,56). Aptamers have better tissue penetration
compared to monoclonal antibodies, and may be able physically to reach CSCs more
readily (TI,58).

RATIONALE AND PURPOSE
16

We believe the field of anticancer aptamers is worthy of further investigation. The
initial intention of this body of work was the isolation of new cancer-specific aptamer
sequences via whole-cell SELEX for potential use in clinical oncology. AS 1411 was
discovered by a chance observation. It is therefore likely that a deliberate approach to
find new aptamers for specific cancer types will lead to even more promising anticancer
molecules that may be used for drug-delivery, imaging, and even veritable
pharmaceuticals.
We hypothesized that G-rich aptamers are likely to form G-quaduplexes, and may
be particularly appropriate due to naturally enhanced molecular stability and ability to
enter cells. We planned to test the utility of a G-rich, non-classical library (specifically,
comprised of only G and T bases) compared with the classic random N library as the
starting point for SELEX. To better understand the intrinsic characteristics of G-rich
libraries in general, we studied the anticancer activity of a number of G-rich libraries in
comparison with non-G-rich libraries. The unexpected observation that robust anticancer
activity was exhibited by certain G-rich libraries, without the isolation of a unique
aptamer sequence, led us to explore biological and biophysical characteristics and attempt
to relate them to this intrinsic activity.
With respect to cancer stem cells, elimination of CSCs and TICs may prove to be
the key to curing cancer and aptamers may be an effective way to target them. A second
project goal of studying the ability of a G-rich aptamer to target cancer stem cells arose
from observation of the clinical effects of AS 1411. Though high risk, a positive result
indicating that AS 1411 is able to selectively target and destroy or neutralize CSCs would
contribute greatly to the scientific bodies of knowledge of both aptamers and CSCs.
17

Thus, this hypothesis-driven project was planned to explore the potential interactions
between a G-rich aptamer and CSCITICs, and possibly elucidate a key ability of a known
G-quaduplex-forming anticancer molecule. To our knowledge, the project described here
is the first to investigate the relationship between aptamers, a new class of cancer drug,
and cancer stem cells, a revolutionary new cancer theory.

HYPOTHESIS AND OBJECTIVE
•

Our hypothesis is that guanine-rich oligonucleotides are optimal for the development
of new aptamers for use in the treatment of cancer, and may have particular utility in
the treatment of cancer stem cells.

•

Our objective is to develop new targeted aptamers specific for the treatment of
prostate cancer.

SPECIFIC AIMS
Aim I: Study guanine-rich oligodeoxynucleotide libraries for use in whole cell-SELEX.
Aim 2: Use non-conventional (G-rich) oligodeoxynucleotide library to identify aptamer
candidates specific for prostate cancer cells and characterize selected aptamer
candidates.
Aim 3: Test the hypothesis that a model aptamer (ASI411) targets CSC/TICs.
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CHAPTER 2
CANCER-SELECTIVE ANTIPROLIFERATIVE ACTIVITY IS A GENERAL
PROPERTY OF SOME G-RICH OLIGODEOXYNUCLEOTIDES

INTRODUCTION
The appended manuscript describes the characterization of general properties of
G-rich and non-G-rich libraries of single-stranded oligodeoxynucleotides (ODNs). This
report has been published in the peer-reviewed journal Nucleic Acids Research (59;
Appendix A). As discussed, the underlying hypothesis of this body of work is that G-rich
ODNs are particularly suited for development as new medical therapies due to naturally
enhanced molecular stability and cellular uptake. We performed a number of experiments
to establish baseline characteristics of G-rich versus non-G-rich ODN libraries, including
anti proliferative effects upon a variety of cell lines. We did this in preparation of the
SELEX project described in Chapter 4, in which we attempt the generation of cancerspecific aptamers from a non-traditional, G-rich ODN library. The purpose of these
experiments was initially to test our hypothesis that G-rich libraries would be enriched in
G-quadruplex forming sequences, which would have increased nuclease resistance and
cellular uptake compared to traditional libraries.
Briefly, eleven libraries and three monobasic ODNs of varying lengths and
nucleotide

compositions

were

studied.

We

originally

anticipated

a

lack

of

antiproliferative activity (as well as lack of molecular stability and cellular uptake) in the
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libraries, whereas after isolating candidate aptamer sequences via SELEX we expected to
demonstrate an enhancement in activity. Although we postulated that G-rich libraries
would contain a higher proportion of biologically active molecules, we presumed that the
effects of any such molecules would be masked by the remaining millions of different
sequences that comprise even a smaller, sequence-constrained library. On the contrary,
however,

we

observed

that

G-rich

libraries

comprised

of G+T

or

G+C

oligodeoxynucleotides exhibited robust inhibition of cancer cell growth while having
little to no effect on the non-cancerous fibroblast cell line. Interestingly, the library
comprised of G+A bases did not have this effect. This manuscript is the first to report
cancer-specific antiproliferative activity exhibited by a library of ODNs rather than a
single, carefully isolated sequence.
Based on these unexpected results, a complete scientific project evolved. Our
experimental ODN samples were divided into those that inhibited the growth of cancer
calls and those that did not. The two groups were then compared for biophysical and
biological characteristics, namely higher order structure, molecular stability, cellular
uptake, and protein binding, in an attempt to correlate these features with this cancerspecific activity.

CONCLUSIONS
In this manuscript, we conclude that cancer-selective anti proliferative activity
requires "nuclease-resistance, efficient cellular uptake, and binding to specific
protein(s)." Though we observed some exceptions, as a general rule we showed that the
libraries that have these biological and biophysical characteristics appear to form G20

quadruplexes. It is noteworthy that, although G-quadruplex formation appears to be a
prerequisite for cancer-selective antiproliferative activity, quadruplex formation alone is
insufficient for this activity. This conclusion has also been reported by previous
researchers in our group (36).
Our results, as well as any other elucidation of features that confer anticancer
activity may aid in the isolation of new cancer-targeting aptamers via the SELEX
procedure. For example, the identification of a sequence motif (e.g. GGTGGT) that
correlates with cancer-selectivity if found specifically at the 3' end suggests the utility of
a starting library in which every sequence ends with this motif. The starting SELEX
library would be enriched in potential anticancer molecules from the outset, and the
SELEX evolution process would select for target specificity.
Additionally, any constraint on the sequence or composition of an ODN pool of a
given length yields a library that contains fewer molecules. Minimizing the length of the
starting library while maintaining optimal biological activity would also reduce the
number of molecules. A library that contains fewer sequences may translate into a
decrease in the number of cycles required before candidate aptamer sequences become
prominent enough to be identified, with potential corresponding effects on the costs of
discovery and manufacture. For these reasons we studied both nucleotide composition
and library length, and observed that a library with as few as eighteen nucleotide bases in
length exhibited virtually the same inhibition of cancer cell growth as one nearly twice as
long (34 bases).
We concluded that, in general, the "active" anticancer libraries showed evidence
of G-quadruplex formation and that this feature was critical to the intrinsic activity of the
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library. We thus pursued the possibility of using a G-rich ODN library, smaller and
enriched in G-quadruplex forming sequences, as the starting point for SELEX rather than
the classic, larger, random N library (Chapter 4).
Regarding the GA 26mer ODN library, we observed that this library had a unique
CD spectrum that is consistent with data previously reported by other researchers for
G+A ODNs. The spectrum is believed to signifY stacked guanine bases, but whether or
not this translates into a G-quadruplex is uncertain at this time. It has been reported that a
GA aptamer that binds to the bovine prion protein does form a G-quadruplex (60,Q.l) but
perhaps the majority of species within the GA 26mer library are unable to form this
structure due to the relatively bulkiness of the adenine base compared to the pyrimidines
(thymine and cytosine). If it is indeed formation of G-quadruplexes that is ultimately
responsible for selective antiproliferative activity against cancer cells, it is likely that the
percentage of G-quadruplex-forming sequences within the library determines the net
presence or lack of antiproliferative activity of the library en masse. Therefore, if fewer
quadruplexes are present in the GA library, it follows that the library would not exhibit
this activity, along with the corresponding lack of the characteristic G-quadruplex protein
binding and cellular uptake. This does not rule out the possibility of potential GAanticancer aptamers. However, regarding SELEX, we conclude that a GA starting library
offers little benefit over the classic N library.
In our EMSA data, we observed unique protein bands in the GC 26mer and C
26mer samples. The identification of the protein targets of the GC 26mer library may be
particularly significant in the development of new aptamers as cancer therapeutics, as this
library had a unique profile of antiproliferative activity against the various cancer cell
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lines (Appendix A, manuscript, Figure 3E). The C 26mer did not exhibit cancer-selective
antiproliferative activity, but had a unique CD spectrum suggestive of the i-motif tertiary
structure (Appendix A, manuscript, Figure 4B) in addition to its unique protein band.
Studies that identifY GC- and/or and C-binding proteins would therefore be a contribution
to the body of knowledge ofaptamers and ODN therapies.
In the following chapter (Chapter 3), we discuss GC and C ODNs in greater
detail. We describe additional experiments that we performed to identifY proteins from
cancer cell extracts that bind to the GC 26mer library and the C 26mer ODN. We discuss
the implications of the identified proteins, including possible mechanisms of action. We
close Chapter 3 with a description of future experiments and directions, especially the
validation of proteins identified as binding to these ODNs of particular interest.
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CHAPTER 3
PROTEIN TARGETS OF THE GC OLIGODEOXYNUCLEOTIDE 26MER
LIBRARY AND POLY-DEOXYCYTOSINE 26MER MOLECULE

INTRODUCTION

The significance of nucleic acid-binding molecules
It was at one time accepted that the role of nucleic acid within a cell was largely
passive. According to the central dogma of molecular biology, DNA acts as an
information repository that is passed down during cell division and contains instructions
to make proteins. Proteins were thought to be the active components of biology that
perform virtually all essential cellular functions. RNA was believed to be little more than
the machinery that translates the DNA information into the final functional protein end
product.
While the central dogma still holds true, it is now known that the nucleic acids of
the cellular genome playa more nuanced and dynamic role that first envisioned. DNA in
and of itself has intrinsic functional activity including regulation of gene expression and
intracellular signaling. Epigenetic modifications have been implicated in a number of
disease states including Alzheimer's disease, rheumatoid arthritis, and several kinds of
cancer (62-64). RNA comes in a variety of subspecies with different functions such as
riboswitches, ribozymes, and microRNAs, in addition to the classic mRNA, tRNA, and
rRNA types (65,66). Clearly, nucleic acids are both more complex and much more
24

biologically active than was once postulated, and will require further investigation in
order to be fully appreciated. It follows that identifying and elucidating molecules that
bind to nucleic acids, including both endogenous and synthetic aptamer species, will have
important implications not only in the development of medical therapeutics (the goal of
this project), but also in fundamental molecular biology.
Treatment strategies in the development of new pharmaceutical agents that utilize
nucleic acid binding may thus be designed in two different ways. The first is by
engineering synthetic nucleic acid aptamer therapeutics to bind to clinically. relevant
targets. The second is by identifying endogenous nucleic acid structures that play
important roles in disease states and designing small molecules, or monoclonal
antibodies, or even nucleic acid aptamers that target them.

Rationale for studying GC ODN library- and dC-binding proteins

Our manuscript (Appendix A) makes the following observation regarding protein
binding using radiolabeled ODN libraries and monobasic samples and a whole cell lysate
from prostate cancer cells: that the GC 26mer library (which has intrinsic and selective
antiproliferative activity against cancer cells) and the C 26mer ODN «dCb, which does
not have antiproliferative activity at all) each exhibit unique protein bands that differ both
from one another and from all the other libraries and monobasic ODNs that we studied
(Appendix A, Figure 7, B3 and B4, respectively).
These unique protein binding data are of particular scientific interest for the GC
library, as this library has different cancer type selectivity than the GT libraries
(Appendix A, Figure 3A); while the GT libraries inhibited the growth of every cancer cell
25

line tested, the GC library exhibited antiproliferative activity similar to the GT libraries
against the lung and prostate cancer cell lines, but only moderate activity against breast
cancer cells. Correspondingly, the fluorescently-Iabeled GC 26mer library exhibited
cellular uptake that was comparable to the GT library in lung and prostate cancer cells,
but relatively reduced in breast cancer cells. [t may be that the GT and GC libraries act by
distinct mechanisms of action and through distinct molecular targets, and that the target
of the GC library is expressed at different levels in the breast cancer cells compared to the
other cancer cell types tested. Identification of such a target would shed light upon a
possible tumor specific target as well as the mechanism of the cancer-selective
antiproliferative effect of the GC ODN library. Such data would also suggest the
possibility of using an ODN library containing only guanine and cytosine as a starting
point for SELEX to generate aptamers against specific cancer types known to be enriched
in that target molecule. As discussed in Chapter I, we hypothesize that guanine-rich
oligonucleotides are optimal for the development of new aptamers for the treatment of
cancer and one of our specific aims is to study guanine-rich ODN libraries for use in
SELEX against cancer cells. The study of proteins that bind to the GC library therefore
furthers the goals of our project.
The primary aim of this body of work is to develop new aptamers for use as
oncology therapeutics. Although the poly-C ODN exhibited no intrinsic anticancer
activity, cytosine-rich stretches of DNA are able to form a highly dynamic, pH-dependent
quadruplex structure called the "i-motif' (discussed further below). This non-canonical
nucleic acid structure may playa regulatory role by acting as a biological switch in the
activity and/or expression of guanine-rich areas, as a cytosine-rich strand is the natural
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complement of such regions. Guanine-rich regions (that may themselves form Gquadruplexes) are prevalent throughout the human genome, and include centromeres,
chromosome 19, immunoglobulin switch regions, and disease states involving the X
chromosome (Fragile X) (67,68). G-rich regions are also seen in the promoters of many
genes important in cancer biology, such as c-myc, c-kit, VEGF, HIF-l, KRAS, MEN-I,
RET, and RB (69). Perhaps the most well-known G-rich area of the human genome is the
telomere, which has far-reaching implications and effects on the biologies of cancer and
of aging, and is an attractive therapeutic target of much pharmaceutical interest. Several
citations in the literature report that the corresponding C-rich telomere strand forms imotifs that may eventually be shown to act in the regulation of the telomere, and thereby
impact in the field of oncology (70-72).
Only a handful of proteins that specifically bind to poly-C ODNs and/or the imotif have been identified (lQ). Therefore, the identification of a new i-motif-binding
protein, though perhaps not overtly pertinent to the development of new anticancer
aptamers, would be a contribution to the scientific field of aptamers and their targets and
could eventually be significant in the development of cancer therapeutics.
We chose not to characterize proteins binding to the GT library because we
suspected that such proteins would have a high degree of redundancy with the proteomic
analysis of AS 1411, ODN comprised solely of guanine and thymine bases that has been
extensively characterized by our laboratory previously (37). As expected, each library
exhibited a high number of protein bands; we focused our efforts only on the bands in the
GC and C 26mer samples that exhibited distinctive features and were likely to provide
novel information.
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Guanine-cytosine ODNs

Endogenously, stretches of nucleic acid that are especially GC-poor or GC-rich
have been reported to have important biologic functions. The guanine-cytosine base pair
is joined by three hydrogen bonds, while the adenine-thymine bond is joined by only two.
Therefore, sections of genomic DNA that require frequent separation, such as promoter
regions, tend to have low GC content. Conversely, nucleic acids with high GC content
may form higher order structures that depend on this strong complementary base pairing.
For example, structured RNA species (e.g. tRNAs, rRNAs, ribozymes) often contain a
high percentage of G + C bases which incur molecular stability to the fragile RNA
molecule by forming shapes such as stem-loops and cloverleaves (73). Riboswitches are
a type of structured RNA that are common in bacterial species, and denote an
untranslated portion of an mRNA molecule that may bind to proteins that regulate
expression of that mRNA - in other words, an endogenous RNA aptamer. One recent
report describes a new class of riboswitch that binds to the biologically important
molecule S-adenosylmethionine which was identified by analyzing regions of genomic
DNA with relatively high GC content that did not contain known genes, but did precede
metabolic genes. The authors' rationale was that stretches of DNA with these features
were likely to be enriched in such metabolically active RNA species (74).
Another role of GC-rich stretches of DNA involves epigenetic modifications.
Epigenetic methylation occurs most often upon cytosine bases that are immediately
followed by a guanine (CpG). The term "CpG island" is defined as a region that 1) is
greater than or equal to 200 bases, 2) is comprised of at least 50% cytosines and guanines
(i.e. GC-rich), and 3) has an observed to expected G+C ratio of at least 0.6. Given this
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definition, CpG islands are found in the 5' promoter region of approximately 60% of
human coding genes, and methylation at or around the CpG islands can block
transcription of those genes. Aberrant methylation of promoters has been implicated in a
number of disease states; global hypomethylation is a known feature of cancerous cells,
as is hypermethylation of important tumor suppressor genes (62). The study of GC-rich
nucleic acids may therefore impact the study of oncology.
In addition to sequences containing approximately equal numbers of Gs and Cs,
individual molecules within the GC library may contain either relatively more guanines
or relatively more cytosines. Guanine-rich molecules may form the highly stable Gquadruplex, while cytosine-rich molecules may form the i-motif. One must also consider
the possibility that multiple molecules within the library may assemble into a multiplex,
forming not only secondary and tertiary, but also quaternary structures with or without
complementary base pairing. It may be that the GC library exhibits its distinct profile of
anti proliferative activity and unique protein binding pattern due to the prevalence of all
three structural features: GC-base pairing, G-quaduplex, and i-motif, and that the
structures may be formed by one or more individual ODN molecules.

poly-de ODN and the i-motif
Although C-rich stretches of nucleic acid are relatively less well-studied than
many other nucleic acid motifs, there exists a small, highly conserved family of
molecules known as poly-C binding proteins (PCBPs) that playa role in posttranslational
regulation as well as acting as transcription factors. Certain PCBPs have been shown to
act in the transcription and posttranscriptional regulation of the androgen receptor, an
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important signaling pathway in prostate cancer (]2,76). An increase in PCBPI levels was
associated with a decrease in AR expression, and knockdown of PCBPI caused an
increase in AR. As AR is not expressed in prostate cancer stem-like cells, PCBPs may be
a potential therapeutic target. The C-rich telomere strand is also known to bind PCBPs.
In addition to the study of PCBPs and their targets, there is a growing field of
study concerning the "i-motif," a higher-order nucleic acid structure based upon the
binding of cytosine residues. The i-motif was first described as "two parallel duplexes
(antiparallel to one another) with .. .intercalating base pairs," i.e., the i-motif is a cytosine
based four-stranded tertiary nucleic acid structure (77). The i-motif has been reported
with both DNA and RNA species, though the RNA structure is much less stable (78).
The i-motif is pH dependent, and is widely believed to require slightly acidic
conditions in order to be formed. However, in our manuscript (Appendix A) we
demonstrate a series of CD spectra of the C 26mer ODN at a range of pH that suggest the
formation of the i-motif up to a pH of 7; other researchers report similar observations at
neutral and even somewhat alkaline pH (59,79). If the i-motif is able to be formed at
physiologic pH, then it is likely to be biologically relevant. Alternatively, the i-motif is
known to be highly dynamic and readily affected by the nucleic acid's microenvironment
(pH, ion concentration) (2009, Zhou et al.), and therefore could function as a regulatory
switch. Manipulation of the i-motif formation and stability could then be used to exploit
biologic function. As an example, single-walled carbon nanotubes have been shown to
induce the formation of the i-motif in telomeric DNA and to stabilize this structure,
enabling the S 1 nuclease to cleave the single-stranded hairpin loops resulting in
degradation of the telomere (IDl). This phenomenon may potentially be exploited for
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therapeutic purposes in the investigation of cancer and also of aging.

Identification of GC- and C-ODN-binding proteins
After submission of our manuscript describing cancer-selective anti proliferative
activity of certain guanine-rich ODN libraries, we subsequently pursued the identification
of proteins that bind to the GC and C ODNs. We studied these ODNs in comparison with
the Nand GT libraries, reasoning that the unique bands seen in the EMS A data
(Appendix A, Figure 7) should be present in samples containing cellular lysate and GC
library or poly-dC ODN, and absent in the Nand GT libraries. The methods and results
from this preliminary experiment identifying GC- and C-ODN-binding proteins are
included here.

METHODS

Pull down of GC 26mer- and C 26mer-binding proteins
Three libraries and one monobasic ODN were ordered with biotin attached to the
5' end: N 26mer, GT 26mer, GC 26mer, and C 26mer. Whole cell lysate of DUl45 cells
was prepared using RIPA buffer (50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.02%
sodium azide, 1% NP-40, 0.5% sodium deoxychol, 0.5 mM DTT, 1 Ilg / mL aprotinin,)
containing 2 mM PMSF and Ix protease inhibitor cocktail (Sigma, St. Louis). One mg of
cell lysate was preincubated with 10 11M biotinylated ODN, then incubated with
Neutravidin (a streptavidin analogue) agarose resin (Thermo Scientific). Beads
containing bound ODN-protein complexes were washed thrice. Bound proteins were
eluted in 2x SDS-PAGE loading buffer containing 5% (3-mercaptoethanol.
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Separation of pull down samples
Samples were subjected to SOS-PAGE using an 8% polyacrylamide gel. The gel
was washed thrice in water, stained with Simply Blue Safe Stain (Invitrogen) for one
hour, and destained in water overnight at room temperature. The binding, elution, and
SOS-PAGE was repeated once, and the samples in the second gel allowed to
electrophorese for a longer period of time in order to achieve better resolution of the
higher molecular weight proteins.

Mass spectroscopy analysis of unique protein bands
Candidate bands from the GC 26mer and C 26mer lanes (e.g. uniquely present in
these samples versus N 26mer and GT 26mer) were excised and digested using a
commercial trypsin-based kit (Trypsin Profile IGO Kit, Sigma). Samples were sent for
mass spectroscopy analysis at the University of Louisville core facility.

RESULTS

GC library and C 26mer bind unique proteins
Based on the EMSA data, we used biotinylated OONs (GC 26mer library and
poly-dC monobasic 26mer) to pull down proteins from OU145 whole cell lysate. Proteins
were eluted from streptavidin beads, run on acrylamide gels, and stained with Coomassie
blue (Figure 1). We then examined the gel for bands unique to either the GC 26mer
sample or the C 26mer sample. Though complicated by the presence of a high number of
bands in the GT library (comparable to the pattern seen with AS 1411), we identified a
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25 1. ATP-dependent DNA helicase 2, subunit 2
2. Isoform 2 of heterogeneous nuclear ribonucleoprotein K
(-)

N26 GT26GC26C26

AGRO
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3. Cd002 protein
4. cDNA FLJ45706 clone FEBRA2028457, highly similar
to nucleolin
5. Hypothetical protein XRCC5
6. 70 kD protein
7-9. Keratin or trypsin
10. Isoform 2 of ATP binding cassette family F member 1
11. Isoform 2 of nucleolin

Figure 1: Precipitation of proteins from DU145 whole cell lysate
with biotinylated oligodeoxynucleotide librares. DONs with
bound proteins were separated using agarose beads with a
streptavidin analog. Excised proteins marked with arrowheads.
Identified proteins as listed. (-) no library, N 26mer, GT 26mer, GC
26mer, and C 26mer monobasic DON .
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number of unique bands in each sample which were excised. Upon analysis by mass
spectroscopy, identifications were made for all eleven bands. The significant
identifications are discussed below:

GC library-bindin2 proteins:

ATP-dependent DNA helicase 2 subunit 2 (Ku80), IPI00220834.8
Hypothetical protein XRCC5 (Ku80), IPI00791570.1
70 kDa protein (Ku70), IPI00465430.5
Cd002 protein, IPI00216746.1
cDNA FLJ45706 fis, clone FEBRA2028457 (highly similar to nucleolin),
IPI00444262.3

Ku80 and Ku70
These proteins are the two subunits that form the heterodimer eukaryotic DNA
repair protein Ku. Ku was originally discovered in the context of autoimmune disease,
and notably is involved in the genetic recombination responsible for the development of
the humoral immune system and the vast variety of antibody species (ill.
Ku plays a critical role in double-strand break repair, both homologous repair and
non-homologous end joining. It acts by binding to the free ends of linear, duplex DNA,
and physically juxtaposing the two ends. Ku may then recruit other proteins into an active
complex called DNA-dependent protein kinase (DNA-PK) to perform the necessary
repair. The activity of the DNA-PK complex is regulated by the Ku protein. Ku therefore
has wide ranging effects on cell proliferation, apoptosis versus tumorigenesis,
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chromosomal stability, and telomere maintenance (ll,83). Mutations in either Ku80 or
Ku70 have been implicated in a variety of cancer types, including gastrointestinal and
hematologic.
In addition to their function as the Ku heterodimer, the subunits Ku80 and Ku70
may act as unique entities with their own specific functions. Data suggest that Ku80 and
Ku70 may be active at many different subcellular locations. Though primarily nuclear,
both subunits have been shown to trans locate into the cytoplasm and to the cell surface.
The impetus, regulation, and significance of these translocations are poorly elucidated at
this time.
Though Ku has not been shown to bind to particular sequences of nucleic acid, it
is known to bind to free ends of duplex DNA including blunt ends, ends with overhangs,
hairpins, and telomeres (which contain a G-rich motif and a correspondingly C-rich
complementary strand)

~).

Because guanines and cytosines are natural complements,

the GC 26mer library likely contains molecules that either self-contain or assemble to
form duplex DNA structures. It is therefore logical and exciting that molecules within our
GC library bind to the Ku subunit proteins.
If compromised in either activity or expression, lack of Ku may lead to
tumorigenesis due to its role in DNA repair. Conversely, if overactive, excessive DNA
repair/end-joining may translate into resistance to chemotherapies. Ku could potentially
be manipulated as therapeutic target, and aptamers evolved from a GC ODN library may
be a good way to target this fundamentally important protein complex.

Cd002 protein
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This ubiquitously expressed human protein has been identified in a number of
different contexts. Cd002

is officially known as endoplasmic reticulum-golgi

intermediate compartment (ERGIC)-2, but is also known as Erv41, PTXI, and CDAI4.
The specific function of this protein is unknown.
As ERGIC2, this protein is reported to play a role in intracellular transport
between the endoplasmic reticulum and the Golgi apparatus. The yeast homologue is
called Erv41. As PTX I, this protein was first identified in 2001 via subtractive
hybridization, i.e. expressed in normal prostate tissue but not in prostate cancer tissue.

(W Cd002 has been shown to be upregulated in nasopharyngeal carcinoma and
downregulated in prostate cancer cells (84,85). PTXI is located on chromosome 12, a
common site for mutations in advanced prostate cancer. When expressed in a prostate
cancer cell line, PTXI induced senescence. When downregulated in the same cell line,
the cells exhibited increased tumorigenicity and invasiveness compared to control
prostate cancer cells

~.

As CDAI4, this protein was shown to have similar effects on a

different prostate cancer cell line as well as being downregulated in three liver cancer cell
lines, and to interact with human EF -I ex (W.

Nucleolin
Nucleolin was first described in 1973. It is a large protein that is ubiquitously and
abundantly expressed with a diverse array of cellular functions. It is intimately involved
in the formation of nucleolus, but is also found in the nucleoplasm, cytoplasm and on the
cell surface. Nucleolin is purported to play myriad roles in RNA transcription, rRNA
folding and ribosome formation, intracellular transport of molecules, mRNA stabilization,
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calcium homeostasis, cell adhesion, and response to viral infections. Nucleolin may be
heavily modified with phosphate and methyl groups in response to different extracellular
signals, and as protein synthesis is a critical element in cell growth, nucleolin acts as part
of the pathways responsible for cellular proliferation. Nucleolin is also known to bind
directly to oncologically important proteins such as c-myc, VEGF, and topoisomerase
(88-90).
As one may expect given nucleolin's role in different aspects of RNA function,
nucleolin is a known generic nucleic acid binding protein. Among other nucleic acid
species (including RNA) to which it binds, nucleolin has been shown specifically to bind
guanine-rich oligonucleotides and G-quadruplexes, including the telomerase sequence
and ribosomal genes

00. We believe nucleolin is involved in the mechanism of action of

AS 1411, the G-rich aptamer discovered by Dr. Bates et al. that has been studied as a
potential therapy for patients with acute myelocytic leukemia. Previous reports from our
laboratory show that AS 1411 binds to nucleolin, and that anti proliferative effect of
AS 1411 on cancer cells is correlated with the formation of a protein complex containing
nucleolin, and that inhibiting nucleolin expression by siRNAs can inhibit certain
biological activities of AS 1411 (.2.l,92).

C 26mer-binding proteins:
•

Isoform 2 of heterogeneous nuclear ribonucleoprotein K (hnRNP K), IPI00216746.1

•

Isoform 2 ofATP-binding cassette sub-family F member 1, IPI00013495.1

•

Isoform 2 ofnucleolin, IPI00827674.1
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hnRNPK
Heterogenous nuclear ribonucleoprotein K was first described in 1992 as a
subunit of the hnRNP complex. The protein K element in particular is highly conserved
across species and is found in multiple subcellular compartments (nucleus, cytoplasm,
mitochondria). This protein has been shown to bind to a vast array of molecular targets
including DNA, RNA, kinases, transcription factors, translation factors, splicing proteins,
a methyltransferase, and a helicase. Like Cd002 (one of the GC-binding proteins that we
identified), hnRNP K is able to bind eF-la and plays a role in translation (2J,W. It has
been shown to bind the promoter region of c-myc and to regulate its transcription. hnRNP
K is dysregulated in a number of different cancer types, and it has been reported as a
prognostic indicator for colorectal cancer (95-100). It also may be involved in viral
infection. In one specific example, the FLIP antiapoptotic protein is believed to be a
prognostic indicator for nasopharyngeal carcinoma; hnRNP K and nucleolin appear to
work together to regulate the transcription of FLIP (100). Isoform 2 (along with isoform
1) is the most abundant species and appears to be the predominant form of hnRNP K
found in the cytoplasm, though distinct properties for this isoform are unknown QQl).
Due to the diversity of molecules to which it binds, the hnRNP K protein is
believed to be involved in a wide array of cellular processes. One role that is postulated is
that hnRNP K acts as a docking platform, able to bind to a variety of players in multiple
pathways and integrate their intracellular signals into a single downstream effect to the
maximal benefit of the cell or organism (102).
One specific capability of hnRNP K is "tenacious" binding to single-stranded
poly-dC nucleic acids, and not to other monobasic nucleic acid polymers - in other
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words, hnRNP K is one of the few known PCBPs, and the identification of hnRNP K
helps to validate our pull-down assay (103, 104). PCBPs are classically believed to bind
to C-rich RNA species, and it is not yet proven whether or not hnNRP K binds
particularly the i-motif structure of poly-cytosine nucleic acid, but if so it may playa role
in any biological switch functions of such structures.

ABCFI
The ATP-binding cassette family is a fundamental class of proteins that is
conserved across species and widely expressed in human cells. Many of these proteins act
as transmembrane pumps, using energy from the hydrolysis of ATP for active transport of
many different molecules. There are seven distinct classes that have been identified.
ABCF is the sixth class, also known as the GCN20 class (54).
ABCFI, a member of the ABCF class, is also known as ABC27 and ABC50, and
was first identified as a protein that is upregulated in response to tumor-necrosis factor
alpha (TNF-a) (lli). It is found in the cytoplasm and the nucleus, but not the nucleolus.
Unlike other members of the ABC superfamily, ABCF 1 lacks a transmembrane region,
and is not believed to function as a transmembrane pump. Rather, ABCFI has been
shown to playa critical role in protein synthesis and cell proliferation. It forms a complex
with eIF2, GTP, and methionyl-tRNA (the initiator tRNA), and is believed to be critical
to translation, initiation, elongation, and the formation of polyribosomes (106,107). It is a
substrate for phosphorylation by CK2 which affects the formation of the polyribosomes
with eIF2, and thus may act in the regulation of ABCF 1 activity (106).
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Nucleolin
A known generic nucleic acid binding protein. Described above as an identified GC
ODN-binding protein

CONCLUSIONS
With this study, we have identified a number of proteins that bind to our GC ODN
library and C monobasic ODN. Some of these proteins (nucleolin, hnRNP K) are known
to bind to guanine and/or cytosine rich nucleic acid molecules. Others, although known to
bind to different types of nucleic acid, have never before been implicated for these
particular subtypes (Ku, ABCFl). One identified protein (Cd002) has not previously been
reported to bind to nucleic acid. Many of these protein targets are important in a wide
array of biologic functions and have potentially major implications in cellular
proliferation and tumor biology. The use of GC and C ODNs to target these proteins
could therefore further the development of novel aptamer cancer therapeutics.
While we have identified several protein candidates, additional studies would be
required in order to confirm their binding and to test for any role in biological activity.
The most immediate future experiments for the completion of this project involve the
verification of the protein targets identified by mass spectroscopy. We must study
whether or not these protein targets are biologically pertinent by targeting living cells
(both cancerous and non-malignant) rather than purified protein lysate. Cells growing in
vitro would be treated with biotinylated experimental and control ODNs, then lysed and

bound proteins purified via biotin-streptavidin association as before. Following this, we
would perform Western blotting with target-specific antibodies against the proteins
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identified by mass spectroscopy. In this way we could assure that the proteins previously
isolated from the whole cell lysate are indeed targeted by our ODNs of interest within the
context of a living cell and may potentially play a role in their mechanism of action or
lack thereof.
The following step would be to examine the relevance of the identified protein
targets of the GC library to its profile of anti proliferative activity across different cancer
types. We are particularly curious about the GC library's markedly attenuated
antiproliferative activity against the MCF7 breast cancer cell line (manuscript, Appendix
A). An important question to answer is whether or not the proteins of interest are present
in differing levels in the growth-inhibited lung and prostate cancer cells versus the less
responsive breast cancer and virtually unresponsive fibroblast cells. If so, these data
could shed light on the mechanism of the antiproliferative activity of GC ODNs. The
specific experiments would depend on the particular protein target and its pathways, but
could include such classic molecular biology techniques such as analysis of gene
expression, a functional assay if one exists, and gene silencing or upregulation of the
purported target to see if the antiproliferative activity can be modulated.
For example, a possible experimental plan to study the GC library targeting of the
Ku proteins is as follows:
•

Determine baseline levels of Ku70 and Ku80 in untreated DU145, MCF7, and Hs27
cells by Western blotting and/or qPCR. Treat cells with GC 26mer, N26mer, AS1411,
and no ODN, and repeat experiment to determine effect on Ku70 and Ku80
expression.

•

Treat DU145 prostate cancer cells in culture with biotinylated GC 26mer, N 26mer,
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AS 1411, and no ODN. Control cell lines (Hs27 and/or MCF7) may also be employed.
•

Make cell extracts from treated cells and isolate proteins bound to biotinylated ODNs
as before.

•

Perform Western blotting for Ku70 and Ku80 to validate our previous identification
of these proteins and determine variations in extracted protein levels.

•

Decrease and increase expression levels of Ku70 and Ku80 in DU145 cells using
siRNA and expression plasmids (with control molecules)

•

Perform MIT antiproliferative and flow cytometry on these modulated cells to
determine the effect of levels of Ku70 and Ku80 on GC 26mer activity and uptake.
Use appropriate control ODNs and cells.
Another interesting follow-up project would be to determine what specific

sequence(s) within the GC 26mer library bind to these identified GC-binding proteins.
The most logical course is to perform SELEX with the GC 26mer library upon the
identified protein target and isolate unique sequences that bind it. We would screen these
candidate aptamers for high affinity binding to the protein target. The evolved sequences
that are in fact aptamers for our target could then be taken through the same biophysical
and biological studies as for the parent library to determine the antiproliferative activity,
structure, stability, cellular uptake, and protein binding of these new potential
therapeutics.
A final possible study could be to test the G-rich GC 26mer library in comparison
with the G-rich GT library for whole cell SELEX. It would be interesting to compare the
candidate aptamers evolved from the GC library versus both the classic N library and the
GT library. Outcomes could include the speed (i.e. number of SELEX cycles) with which
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candidate aptamers are identified, location and prevalence of guanines within the
candidates, and increases in cellular uptake and antiproliferative activity relative to the
parent libraries. Given the attenuated activity of the GC library in breast cancer cells, one
could argue that GC aptamers are therefore ill-suited for SELEX to find aptamers specific
for that tumor type. However, the partial anti proliferative activity of the GC library
against that cell line suggests that it does indeed contain sequences that inhibit the growth
of those cells. Perhaps the GC library contains more potential anti-breast cancer
sequences than the N library, but fewer than the GT library. We could perform whole cell
SELEX with these three libraries on breast cancer cells to study how the antiproliferative
activity of the parent library affects the SELEX outcomes.
With the data we have generated from this project involving ODN libraries
(Chapters 2 and 3), there are a plethora of possible experiments we could perform that
would help elucidate the nature of G-rich libraries, G-rich ODNs, proteins that bind to
them, and their mechanisms of action. We decided instead to refocus our efforts on the
specific aims of this project and attempt the generation of new anti-prostate cancer
aptamers.
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CHAPTER 4
IDENTIFICATION OF A NEW ANTI-PROSTATE CANCER
APTAMER BY SELEX

INTRODUCTION
Therapeutic applications of aptamers
The field of aptamers (oligonucleotides that form specific three-dimensional
structures and have target-binding specificity) is new and largely untapped. In terms of
clinical use, aptamers could potentially be used in a multitude of ways: as imaging
agents, as vectors for the targeted delivery of drugs, as histology stains for tissue
specimens, and as bona fide pharmaceuticals. Relative to monoclonal antibodies,
aptamers are inexpensive and simple to manufacture. Relative to small molecule drugs,
they are target-specific and because of this have few side effects. Aptamers are more
easily modified than either of these two other classes of drugs such that the development
of one target-specific aptamer could easily result in more than one application simply by
the affixation of different molecules; an aptamer that binds to cancer cells could both be
tagged with a radionuclide for use in tumor imaging and be conjugated to a drug with
poor tumor specificity resulting in targeted delivery of that drug:

Aptamers as chemotherapy
We believe there is immense potential in the development of new aptamers for
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clinical use, especially in the management and treatment of cancer. Chemotherapy
regimens are notoriously difficult for cancer patients to tolerate. The side effects of these
treatments can be so debilitating that doses must be limited to less than the recommended
therapeutic level with correspondingly less anticancer efficacy. Consideration for
nonspecific toxicities is particularly important in patients with poor reserves, such as
those who are elderly or have other comorbidities (e.g. obesity, heart failure, chronic
obstructive pulmonary disease, high blood pressure). In today's aging and increasingly
inactive American society, an ever higher percentage of patients are clinically
compromised in these ways. Physicians, patients, and patients' caretakers together must
consider the impact of chemotherapy on the patients' quality of life versus any possible
extension of life, and strike a careful balance between maximizing the treatment for the
malignancy while keeping the side effects to a tolerable level.
Even when the recommended doses of chemotherapy are able to be administered,
there remains much room for improvement in the generally poor efficacy of most
chemotherapy regimens. For example, almost half of young patients with early stage
breast cancer (age less than 50 years; disease restricted to the breast and locoregional
lymph nodes such that surgery can be curative) will die from their malignancy within
fifteen years. Adjuvant chemotherapy has been shown to decrease the likelihood of
recurrence in these patients, but there has been only a modest effect on overall survival
(42.4% vs. 32.4% mortality at 15 years). The effect is even less robust in older patients
(50-69 years old; 50.4 vs. 47.4% mortality at 15 years) (108). For metastatic castration
resistant prostate cancer (CRPC), two landmark clinical trials reported a significant
increase in survival with docetaxel in 2004. The findings were so compelling that the
45

standard of care for CRPC was quickly revised to incorporate the new data. While any
improvement in overall survival is good news, the sad fact remains that even this high
profile, high impact result translates to an increase of only 2-3 months of life (18.9
months vs. 16.4 months)

(1,~).

Three new drugs for the definitive treatment of metastatic

CRPC have been approved in the last year, each of which may confer an additional few
months' survival (§). These drugs provide important further opportunities for CRPC
patients, but it is clear that although progress is being made, we must strive for even
greater advancements in the treatment of patients with cancer.
The goals in the development of new cancer drugs must therefore be twofold: first
and foremost, treatments should positively and significantly impact patient survival.
Second, treatments must have tolerable side effects that have been minimized as much as
possible. Aptamer drugs may be particularly well suited to meet these two criteria. In
terms of efficacy, aptamers may be engineered against virtually any target, including any
identified tumor specific antigen. If such an antigen is truly a valid target in the treatment
of cancer, an aptamer that is able to be delivered to that target and specifically bind it will
be a valuable pharmaceutical tool. Aptamers also typically have very few side effects,
likely for multiple reasons including target specificity, lack of immunogenicity, small
size, and rapid systemic clearance. In clinical trials, aptamers consistently exhibit large
therapeutic windows and comfortable safety margins (11, 109, 11 0). The Phase I clinical
trials of AS 1411 were remarkable not only for the tumor regression seen in multiple
patients, but also for the virtual absence of major adverse events such that no maximum
tolerated dose (the dose at which toxicities are no longer acceptable) was seen; in other
words, all the patients were easily able to tolerate even high doses of AS 1411 (11JID.
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Selective evolution of ligands by exponential enrichment (SELEX) on whole prostate
cancer cells
As discussed in Chapter 1, aptamers have an additional advantage over both
antibodies and small molecules (i.e. traditional classes of chemotherapy) in that they may
be engineered to bind specific targets with relative ease. The most powerful aptamergenerating technology is SELEX, an iterative and evolutionary method to screen large
pools of billions of different sequences for aptamers that specifically bind a target of
interest (for a more detailed description of the basic SELEX methodology, see Chapter 1,
Figure 1). Many features of SELEX may be fine-tuned by the user. For example, the
lengths of the variable and the primer-binding regions may be adjusted as shorter
aptamers are less expensive to manufacture. It has also been postulated that minimizing
the lengths of the primer regions reduces non-specific binding and experimental artifact
(111). For the critical step of purification of single-strand molecules from the PCR
product, different methods have been described including asymmetric PCR, biotinylated
primers and streptavidin beads or fixed matrix, gel electrophoresis, and lambda
exonuclease digestion, each with different advantages and disadvantages (112).
In the years since its inception in 1990, a plethora of major variations of the basic SELEX
procedure have been developed (113):
Library modifications
•

Tailored SELEX - To reduce primer-based artifact, primer binding regions are ligated
to primerless ODNs before the PCR reaction, then removed from the amplified
product before the next round of selection (114, 115).
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•

Genomic SELEX - To identify endogenous RNA aptamers and the proteins that bind
to them, the starting library is based upon the genome of the organism of interest.
This method can identify protein-binding RNAs and elucidate significant nucleic acid
regulatory pathways (116, 117).

Separation of bound versus unbound ODNs
•

Capillary electrophoresis (CE) SELEX - Sequences that bind the target of interest
experience a motility shift which is exploited during the separation of bound versus
unbound ODN s using capillary electrophoresis (118-120).

•

Micromagnetic separation (MMS) SELEX - Disposable microchips with large
magnetic field gradients are used to separate sequences bound to targets affixed to
magnetic beads (121, 122).

•

Monolex - ODNs are passed through an affinity column and sorted into unbound, low
affinity and high affinity fractions. The fraction containing the highest affinity
sequences are amplified once and tested (123).

Types oftargets (124)
•

Counter SELEX - Many targets are only subtly distinguishable from a related
counterpart (e.g. disease prion protein vs. endogenous prion protein, ATP vs. ADP).
To increase target-specificity, the ODN pool is applied to the negative target to
remove sequences that are able to bind to this undesired target. Unbound ODNs are
recovered and then applied to the positive target (125, 126).

•

Toggle SELEX - The ODN pool is applied to different protein targets in alternation,
for example human vs. murine epitopes, to select for aptamers that will have crossreactivity (127).
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•

Cell-SELEX - Discussed in greater detail below.
Cell-SELEX, the variation that may prove particularly relevant for the generation

of clinically useful aptamers, involves the nature of the target. Rather than using a
purified molecule as the substrate upon which the ODN library is applied, the target is
whole cells in culture (128-130). Both prokaryotic and eukaryotic cells have been
targeted. The method of cell-SELEX has the advantage of applicability; instead of
targeting a molecule that mayor may not ultimately prove to be clinically useful, the cell
itself is targeted. With proper selection, the evolved aptamers are able to bind target cellspecific antigens. It is not necessary to know the identity of the antigen; indeed, cellSELEX may very well result in the identification of a novel biomarker. Moreover, the
aptamers are selected to bind the antigens in their native configuration in their natural in
situ environment. Experiments may be performed in serum-containing cell-culture

medium such that sequences are automatically selected for nuclease resistance as well as
target specificity. Cell-SELEX has been used to identify aptamers that bind to such
targets as S. aureus bacterium, T. brucei parasite, influenza virus, endothelial cells,
leukemia cells, and glioblastoma cells (1.2, 125, 130-132).
We have undertaken two particular innovations to the cell-SELEX technique. The
first is to amplify only those sequences internalized by the cell as opposed to simply
binding to the cell surface. The overall objective of this project is to develop new targeted
aptamers specific for the treatment of prostate cancer, and the major goal of this portion
of the project is to identify aptamers that are efficiently able to enter prostate cancer cells.
One of the major hurdles of nucleic acid therapies of all types is poor cellular uptake.
Although aptamers don't necessarily require uptake in order to function, any aptamer
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than binds an intracellular target requires a mechanism to cross the cell membrane. An
exciting potential utility for aptamers with naturally high levels of intracellular uptake is
as vehicles for other drugs with poor uptake, including almost all other oligonucleotide
therapies (antigene, antisense, RNA silencing, and transcription decoy strategies,
discussed in Chapter 1). For therapies that do not require a vector to become internalized,
a targeted aptamer that is able to achieve high levels inside a cell may still enhance their
delivery and result in higher cellular concentration. Additionally, should the aptamer be
cancer-selective, then the appended drug need not be. Identification of cancer-selective
aptamers with high levels of cellular uptake may thus both allow the introduction of
molecules that are limited by uptake and confer specificity to molecules that lack it.
Rather than identifying aptamers against prostate cancer cells and then modifying them
downstream to enhance cellular uptake, we propose to let evolution determine from the
start which of the millions of sequences within the library are most able to enter the cells.
We describe our protocol for isolating only the internalized sequences in some detail
below, including verification that we discarded both the unbound ODNs from the cell
media and the ODNs bound to the cell surface.
Our second SELEX innovation is to test our GT library in parallel with the classic
random N library. By starting with a library that is smaller (i.e. contains fewer different
sequences) and is already enriched in molecules that can form G-quadruplexes with the
desirable characteristics of thermal stability, antiproliferative activity, nuclease resistance,
and enhanced cellular uptake, we hypothesized that the SELEX procedure would be more
efficient and require fewer cycles before aptamers sequences can be isolated, and that the
resultant aptamers would be less likely to require chemical modifications for clinical use.
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MATERIALS AND METHODS
Oligodeoxynucleotides

Oligonucleotides were purchased from Integrated DNA Technologies, Inc. (Coralville,
IA) or from Invitrogen (Carlsbad, CA):
•

N library

(5' - GCG TCA TCA TCG GCT T (Nh6 ACG ACG ATA CTC

ACG AGC - 3') where N has equal probability of being A, C, G, or T
•

GT library

(5' - GCG TCA TCA TCG GCT T (K)26 ACG ACG ATA CTC

ACG AGC - 3') where K has equal probability of being G or T
•

5' primer

(5'-GCGTCA TCA TCG GCTT-3')

•

3' primer

(5' - GCT CGT GAG TAT CGT CGT- 3')

•

N cap (5' - ACT ACG GAG GGG CTA GAG CAA CAA GT - 3')

•

N 60cap

( 5' - GCG TCA TCA TCG GCT TAC TAC GGA GGG GCT AGA

GCAACAAGT ACG ACG ATA CTC ACG AGC - 3')
•

N 26mer

(5' - (Nb - 3') where N has equal probability of being A, C, G, or

T
•

GTcap

(5' - GGG TGG GGG TGT TGG GTG ITG GTT TG - 3')

•

GT60cap

(5' - GCG TCA TCA TCG GCT TGG GTG GGG GTG ITG GGT

GTT GGT TTG GCT CGT GAG TAT CGT CGT - 3')
•

GT 26mer

(5' - (Kb - 3') where K has equal probability of being G or T

•

AS1411

(5'-GGTGGTGGTGGTTGTGGTGGTGGTGG-3')

Lyophilized libraries were resuspended in filtered-sterilized water, then heated at 65°C
for 10 minutes and vortexed vigorously to dissolve. For uptake studies, three thymidine
bases (TTT) were added to the 5' end of the library sequence to avoid quenching the 5'
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fluorophore (FAM for flow cytometry and Alexa 488 for confocal microscopy), which
occurs when immediately proximal to a G-quartet (37).

Cells
Four cell lines were used in this study: PC3 and DU145 prostate adenocarcinoma, A549
lung adenocarcinoma, and Hs27 non-malignant skin fibroblasts. All cell lines were
acquired from ATCC. Cells were grown in complete cell culture medium of F-12K (for
PC3) or DMEM (for all others) supplemented with 10% heat-inactivated (15 minutes at
65°C) FBS and 1% penicillin/streptomycin. All cells were cultured at 37°C in 5% C02.

SELEX, selecting for sequences internalized by whole cancer cells
In a 6-well tissue culture plate, 4 x 105 PC3 prostate cancer cells per well were
plated in a volume of 1.2 mL complete medium and incubated overnight. For the first
round of SELEX on the following day, the medium was removed, fresh complete cell
culture medium was added, and ODN library synthesized with primer binding regions (N
library, GT library, or no library) was added to a final concentration of 10 f.lM. Cells were
incubated with the ODN library for one hour, then washed with PBS to remove any
unbound ODNs. The cells were harvested by scraping in PBS, spinning down, and
removing the supernatant. To strip away surface proteins and any surface-bound (i.e. not
internalized) ODNs, cells were incubated with 0.5 mL of glycine-HCI (pH 5.0) for 5
minutes. Cells were washed thrice with PBS, and finally incubated overnight at 55°C with
Proteinase K (0.1 mg / mL, Invitrogen) in PK buffer (15 mM Tris-HCI, (pH 8.0), 50 mM
KCI, 2.5 mM MgCh, 0.5% Tween 20)). The following day, samples were spun down to
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pellet cell debris and the cell lysate supernatant transferred to fresh tubes, completing the
first round of SELEX.
In preparation for the second round, the lysate was used as template for PCR to
amplify the internalized sequences. PCR reaction tubes were set up using a PCR
supermix containing enzyme and dNTPs (Invitrogen). In order to produce an excess of
ssDNA product, the primers corresponding to the ODN libraries' primer binding regions
were added at a ratio of 20: 1 (4 )lM vs. 200 nM). The deficient primer was manufactured
with a biotin tag for subsequent removal of dsDNA species from the PCR product. Five
IlL of lysate or water for negative control were added last. The PCR program began with
2 minutes at 94°C before going through 25 cycles of 25 sec at 94°C, 25 sec at 55°C, 30
sec at

noc.
To separate dsDNA from the PCR product, samples were combined with magnetic

streptavidin beads (Thermo Scientific) for one hour. The supernatant containing unbound,
unbiotinylated, ssDNA PCR product was removed to fresh tubes. Approximately one
tenth of this purified product (5 IlL) was added to new cells for the subsequent round of
SELEX. The remaining cell lysate was stored at -20°C.

Radioactive peR to detect effectiveness of final wash before lysis
To ensure that we enrich the sequences that have been internalized by the cells, we
performed PCR to detect ODNs in the cell culture medium after the addition of ODN, in
the final wash before lysing the cells, and in the cell lysate. The PCR reactions were set
up as described above with the addition of 2 microcuries of radio labeled guanine
nucleotide ([a)2P]-dGTP). Unincorporated nucleotide was removed with TE-Midi
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SELECT-D G-25 columns (Shelton Scientific, Shelton, CT) according to manufacturer's
directions, then electrophoresed on denaturing 12% polyacrylamide gels. Gels were
exposed to film overnight at -80°C and the films developed the following day.

Sequencing and selection of candidate aptamers

To identify internalized sequences from each round of SELEX, a portion of the SELEX
cell lysates were used for sequencing. PCR reaction tubes were set up using a PCR
supermix containing enzyme and dNTPs (Invitrogen), SELEX primers (not biotinylated;
Integrated DNA Technologies) at a final concentration of 200 nM each, and 5 )..lL of
lysate or water for negative control. The PCR program was as described for SELEX with
the addition of a final step of 10 minutes at

n°c. The PCR reactions were used directly

for cloning using a TOPO vector cloning kit (Invitrogen) according to manufacturer's
direction and transforming into chemically competent E. Coli. Colonies containing the
plasmid with the PCR product insert were selected for ampicillin resistance and identified
by loss of j3-galactosidase function in X-gal screening. Plasm ids from positive colonies
were purified using a vacuum manifold 96-well high-throughput miniprep system
(QIAGEN QIAprep Spin Miniprep Kit) according to manufacturer's direction which
yielded approximately 250 ng/)..lL of plasmid per sample. Plasmids were sequenced at the
University of Louisville Center for Genetics and Molecular Medicine Nucleic Acid Core
facility. Approximately twenty sequences were identified from each round of SELEX.
Sequences were organized by SELEX round, and analyzed for increasing prevalence of
sequences and/or motifs of nucleotide bases across multiple rounds.
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Cellular uptake of candidate aptamers
Flow cytometry

Uptake experiments were performed with the two candidate aptamers (N cap and GT cap)
versus the respective parent libraries (N 26mer and GT 26mer). All ODNs were labeled at
the 5' end with FAM (6-carboxyfluorescein). Four cell lines were studied (PC3, DU145,
A549, and Hs27). For each sample, 4 x 105 cells were plated and incubated overnight.
The following day, FAM-Iabeled ODNs were added to make a final concentration of 10
~M

and plates were incubated for one hour. The medium containing unbound ODN was

removed. Cells were washed thrice and treated with trypsin or TrypLE (Invitrogen) to
remove surface-bound oligonucleotides and to harvest cells. Cells were kept on ice and
protected from light until analysis. Propidium iodide (2

~g

per sample) was added as a

marker of viability. Ten thousand cells were counted after gating to exclude PI-positive
(non-viable) cells from analysis. Cells were analyzed using a FACScan cytometer. The
mean fluorescence of cells for each sample was determined using the FlowJo software
program.

Confocal microscopy

Three ODNs samples were manufactured with conjugated Alexa 488: N 26mer, GT
26mer, and GT cap. Thirty thousand PC3 cells were plated in each chamber of fourchambered microscopy slides and incubated overnight. The following day, Alexa 488
ODNs were added to a final concentration of 10

~M

and incubated at 37°C for 2 hours.

Cells were washed thrice, fixed with 4% paraformaldehyde for 25 minutes, and washed
thrice more. Coverslips were applied to chambers with a drop of Antifade containing
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OAPI (Millipore). Cells were analyzed by confocal microscopy using a LSM 510
inverted confocal laser scanning microscope (Carl Zeiss).

Quantitative peR of lysa tes of cells exposed to ODNs

PCR requires the use of primer binding regions. Therefore, candidate aptamers
were ordered as 60mers (N 60cap, GT 6Ocap) comprised of the captamer sequence (N cap
or GT cap) with flanking primer binding regions as for the parent 60mer OON libraries.
To prepare cell Iysates for qPCR analysis for OON uptake: In a 6-well tissue
culture plate, 4 x 105 PC3 prostate cancer cells per well were plated in a volume of 1.2
mL complete medium and incubated overnight. On the following day, the medium was
changed and OONs added (N 60mer, N 60cap, GT 60mer, or GT 60cap) to a final
concentration of 10 ).lM. Cells were incubated with the OON library for one hour, then
washed with PBS to remove unbound OONs. The cells were harvested by scraping in
PBS, spinning down, and removing the supernatant. To strip away surface proteins and
any surface-bound (i.e. not internalized) OONs, cells were incubated with 0.5 mL of
glycine-HCI (pH 5.0) for 5 minutes. Cells were washed thrice with PBS, and finally
incubated overnight at 55°C with Proteinase K (0.1 mg / mL, Invitrogen) in PK buffer (15
mM Tris-HCI, (pH 8.0), 50 mM KCI, 2.5 mM MgCb, 0.5% Tween 20)). The following
day, samples were spun down to pellet cell debris and the cell lysate supernatant
transferred to fresh tubes.
For the qPCR reactions, Iysates were prepared at six ten-fold dilutions (neat 1: 105) and plated in triplicate with appropriate negative controls in a 96-well qPCR plate.
Reactions were set up using a 2x SYBR PCR master mix (Applied Biosystems)
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according to manufacturer's directions. Samples were run on an Applied Biosystems
7500 Real-Time PCR System machine.

Mechanistic studies of candidate aptamers (GT cap and N cap)
MTT anti-proliferative assay

The candidate aptamers and their parent libraries were tested in triplicate at eight
concentrations (0, 2, 4, 6, 8, 10, 12, 14 11M) in four cell lines: PC3, OU145, A549, and
non-cancerous Hs27. We modified previously published MTT [3- (4,5-0imethylthiazol2-yl)-2,5-diphenyltetrazolium bromide] assay protocol (16). Briefly, cells were seeded in
96-well tissue culture plates and incubated overnight. To account for intrinsic differences
in growth rate, the A549 and OU145 lines were plated at 1000 cells per well, PC3 at 2000
per well, and Hs27 at 3000 per well. OON stock solutions were then added to each well
to yield the desired final concentration. Plates were incubated with the OON for five
days, during which the cell culture medium was not changed. On day five, cell viability
was determined and the background corresponding to medium alone (no cells) was
subtracted. For each concentration, the average of the three wells was calculated and
plotted. Assays were repeated to ensure reproducibility.

Circular dichroism spectroscopy

Candidate aptamers and their parent libraries were diluted to a concentration of 5 11M in
1.5 mL of either water, or 100 mM sodium chloride, or 100 mM potassium chloride.
Samples were incubated at 95°C for 5 minutes, then cooled on ice until analysis. CO
spectra were collected at 20°C using a Jasco J-715 spectropolarimeter between 340 and
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220 nm wavelengths, using 200 nm/min scanning speed, 2 s response time, 5 nm
bandwidth, and 1 cm pathlength. For each set of samples, the same solution used to
prepare the ODNs was used as the reference.

Protein binding to whole cell lysate using electromotility shift assay (EMSA)

Candidate aptamers were tested in comparison with their parent libraries. Each ODN was
5'-end-Iabeled with

32 p

using T4 kinase (Invitrogen). Unbound isotope was removed

from samples using TE-Midi SELECT-D G-25 columns (Shelton Scientific, Shelton, CT)
according to manufacturer's directions. Collection tubes containing end-labeled libraries
were kept on ice, or stored at -20°C for up to one day. The radioactivity of end-labeled
libraries was measured in a scintillation counter on the day of the experiment. Whole cell
Iysates from PC3 cells were prepared as follows: Cells were grown till confluent, then
washed and scraped with HEDG buffer (20 mM HEPES-NaOH, pH 7.8, 0.5 mM EDTA,
0.5 mM dithiothreitol (DTT)) containing 10 % glycerol, Ix protease inhibitor cocktail
(Sigma, st. Louis) and 0.42 M NaCI at a ratio of 100 f.lL per 75 cm2 culture area. The
solution was harvested and subjected to three freeze-thaw cycles (liquid nitrogen versus
room temperature). Samples were centrifuged at 16,000 x g at 4°C for 45 minutes to
pellet cell debris. An equal volume of HEDG with glycerol and protease inhibitor but
without NaCI was added to reach a final concentration of 0.21 M NaC!. Fifty thousand
cpm of radiolabeled-ODN were combined with 2.5 f.lg of cell extract and 5x protein
binding buffer (Ix is 20 mM Tris-HCI, pH 7.4, 140 mM KI, 2.5 mM MgCh, 1 mM
dithiothreitol, 0.2 mM PMSF [phenylmethylsulfonyl fluoride D. Samples were incubated
at 37°C for 15 minutes, then run on a 5% non-denaturing polyacrylamide gel. The gel
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was fixed in a solution of 10% (v/v) methanol + 10% (v/v) glacial acetic acid in water for
10 min at room temperature, then exposed to a storage phosphor screen for 2 hours at
room temperature before scanning.

Nuclease-resistance in serum-containing medium and PC3 cytoplasmic extract

Four ODN samples were studied: N 26mer, N cap, GT 26mer, and GT cap. The ODNs
were 5'-end-Iabeled with

32 p

using T4 kinase (Promega) and unincorporated

y_32 p _ATP

was removed from samples using TE-Midi SELECT-D G-25 columns (Shelton Scientific,
Shelton, CT, USA) according to manufacturers' directions. Collection tubes containing
end-labeled samples were stored at -20°C. The radioactivity of end-labeled samples was
measured in a scintillation counter on the day of the experiment. For each ODN or library
to be tested, four reaction tubes containing complete cell culture medium without
antibiotics and four reaction tubes containing 2.5 ).lg PC3 cytoplasmic extract in DMEM
were prepared. Fifty thousand counts per minute of end-labeled ODN were added to each
of four tubes. Samples were incubated at 37°C, and tubes were flash-frozen in a dry
ice/ethanol bath at 0, 1, 4 and 24 h. Frozen samples were stored at -80°C until all samples
had been harvested. Samples were then thawed on ice and run on 12% denaturing
polyacrylamide gels. Band density was measured using the UN-SCAN-IT gel
densitometry application (Silk Scientific, Orem, UT, USA). The percent sample
remaining was calculated taking the signal of the zero time point lane to be 100%.

RESULTS AND DISCUSSION

Radioactive peR indicates success of washes and isolation of internalized ODNs
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Our goal was to isolate aptamers that were efficiently able to enter the cell. Our
cell-SELEX protocol must therefore include not only washing unbound ODNs away from
the prostate cancer cells, but also stripping away any surface bound molecules. Different
methods have been employed for this purpose. At the beginning of this project, we tested
both the glycine method described above (harvesting cells by scraping and treating with
glycine HCl) and a standard trypsin digestion to both digest surface epitopes (along with
any bound ODNs) and resuspend the cells. An initial round of cell-SELEX was
performed and the final wash and the cell lysate from both methods tested by radioactive
PCR for the presence of ODNs. Samples were run on denaturing polyacrylamide gels
(Figure 1). A detectable band was amplified from the cell lysate but not the final wash for
the samples from the glycine-treated cells, indicating that ODNs were present in the cell
lysate after removing cell debris, and that the washing process was effective at removing
all detectable ODNs after incubation with glycine. The converse was true for samples
from the trypsin digest, indicating the presence of ODNs in the final wash and a dearth of
ODNs in the cell lysate. A possible reason for these data is that that the trypsin
permeabilizes the cells such that internalized ODNs are able to leak out, thus increasing
the amount of amplifiable ODNs in the wash and decreasing the amount in the lysate. We
concluded that the trypsin digest was not optimal for our purposes, and utilized the
glycine stripping method for the isolation of internalized aptamers using the cell-SELEX
procedure.

Candidate aptamers identified from both the N library and the GT library

On the order of 20 samples from the cell lysates of each round of SELEX were
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glycine

trypsin

26 bp-

Figure 1: Radioactive PCR of final wash and lysate. In optimizing our
SELEX protocol to select for internalized ~ONs, we tested two different
methods to strip away surface-bound molecules (glycine vs. trypsin) . The final
wash after stripping was clean of OONs for the glycine strip, but not for the
trypsin. The crude cell lysate contained detectable ~ONs for the glycinetreated cells, but not the trypsin-treated cells.

Rd 2

Rd 1
(

'1(

Rd 3
'1(

Rd 4
'1(

'I

26 bp-

Figure 2: Radioactive PCR from sequential rounds of SELEX. In round
one, a 26mer band (the length of the OON starting library) was detectable in
the cell culture media after adding the OON library, and in the cell lysate after
1 hour incubation. In later cycles, bands of much higher molecular weight
were strongly present while the 26mer band was undetectable. These data
suggest the production of experimental artifact with subsequent cycles.
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sequenced, yielding a long but by no means exhaustive list of ODNs (Appendix B). As
expected, in the first two rounds of SELEX for the N library there were few sequences
that appeared more than once, implying that many more ODN species were present that
were not selected for sequencing, and that no particular sequence was yet enriched. We
were surprised to see some sequences repeated from multiple bacterial clones as early as
round 3, indicating that those sequences were becoming more prevalent in the ODN pool.
By rounds 4 and 5, the N library candidate aptamer (N cap: 5' - ACT ACG GAG GGG
CTA GAG CAA CAA GT - 3 ') was virtually the only 26mer that was present.
It was more difficult to identify candidates from the GT library; as every sequence
is made of combinations of G and T bases, patterns of bases are more inscrutable. We
identified some common base motifs among the sequences that appeared to become
enriched over subsequent cycles. From these, we composed a candidate aptamer (GT cap:
5' - GGG TGG GGG TGT TGG GTG TTG GTT TG - 3'). These two candidate
aptamers, N cap and GT cap, were characterized using the same panel of assays we
utilized for our ODN libraries study and tested for our SELEX selection criterion of
enhanced cellular uptake in comparison with the parent libraries.
As N cap was the only candidate seen with the N library SELEX by round 5, we
discontinued further SELEX cycles for both libraries. For both the N and the GT SELEX,
we noted some obvious artifacts. An example includes an approximately 400 base
sequence that evolved clearly in a textbook SELEX manner, becoming increasingly
prominent with subsequent rounds (Appendix B, Round 3, Sequence 2). There were no
obvious difference in either frequency or size of artifacts between the Nand GT SELEX.
Radioactive PCR was performed with media, final wash, and lysates from sequential
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rounds of N library SELEX (Figure 2). Bands at the 26mer location were seen in the
media and lysates for the first two rounds, but from round 3 onward we observed several
bands of much higher molecular weight in all samples. The smaller 26mer band was not
seen, and we postulate that the larger molecular weight species are preferentially
amplified resulting in loss or obscuration of the 26mer species. This could explain the
relative lack of 26mers in the cell lysates as identified by sequencing. The denaturing gel
data are largely consistent with the sequencing data.

Candidate aptamers do not exhibit enhanced cellular uptake as compared to parent
libraries
Consistent with the SELEX literature, we initially focused our studies on our
candidate sequences without the primer binding regions. We acquired the candidates and
their parent libraries without the primer binding regions and with FAM-fluorophore
tagged at the 5' end: N cap, GT cap, N 26mer, and GT 26mer. To avoid quenching, we
added three thymidine bases at the 5' end between the sequence of interest and the
fluorophore for all four OON samples. This modification has previously been shown to
have no effect on anti proliferative activity for AS 1411 and is standard operating
procedure in our laboratory. PC3 prostate cancer cells were treated with these OONs and
then subjected to flow cytometry. To our chagrin, we did not see any enhancement in
fluorescence with the candidate aptamers relative to their parent libraries (Figure 3A). We
repeated the experiment using other cell lines (OU145 prostate cancer, A549 lung
adenocarinoma, and Hs27 non-malignant fibroblasts). We also ordered fluorescent
libraries and candidate aptamers synthesized with the primer binding regions, reasoning
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Figure 3: Cellular uptake of FAM-Iabeled oligodeoxynucleotides.
A) Mean fluoresence in PC3 prostate cancer cells. No enhanced
uptake seen by candidate aptamers. 8) Confocal microscopy of PC3
cells. GT cap has less fluorescence than parent library. C)
Fluorescence of OON stocks alone show a high degree of variation. 0)
Cellular uptake as measured by corrected mean fluorescence in
different cell lines. Correction factor based on relative fluorescence of
OON stock samples . Candidate aptamers have higher uptake than
parent libraries in all cell lines. GT samples have higher fluorescence
than N samples. Pilot experiment performed once with no statistical
analysis.
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that the candidates' selection was performed with these additional bases and that perhaps
the primer binding regions are required for cellular uptake. Even with these additional
attempts, we were still unable to demonstrate enhanced cellular uptake (data not shown).
We also performed confocal microscopy with the fluorophore-tagged 29mer libraries and
GT cap (N cap was omitted due to consideration of cost and our particular interest in Grich ODNs), and again did not observe any enhanced activity (Figure 3B). Relative to its
parent library, the GT cap sequence actually appeared to have decreased internalization as
visualized by fluorescence.
We then examined the ODN stocks themselves. We observed a confounding
difference in the relative fluorescence of the commercial ODN stock solutions even
before applying to cells in culture (Figure 3C). In other words, some ODN stocks were
inherently more fluorescent than others. This difference in relative fluorescence was most
pronounced in the GT cap sample and could be due to multiple reasons including varying
degrees of quenching of the fluorophore by higher order structures of the ODNs or
simply to differences in coupling efficiency during synthesis. To correct for this, in
parallel with the flow cytometry experiment, FAM-Iabeled ODNs were added in triplicate
to a 96-well plate containing cell culture medium to make a final concentration of 10 11M
and incubated for one hour. The relative fluorescence of the samples was measured, and
applied as correction factors to the measured mean fluorescence observed by flow
cytometry (Figure 3D). When this method of data analysis was utilized, there was in fact
enhancement of cellular uptake seen with GT cap relative to the GT 26mer parent library.
This enhancement was not exclusive to the PC3 cells, but was most marked in this line. N
cap also had a modest degree of enhancement relative to the N 26mer library in all four
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cell lines. These data were consistent with MTT data from experiments performed in
parallel (described below), and indicated that our SELEX protocol did indeed evolve
aptamers with cellular uptake and that this uptake correlated well with the degree of
enhancement of antiproliferative activity seen with the candidate aptamers relative to
their parent libraries.
We therefore attempted to standardize both fluorescence and ODN concentration
by measuring fluorescence before treating cells, ensuring that cells were treated with the
same amount of measured fluorescence (E530

=

100,000), then standardizing the ODN

concentration by adding unlabeled ODN as needed to a final concentration of 10 f..lM.
Unfortunately, with this method we were again unable to show enhanced cellular uptake
by our candidates (data not shown).
An alternate method to show cellular uptake of aptamers that does not require
fluorescent ODNs is quantitative PCR. Cells were treated with candidate aptamers and
their parent libraries, all necessarily with the primer binding regions affixed (i.e. 60mers).
Cell lysates were prepared, and the lysates used as template in a range of dilutions for
quantitative PCR using the SYBR green technology. With this protocol, sequences
internalized by the cell should amplify, and a higher number of ODNs in the lysates
should require fewer PCR cycles before the SYBR green signal exceeds the background
threshold. Despite multiple attempts, we were unable to get reproducible data (data not
shown). One replicate showed increased levels of ODN in the lysates of cells treated with
GT cap relative to those treated with the GT library, but other replicates showed no
difference between the samples. Other molecules within the cell lysate may have
disrupted the PCR reaction. We reasoned that with increasing dilutions (1 part lysate in
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105 parts water), any disrupting molecules would become so sparse as to be essentially
absent, but in retrospect perhaps the lack of reproducibility was due to this factor. For
further attempts one should consider the purification of ODNs from the crude cell lysate.
However, we did not undertake this task because of the unavoidable issue of the primer
binding regions. The qPCR required the use of the primer binding regions in order to
amplifY the ODNs in the template sample. This may ablate any enhanced uptake of the
candidate aptamers. We have performed anti proliferative MIT assays using our candidate
aptamers with primer binding regions and found the GT cap had cancer-selective
antiproliferative activity only without these regions (data not shown). We therefore
concluded that the aptamer sequence is in fact the 26mer, not the 60mer, and did not
further optimize this qPCR assay which would require the primer binding regions.
In summary, despite employing a number of methods, we were unable to
consistently demonstrate enhanced cellular uptake by our candidates.

GT cap selectively inhibits the growth of cancer cells with greater potency than the
GT library
In parallel with the

cellular uptake

experiments, we

also

undertook

characterization of the candidates with the assays described in our ODN libraries
manuscript (Appendix A). To assess antiproliferative activity we employed the MTT
assay. We did not necessarily expect any enhancement in antiproliferative activity in our
candidates relative to the parent libraries, but believed that the GT cap would likely have
cancer-selective antiproliferative activity as its parent library does, while the N cap, as a
non-G-rich sequence from a non-G-rich library, would not. A difference in
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antiproliferative activity with GT cap versus N cap would illustrate the possibility of
different utilities for two ODN libraries in SELEX: 1) starting with a GT library and
selecting for cellular uptake to identifY aptamers that may be used as cancer drugs by
entering cells and haIting their growth, or 2) starting with the N library and selecting for
cellular uptake to identifY aptamers that may be used as vehicles but have no intrinsic
anticancer activity oftheir own.
We tested our ODNs on four different cell lines: two prostate cancer, one lung
cancer to study organ specificity, and one non-malignant fibroblast to study cancer
selectivity (Figure 4, A-D). Consistent with the SELEX literature, we focused our studies
on our candidate sequences without the primer binding regions (N cap and GT cap). The
two parent libraries without primer binding regions (N 26mer and GT 26mer) and
AS1411 were included for comparison. As before (Chapter 2), to illustrate the relative
activities of the samples, we tabulate the percentage reduction in cell number at 6 f.lM
oligonucleotide concentration (Figure 4E). For stratification, we consider a reduction of
30-50% as intermediate antiproliferative activity, and greater than 50% as high.
We observed an enhancement of antiproliferative activity with the N cap sequence
relative to the N library in the PC3 cells (28% versus 9% growth inhibition respectively).
While the change in activity is substantial, the N cap sequence still had only a modest
absolute effect. Additionally, the antiproliferative effect of the N cap ODN in the nonmalignant fibroblast line was comparable to the effects seen in the prostate cancer cells.
Both the N cap and the N library had negligible effects on the growth of the lung cancer
cells which may imply a degree of specificity for prostate cancer cells. We conclude that
the N cap has only minimally enhanced antiproliferative activity over the parent library.
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In contrast, the GT cap sequence exhibited a substantial inhibition of cell
proliferation that was more potent than the parent library for both prostate cancer cell
lines. The fold-change was most pronounced in the PC3 cells that were used as the target
of the SELEX protocol (3-fold for PC3 versus 2-fold for DUI45). Despite selecting our
GT candidate using prostate cancer cells, the antiproliferative effect was not limited to
that organ; a similar observation was made upon testing our ODNs on lung cancer cells.
Though the GT cap had the highest absolute inhibition of proliferation in the A549 lung
cancer cells, the parent GT library itself has high antiproliferative activity in these cells
making the fold-change seen with the selected GT cap ODN less than one. Both the GT
cap and library had virtually no effect on the non-malignant fibroblasts. Excitingly, until
this study we have not seen an ODN with antiproliferative activity to equal AS 1411. We
observe that the GT cap sequence is on par with the activity of ASI411 in both DU145
and A549 cells.
The data for the parent libraries (N and GT 26mers) in the DU145 and A549 cells
were largely consistent with our previous findings (Chapter 2). As before, all libraries and
ODNs have little effect on the growth of the non-malignant cells and all dose-dependence
curves plateau at a non-zero value implying that the ODNs are inducing a cytostatic
rather than a cytotoxic effect. We did also assay our candidates and libraries as 60mers
that included the flanking primer binding regions and tested them for antiproliferative
activity in the four cell lines. No growth inhibition was seen with these ODNs (data not
shown), and we conclude that it is indeed the 26mer sequences, not the 60mers, that
should be considered as the candidate aptamers.
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CD spectra of GT cap suggests formation of the guanine-quaduplex conformation
We have previously discussed the limitations of CD data, but CD is well suited to
offer initial insight into the secondary structures of nucleic acids given consideration for
ease and cost. In terms of G-quadruplexes, it is generally accepted that positive peaks
close to either 260 nm or 290 nm are indicative of this conformation (133,134). The
relative height of these peaks is influenced by the proportion of "parallel" to
"antiparallel" G-quadruplexes QQ). To assess the molecular structure of our ODNs and
their parent libraries we studied the CD spectra in three different solutions: 100 mM KCI,
100 mM NaCI, and water (Figure 5).
As before, the N 26mer spectra are classic for unstructured nucleic acid with a
negative peak at 250 nm, a positive peak at 275 nm, and only small changes with
differen,ces in solution. The N cap ODN, however, does exhibit polymorphism with
solution. The peaks of the N cap spectra are of highest magnitude in potassium buffer,
and the spectrum in this solution appears very similar to the unstructured N 26mer
library. With water, however, the spectrum is suggestive of G-quadruplex formation with
peaks at 240 nm and 260 nm wavelengths, and a positive peak at 290 nm (.ill). The
spectrum ofN cap in sodium buffer appears to be intermediate between the spectra of the
other two solutions. While the sequence of the N cap is not G-rich containing less than
50% guanines (9 guanines out of 26 bases) and is not particularly suggestive for Gquadruplex formation, it does contain a guanine-rich stretch that could contribute to this
structure, especially should multiple molecules assemble. As the positive peak at 290 nm
is less pronounced in potassium than in water, one could argue against the formation of
the G-quadruplex by this sequence. Alternatively, these data may be due to simpler
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secondary structures such as hairpins or duplexes.
For the GT 26mer library, the CD spectra were similar to those previously seen
(Chapter 2) and are in accordance with our previous conclusion thatthe GT library has a
high proportion of molecules that adopt a G-quadruplex structure (a mixture of the
"parallel" and "antiparallel" forms). We reach the same conclusion for the GT cap
sequence, as the spectra exhibit peaks at the characteristic wavelengths for "antiparallel"
G-quadruplexes and are most enhanced in the presence of potassium. The spectra of both
the GT cap and GT 26mer library exhibit substantial polymorphism between the different
solutions, again consistent with G-quadruplex formation.

GT cap has modestly enhanced stability relative to parent library
In our manuscript (Appendix A), we show that maximal degradation of our libraries was
achieved before 24 hours with no further degradation seen as far out as 72 hours. We
therefore tested the nuclease resistance of our candidates and their parent libraries for up
to 24 hours (0, 1, 4, and 24 h). We tested both complete cell culture medium (containing
10% heat-inactivated FBS) and PC3 cytoplasmic extract (Figure 6) in order to mimic the
SELEX conditions in which the candidate aptamers were selected. With the cell culture
medium, little degradation was seen for any of the samples. These data for the libraries
are consistent with our previously published stability assay (Chapter 2). As the parent
libraries themselves are largely stable under these conditions, we are unable show
enhanced stability from our candidate aptamers. We do demonstrate that unlike some of
our previously studied samples (e.g. AT 26mer, C 26mer) our candidates are not
appreciably less stable than their parents under these conditions.
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In the PC3 extract samples, the N cap was clearly less stable than the parent library, and
was fully degraded by 24 hours while the parent library persisted at that time point. Both
the GT cap sequence and the GT library exhibited stability for all time points tested.
Although it is difficult to demonstrate enhanced stability by our GT cap OON because the
parent library itself was largely stable even at 24 hours, densitometric analysis of the
bands did indicate that the GT cap sequence was slightly more stable at 24 hours (81 % of

ohr versus 54%).

Candidate aptamers have more complex protein binding than parent libraries
Radiolabeled OONs were incubated with PC3 whole cell extract and subjected to
an electrophoretic mobility shift assay (EMSA) to study protein binding. ASI411 is
included for comparison. Samples were analyzed alone (without protein) to examine
labeling and molecular integrity (Figure 7). The labeling appears unequal across samples,
and the protein binding data must accordingly be interpreted with caution. As before, we
observed a difference in migration due to base composition, with the N library and N cap
migrating faster than the G-rich samples.
In general, our candidate aptamers displayed more shifted bands than their parent
libraries. We observe that the band marked "B 1" is present in all samples. A similar band
was previously seen for both the Nand GT libraries in four different celllysates (Chapter
2). In our prior study we proposed that this band may represent a general nucleic acidbinding protein which may incur molecular stability, and these new data are consistent
with that postulate. The less distinct band/region labeled as "B2" is perhaps very faintly
visible in all samples, but is certainly most intense in the candidate aptamer samples. This
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may be due to the heterogeneity of the libraries (which are comprised of millions of
possible sequences) versus the single species of each of the candidates; the libraries may
contain only a fraction of molecules that bind the proteins seen in the B2 band whereas
likely all the molecules in the candidate aptamer samples will bind.
As both the EMSA and the nuclease-resistance assay was performed in PC3
extract, and all OONs were present at the earlier time points that would correlate to the
time required to perform the EMSA, we are confident that the absence of shifted bands in
a given sample as seen on EMSA is not due to OON degradation. We conclude that our
isolated candidates have more complex and more intense (though qualified by the
difference in labeling efficiency across samples) protein binding in comparison with the
originating libraries. In our previous work involving OON libraries, we suggested that
protein binding may be responsible for resistance to nucleases, and these data are
consistent with our prior results.

CONCLUSIONS
Although we were initially gratified to have a single clear candidate from our cellSELEX using the N library after only five rounds of SELEX, we were unable to show
enhanced uptake with the N cap sequence. Though we also examined molecular stability
and anti proliferative activity, N cap did not display enhancement of these features. The N
cap was eventually the only 26mer present in our sequencing samples, and we therefore
conclude that the N cap is an artifact. In the time since we have performed these studies,
newer literature reveals that a major shortcoming of SELEX is its vulnerability to
amplification of artifactual error (ill, 130, 136, 137). If even a single molecule of a
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sequence that binds to an unintentional target is present, it will be amplified by the PCR
reaction and will become enriched should the false target persist. Although not considered
necessary at the time, many researchers now incubate the ODN library with the target in
the presence of salmon sperm DNA, transfer RNA, and/or bovine serum albumin to block
nonspecific binding. In addition to contamination with an unintended target, there are
many other potential sources of artifact. One source in particular is the method that we
employed to separate single- from double-stranded ODNs in the PCR product. Though
the use of biotinylated primers and streptavidin beads was at the time believed to be
sound, a subsequent report illustrated significant contamination of the "purified" PCR
product by double-stranded DNA molecules, streptavidin, and biotin (137). The free
streptavidin molecules were associated with the formation of cell and ODN aggregates.
The researchers had previously identified aptamers with high binding affinity from a cellSELEX procedure, but when these candidates were ordered for verification and further
testing, no binding was observed. They concluded that the SELEX procedure was
confounded by the contamination, particularly the presence of streptavidin which, in
addition to stimulating the formation of aggregates, may act as an unintentional protein
target.
Another source of artifact particular to cell-SELEX is the presence of dead cells
in the target sample. It is well known that dead cells are more likely to have permeable
cell membranes, and it has been reported that free ODNs are fifty-fold more likely to
associate with dead cells than live cells (138). Consistent with this, a recent study found
that dead cells preferentially bound fluorescently-Iabeled ODNs during the SELEX
process. Virtually all cells that stained with the viability marker 7-AAD were also
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strongly positive for ODNs. The authors report the failure in their hands of previous
experiments (i.e. enrichment of sequences that did not exhibit enhanced binding) that
neglected the issue of dead cells (136).
We attempted the SELEX method using a novel GT library and indeed, we were
able to selectively evolve a candidate aptamer that had enhanced antiproliferative activity
and nuclease resistance relative to the parent library. Consistent with our previous work
using ODN libraries, the activity of the GT cap ODN may be dependent upon Gquadruplex formation, protein binding, and stability. However, despite our identification
of the GT cap sequence, performing SELEX with the GT library was associated with a
number of difficulties. The first was the problem of identifYing candidate aptamers. Few
ODN sequences were repeating by round 5, and the artifact sequences (on the order of
400 bases in length) were increasingly prominent and likely depleting reagents in the
PCR reactions. We were forced to resort to an unconventional method of motif-searching
to find a candidate 26mer. For libraries such as the GT, a pattern analysis software
program to score sequences and motifs that are becoming enriched could provide some
clarity. Discussions with the UL biostatistics department indicated that it is possible to
design such a program for this specific purpose. We would test this program on our data
set to see if it identified the same motifs/candidates that we identified by hand, and then
use it on subsequent SELEX experiments (after addressing the issues of artifact).
Another problem unique to the GT library lies with the PCR reaction, a critical
step of the SELEX protocol. G-rich ODNs are notoriously difficult to PCR, such that the
GC content of primers and sequences is an important factor in designing the PCR
thermocycler program. Variables such as the concentration of magnesium in the buffer
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must be adjusted in order to effectively amplify GC-rich stretches. In genotyping
reactions, one group reports that the presence of G-quadruplexes and i-motif sequences in
the DNA to be amplified consistently produces preferential amplification of one allele
over the other resulting in error in diagnostic testing (133). Though we did not appreciate
any differences in the quantity of artifact in the N versus GT SELEX, the high number of
guanines in the GT library may have been a contributing factor. We used the same PCR
program for both the Nand GT SELEX, but the GT SELEX PCR could have been
optimized independently. We expect this procedure would be cumbersome and costly in
both time and funds as on the order of 25-50 sequences would likely have to be cloned
for each set of conditions tested. An alternate way to explore this issue is to perform
SELEX as before with additional samples in which the libraries are applied to no target.
These controls would help illustrate differences in PCR amplification of the N versus GT
library.
Our SELEX protocol was intended to select for cellular uptake, operating under
the widely accepted premise that increased uptake of our molecule would translate to
increased activity. Recently published developments from Dr. E. M. Reyes-Reyes from
our laboratory regarding the mechanism of action of AS 1411 have called this basic
premise into question (92). At early time points (2 h) the levels of uptake of AS 1411
actually appears to be higher in benign cells than in cancerous cells, despite the fact that
AS 1411 has minimal effect on the growth of benign cells while strongly inhibiting the
growth of cancer cells. Upon further investigation, it was discovered that initial uptake of
AS 1411 in the cancer cells (but not the nonmalignant cells) is by a unique endocytic
mechanism called macropinocytosis. Macropinocytosis, as the name suggests, is a
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process by which cells ruffle the cell membrane and extend a relatively large appendage
to engulf a sample of their immediate environment. By this endogenous method of
uptake, cells are able to internalize large volumes of the surrounding media (along with
any nearby molecules such viruses, bacteria, or drugs) in vacuoles termed
macropinosomes (139). Macropinocytosis has been shown to occur routinely in a variety
of cell types, including epithelial cells, fibroblasts, and macrophages. At later time points
in the cancer cells, AS 1411 triggers hyperstimulation of macropinocytosis by a nucleolindependent mechanism. According to these new data, the absolute level of cellular uptake
may be less important than the method of uptake by the cell. Therefore, in addition to
technical improvements to the SELEX protocol, the selection of sequences that are able
to stimulate macropinocytosis rather than merely internalized by cancer cells may be
more apt in the study ofG-rich ODNs. A preliminary study in that case would be to study
the method of uptake of our ODN libraries (N 26mer, GT 26mer, GC 26mer) and to
investigate which libraries, if any, are able to hyperstimulate macropinocytosis.
Despite many hurdles, with the utilization of the G-rich GT library we have
identified a new anticancer aptamer with enhanced antiproliferative activity that is
selective for cancer cells versus normal cells relative to its parent library. This aptamer
also exhibited moderately enhanced nuclease resistance and complexity of protein
binding than its parerit library. The data from the GT cap sequence are consistent with our
previous conclusions from studying ODN libraries, namely that the cancer-selective
antiproliferative activity we have observed likely requires nuclease-resistance and
binding to a specific protein or proteins. As others have also postulated, we believe that
ODN stability may be necessary for antiproliferative cancer activity, but it is not
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sufficient in and of itself (37). Although GT cap does appear to form the G-quadruplex
structure, we reiterate that the causal relationship between G-quadruplexes and
anti proliferative activity is not yet determined.
There are now several biotechnology companies that are developing automated
SELEX procedures (N). As the technology improves, it may soon be possible to order
aptamers against a particular target as one is currently able to order antibodies against an
antigen of interest. In terms of commercial generation, SELEX has many advantages over
antibodies. Not only are aptamers generated ex vivo with the associated simplification in
standardization and purification, but the random SELEX starting library typically
contains more different molecules by several orders of magnitude than a mouse possesses
in its antibody spectrum (136). Screening of so many more different possible molecules
may lead to greater specificity and selectivity in the evolved aptamers compared to
antibodies. Alternatively, some reviewers suggest that it may eventually be possible to
order commercial microtluidic kits for SELEX that would allow the rapid generation of
target-specific aptamers in individual laboratories (20, 140).
For these reasons and with consideration for the cost and effort that would be
required for optimization in our hands, we chose not to repeat this project. However, one
variation that we believe would be worthy of pursuit as a pilot study is in vivo SELEX.
As whole cells are arguably a more clinically relevant target than purified proteins,
aptamers selected against cancer cells in a true physiological environment may be the
most applicable variation of SELEX in the development of new cancer drugs. To date,
very few reports of in vivo SELEX exist. The majority involve the use of plants as the
target (141,142). A single recent report has generated an RNA aptamer with selective
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uptake in liver metastases in a mouse model after fourteen rounds of SELEX (143). The
target of this aptamer has been identified as p68, an intracellular protein that functions as
an RNA helicase. We suggest an in vivo SELEX proof of principle protocol in mice as
follows: implant subcutaneous DU145 prostate cancer tumors to athymic nude mice,
allow tumors to grow until palpable, intravenously inject SELEX starting library (GT
26mer, N 26mer, or negative vehicle), euthanize animals after one hour, harvest tumors,
homogenize the tissue, purify nucleic acid from the homogenate, and peR. A new in vivo
process such as this would likely require a great deal of optimization, but should it prove
successful would comprise an early and significant contribution to the field of SELEX,
aptamers, and potentially cancer therapeutics.
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CHAPTERS
EVIDENCE THAT AS1411 (A G-RICH APTAMER) INHIBITS
THE GROWTH OF TUMOR INITIATING CELLS

INTRODUCTION

The cancer stem cell hypothesis
Perhaps the most revolutionary new concept to impact clinical and experimental
oncology in recent years is the cancer stem cell (CSC) hypothesis GJ,44,49,50,144).
Though first proposed decades earlier, this hypothesis has truly risen to prominence since
the mid-1990's. The central postulate is that a self-renewing subpopulation of cells within
a cancer is responsible for its initiation and perpetuation. A popular representation of the
CSC hypothesis is the "dandelion model": the malignancy is represented by a dandelion
weed with the bulk of the tumor comprising the visible portion of the plant and the CSCs
representing the hidden roots (145, 146). Cutting off the weed at the surface is analogous
to cancer therapies that merely debulk the tumor. According to the CSC hypothesis, if the
CSCs are not targeted and destroyed, they will, with time, reestablish the weed of
malignancy. In theory, this correlates with clinical relapse, which is all too commonly
seen even after dramatic initial tumor regression. Conversely, a therapy that destroys the
CSC roots beneath the surface may initially appear to have no effect on the weed, but
eventually the dandelion would wither away. This is a stark contrast to both classic
oncology goals of therapy and cancer research end points which include rapid reduction
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in tumor volume. Should the CSC hypothesis hold true, it will have (and is already
having) fundamental effects on how cancer is studied and how new cancer therapies are
developed.
It has been known for many years that cancer patients in remission routinely have

cancer cells spread throughout their bodies, yet the vast majority of these cells will not
proliferate (147-150). This phenomenon suggests the possibility that while many cancer
cells may be shed from the primary tumor, not every cancer cell is able to establish a
metastasis. In animal studies, millions of cells from immortalized cancer cell lines are
routinely injected per mouse in order to establish a xenograft, which implies that not all
cancer cells within the injection are able to engraft. Although as of yet there are no
reports showing that CSCs are directly responsible for relapse, a recent study of breast
cancer patients have shown that following treatment, CSCs make up a higher percentage
of the residual tumor population and correspond to a poorer prognosis (ill). Another
group reports a statistically significant relationship between the number of CSCs
remaining in multiple myeloma patients following treatment and progression freesurvival (152). Though at this point such reports may be considered anecdotal, these
articles contribute to a growing body of work that supports the CSC hypothesis.

Clinical implications of the CSC hypothesis

Current cancer treatments are able to decrease tumor burden and thus morbidity in
patients. However, response to treatment does not necessarily translate into an increase in
survival. It is well-known that although most patients with advanced cancer do initially
respond to oncology treatment (typically a combination of surgery, chemotherapy, and/or
radiation), the majority of these will relapse and eventually die from their disease, and the
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difference in time until death for responders and non-responders is often not statistically
significant. Cancer types for which this has been shown include prostate, pancreas,
lymphoma, and multiple myeloma (152,153). This phenomenon is in accordance with the
CSC hypothesis. CSCs are believed to have many features that distinguish them from
bulk tumor cells and make them intrinsically more resistant to classic cancer therapies,
including those that target rapidly cycling cells, induce DNA damage, and are substrates
for transmembrane efflux pumps. This means that current treatments may be effective
only at mowing down the dandelion at surface level. Such efficacy against bulk tumor
cells but not CSCs is the logical result of the standard cancer research models - for which
decrease in tumor volume is a primary research endpoint - used to develop cancer
therapies. According to the CSC hypothesis, if the CSCs are not destroyed they will
divide, differentiate, and with time reestablish the malignancy. Worse, the treatment may
have increased the proportion of cells that are resistant to treatment and/or more
malignant. In prostate cancer it has been proposed that androgen ablation (castration)
may stimulate a castration-resistant CSC compartment from quiescence to proliferation.
This may trigger the development of a castration-resistant phenotype; that is to say,
castration treatment of prostate cancer patients may actually hasten the progression to
CRPC (154). To use the CSC analogy, castration is like denying the dandelion nutrition
and causing it to wither only to stimulate the regrowth of a hardier, starvation-tolerant
specimen.
Conversely, targeting the CSC subpopulation alone may also prove clinically
insufficient depending on the lifespan of the non-CSC population. Although the
terminally differentiated tumor cell population will, in theory, eventually senesce or
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apoptose, it is possible that the overall tumor burden may become clinically
overwhelming to the patient before the tumor regresses. Destroying CSCs without taking
steps to address the bulk tumor cells may thus result in unacceptable morbidity and
mortality. Another possibility is that from among the genetically unstable cancer cells
will evolve a new self-renewing population that can reestablish a CSC compartment. In
all probability, leaving the bulk tumor cells untreated would increase the chance of such a
mutation occurring.
Ultimately, cancer therapeutics will likely evolve into a multi-pronged,
combinatory approach in which a cytotoxic agent will be combined with drugs that
targets CSCs. This strategy theoretically will decrease the current tumor burden from
bulk tumor cells as well as inhibiting regrowth from the stem-like subpopulation. A trial
recently described for multiple myeloma patients studied the effects of a classic cytotoxic
chemotherapy drug (cyclophosphamide) in combination with a drug aimed at destroying
myeloma CSCs (rituximab). In addition to the significant relationship between CSC and
progression-free survival mentioned above, the researchers found that the surviving CSCs
had surface-bound rituximab, indicating that the drug was targeting the CSCs
appropriately but was unable to destroy them in certain patients (152). This report
strengthens support for the CSC hypothesis of cancer and encourages further study in the
combinatorial therapy field.

Theoretical ways to target cancer stem cells
The most basic strategy in the treatment of cancer is to find the cancer cells and
kill them, typically by identifying tumor-specific functions or antigens and exploiting
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them with targeted therapies. Destruction of the CSC subpopulation will likewise involve
the identification of CSC-specific features. As CSCs are believed to have a unique stem
cell-like biology, a variety of theoretical strategies to target and neutralize them take
advantage of stem cell capabilities or requirements. Should such targets be found, a single
anti-CSC therapy may potentially be effective against many different types of cancer.
One of the defining characteristics of CSCs is the ability to self-renew. It is this
ability that allows the CSC compartment to maintain a malignancy. Therefore, one
therapeutic strategy is to block self-renewal, forcing CSCs to either senesce or divide into
two differentiated daughter cells with no self-renewal capabilities. With the loss of the
self-renewing roots of the tumor, the cancer as a whole will eventually wither away. A
possible complication is that if differentiation is induced, the ex-CSCs would join the
pool of transit (or "transient") amplifYing cells. Transit amplifYing cells exist in a
transitory state between stem cells and fully differentiated cells, and are characterized by
a proliferative capacity that is more limited yet typically more rapid that stem cells. Thus,
by forcing the differentiation of the entire CSC subpopulation, the global effect on the
tumor could actually be accelerated growth. This effect should be self-limited, because
with the loss of the CSC compartment, the terminally differentiated cells will eventually
senesce. This is a situation in which combination therapy to control the overall tumor
burden could be employed and keep this transient aggravation of tumor burden within
clinically acceptable limits.
Another potential stem cell characteristic that may be exploited in the treatment of
CSCs is the protected microenvironment known as the stem cell niche. The relationship
between stem cells (benign or malignant) and their niches is complex and poorly
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elucidated, but it is certainly highly interactive. It is likely that the stem cells themselves
contribute to the formation of their niche, and it is known that in normal, benign
physiology the niche is critical to maintaining the stem cell phenotype. Disruption of the
niche may mean that the CSCs can no longer survive or function as stem cells and could
translate into loss of the CSC compartment. An alternate scenario is that an endogenous
disruption in the regulation of the balance of the niche may have contributed to the
formation of the cancer in the first place. In the prostate, it has been reported that stroma
from prostate cancers may actually induce malignancy in previously benign epithelial
cells (154). That is to say, the niche may not only protect CSCs, but may have caused
them to develop in the first place. Correction of the aberrant biology of the niche may
restore benignity to the stem cells within it. The interactions between the CSC and the
niche is of great therapeutic interest, but should be studied with caution and rigor before
interventions are attempted.
As the development of anticancer therapeutics specifically targeted against CSCs
progresses, it will be important to minimize clinical side effects by sparing benign stem
cells which share many markers, pathways, and characteristics (e.g. self-renewal and
niche dependence) with their malignant counterparts. Anticancer therapy of any type
should have high specificity for cancerous versus normal cells, but the stakes may be
even higher when considering stem cells. Consider the hematopoietic stem cell; it would
be wholly unacceptable to target leukemia stem cells only to cause life-threatening
complications due to compromised immunity or hemostasis. However, in certain organ
systems the distinction between CSC versus normal stem cell may be of little import
depending upon the relative significance of the normal stem cell. As an example, breast
90

cancer is most common in older women who have typically undergone menopause and
have no particular need for the normal breast stem cell population. A therapy that targets
breast CSCs could therefore also affect the normal breast stem cells with virtually no
impact on the patient's quality of life. This also holds true for the prostate. Indeed, as
benign prostatic hyperplasia (BPH) is a common medical condition that negatively
impacts quality of life in the vast majority of the elderly male population, nonspecificity
in targeting prostate stem cells could actually be beneficial even outside the field of
oncology. If a PrCSC-targeting drug is easily tolerated, it could potentially also be used
as a treatment for this notoriously inconvenient and widespread disease.
A final caveat is that the CSC compartment may comprise a "moving target" in
clinical oncology; elimination of CSCs does not rule out the possibility that another CSC
compartment may arise. One potential source for CSCs is the bulk tumor cells, which are
notoriously genetically unstable and may undergo mutations that translate into dedifferentiation to achieve a more primitive phenotype. This could perhaps occur when
subjected to unknown external stimuli from CSC-targeted therapies, similar to the natural
selection of drug-resistant clones following chemotherapy. Also, the question of the cell
of origin for cancer in general must be considered. It is possible that a CSC may arise
from benign stem cells, transit amplifying cells, or fully differentiated somatic cells. A
recent report from the University of Louisville describes a combination of genes that may
be manipulated to convert benign mouse fibroblasts to a CSC-like phenotype (155). In
leukemia, it has been shown that both hematopoietic stem cells and non-stem bone
marrow cells may act as the cell of origin for cancer (156,157). Another group reported
that a series of oncogenic insults converted benign prostate basal cells (which likely
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includes the stem cell compartment) to CSCs, but the same mutations applied to benign
prostatic luminal cells were insufficient to create a similar effect (158, 159). The
researchers argue that in the prostate, one possible cell of origin for prostate cancer is the
benign prostate stem cell. These studies provide insight regarding the fundamental
question of how cancers develop. Although this question has yet to be answered, factors
clearly exist that cause one person rather than another to develop cancer in the first place,
and elimination of CSCs does not remove the potential for another CSC developing from
other cells with the same environmental exposures and genetic risk factors.

Cancer stem cells versus tumor initiating cells
As discussed in the introduction (Chapter 1), the definitions, terminology, and
methodology of the study of CSCs is far from standardized. For this body of work, we
will utilize the American Association of Cancer Research definition of "cancer stem cell,"
whereby a CSC is characterized by the ability both to self-renew and to differentiate so as
to establish and maintain a tumor. (50) The feature of self-renewal translates into the
long-term survival of the CSC and therefore of the cancer. Asymmetric division allows
the CSCs to proliferate into a diversity of cells that typically divide rapidly at the outset
(as transit amplifying cells) and are ultimately responsible for clinical symptoms.
We observe that many reports involving the characterization of "CSCs" do not
address the issue of self-renewal. We hold that the more appropriate term for this type of
cell is "tumor initiating cell" (TIC). TIC refers most simply to a cancer cell type that has
the capacity for tumorigenesis. Although this property implies the capacity for
differentiation (i.e. the TIC can give rise to daughter cells that comprise the heterogenous
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bulk tumor population), TICs mayor may not possess the ability to self-renew; in other
words, CSCs are a subclass within the broader category of TICs. The general
characterization of TICs is far from complete and sometimes hotly debated, but in
addition to the defining characteristic of tumorigenesis, several features have come to be
widely accepted. These include primitive, stem-like characteristics such as transient
quiescence, membrane efflux pumps, and enhanced DNA repair mechanisms. Features
such as these translate into resistance to classic anticancer treatments, and CSC/TICs
have been strongly correlated to drug resistance and poor clinical outcome in a variety of
settings (64,160-163).
One particularly interesting topic in the field of TICs is the discussion of the
existence of different TIC subtypes. It is known that within the total cellular population of
a given cancer, there exist subpopulations of cancer cells with different capacities for
malignant characteristics such as tumorigenicity, proliferation, invasion, DNA repair, and
drug resistance. In addition to a CSC class within the TIC compartment, perhaps enough
heterogeneity exists such that some TICs are more tumorigenic than others or some are
important in certain physiologic settings but not in others. For example, one subclass of
TICs may be essential to the primary tumor while another variation of TIC is responsible
for the formation of distant metastases. Information regarding TICs and variations within
the TIC compartment may prove essential in the treatment of cancer.
Regardless of the precise definitions of CSCs versus TICs, the degree to which
these cancer cell classes overlap, and their relative prominence in the total cancer cell
populations, ultimately it is likely that complete cures from cancer will require specific
targeting of unique subpopulations and their unique features. This makes the
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identification of pharmaceuticals that can target these cell types highly relevant in
oncology research.
Methods to study tumor initiating cells
Surface markers
The first and most common method to characterize TICs is by dividing cancer
cells into subtypes based on cell surface markers. These markers sometimes have no
known function, but may descriptively divide the cancer cell population until a signature
is identified that is enriched in TICs in a process that is similar to the fractionation of an
organic chemical solution (such as a plant extract) with anticancer activity. The chemical
solution is divided into fractions that are tested for anticancer activity and the fraction
with the highest activity identified. This fraction may then be subfractionated and the
process repeated until in theory a single anticancer molecule may be identified. In the
case of TICs, the criterion for fractionating cancer cells is tumorigenicity.
In our project, we investigate the following surface markers:
•

CD24-/CD44+ - CD44+ primary prostate cancer cells have been shown to have
higher proliferation, tumorigenicity, and metastatic potential than CD44- cells.
This feature also holds true in prostate cancer cell lines routinely used in cancer
research (DUI45, PC3 cells) (164,165). The CD24-/CD44+ signature was
originally described as enriched in CSCs for breast cancer (166). In the prostate,
cancer cells with this signature have been shown to have higher soft agar colony
formation, higher tumorigenicity in a limiting dilution nude mouse model,
differentiation capacity in vivo, and gene expression patterns that are predictive of
poor outcome (ill). CD44 has also been reported as a predictive factor for
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prostate cancer recurrence (Qi).
•

C0133 - a marker of sternness in many different benign and malignant cancer
types, C0133 (in combination with C044 and

a2~1

integrin) was among the first

markers described for prostate CSCs (167-169).
•

Tumor-associated calcium signal transducer 2 (Trop2) - Also known as
TACST02, MISI, and GA733-1, Trop2 is a transmembrane protein of the
EpCAM family with unknown function. Trop2 is enriched in prostate tissue
samples after castration, in benign prostate spherocytes, and in the basal fraction
of prostate epithelium. It has been reported as a marker for both prostate TICs and
benign prostate stem cells (170). It has also been suggested that Trop2 plays an
active role in the tumorigenicity and invasion of prostate cancer.

Functional markers
•

Side population

•

Aldehyde dehydrogenase
Side population: ATP-binding cassettes (ABCs) comprise a large family of

nucleotide-binding molecules, with on the order of 50 types in humans organized into
seven families (ABCA to ABCG). Most ABCs contain characteristic membrane-spanning
domains and are believed to be involved in the transmembrane movement of small
molecules. More specifically, they function by using energy from ATP to constitutively
and non-specifically eject small molecules from the cytoplasm of cells. Particular ABC
subtypes that are enriched in normal stem cells and CSCs include ABCG2 and ABCB 1.
(55) Prostate TICs have been reported to be enriched specifically in the ABCG2.
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One class of substrate for these pumps is small fluorescent dyes including
Hoescht 33342 and rhodamine 123 (rho123). (171,172) These molecules freely diffuse
across the plasma membrane, such that all cells will fluoresce by default when exposed to
these dyes. However, cells that express high levels of these efflux pumps will remain
dark. When subjected to flow cytometry, this population of unstained cells lie literally to
the side of the main population and comprise the side population (SP). A SP, by
definition, must disappear in the presence of a pump-inhibitor such as verapamil.
SPs have been shown to be enriched in TICs for many cancer types in both
primary and established human cultures by a variety of methods (173-179). Moreover,
SPs are clinically relevant. One small study of clinical samples of ovarian cancer found
that recurrent cancers were more likely to have a SP than primary cases, and that cancer
cells harvested from ascites fluid or from peritoneal metastases (i.e. no longer localized)
had a larger SP than cells from the primary tumor. More importantly, even with this small
sample size, the authors report a statistically significant difference in prognosis for
patients whose tumors had a SP versus non-SP cancer (160). The authors add that a
significantly greater percentage of cells lie within the SP for chemoresistant ovarian
cancer cell lines versus chemosusceptible lines. The level of ABCG2 expression has also
been reported as a predictor of poor outcome indicator for esophageal squamous cell
carcinoma (163). In neuroblastoma cell lines derived from patients at presentation and at
relapse, the size of the SP was significantly increased for cells from the relapse samples
(162).
Aldehyde dehydrogenase (ALDH): ALDH is an intracellular enzyme highly

expressed by stem-like cells. ALDH is believed to be a marker of TICs in many cancer
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types including liver, breast, and prostate. For prostate cancer, ALDH has been described
as a marker for clonogenic, migratory, tumorigenic, and metastatic potential in both cell
lines and primary human cells (180,ill). Even more exciting, subtypes of ALDH have
been reported as clinical prognostic indicators in breast (182, 183 ), ovarian, (184) and
prostate cancer (185). To measure ALDH activity, a commercial molecule called
ALDEFLUOR which freely diffuses into cells and is a substrate for the ALDH enzyme
may be used. Cells that express ALDH will cleave ALDEFLUOR, yielding a fluorescent
product that can no longer diffuse across the cell membrane. Therefore, ALDH br cells
(some of which presumably will be TICs) will fluoresce more brightly than ALDK cells.
As a negative control, samples containing cells and ALDEFLUOR are co-incubated with
an ALDH inhibitor (DEAB). As with the side population assay, the ALDH br population is
defined as those cells that are fluorescent with ALDEFLUOR, but not fluorescent with
ALDEFLUOR plus the ALDH enzyme inhibitor.

Sphere assays
Among cancer cells that are typically cultured as mono layers, the vast majority
require cell adhesion for survival. However, it is known that a subpopulation of cells will
survive when grown in non-adherent culture conditions (with or without growth factors to
stimulate sternness pathways such as bFGF and EGF). These cells may proliferate
robustly under these conditions to form spheres (dense round clusters) of cancer cells up
to on the order of a millimeter in diameter. Cancer spheres have been reported for many
tissue types including breast (mammosphere), brain (neurosphere), and prostate
(prostasphere, or prostatosphere) (186-189). It has been reported by many groups that
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sphere culture conditions enrich the total cell population for cells with stem-like features.
The term spherocyte refers to a cell from a sphere. Spherocytes have been shown to have
an increased proportion of TICs for many different cell types including both primary
prostate cancers and prostate cancer cell lines (DUI45, PC3) (190-192).
Different ways to utilize spheres in the study of TICs exist. As CSCITICs are
typically believed to comprise a small percentage of the total cancer cell population,
some researchers culture spherocytes simply for the purpose of having a larger population
of TICs to analyze. Another method is to plate cells in sphere culture to see if an
experimental agent is able to block the formation of spheres. Still another is to allow
spheres to form, and test different components or conditions to observe for dissolution of
the spheres. The sphere culture model at this time is widely held to be the most applicable
in vitro method in the study of TICs.

In vivo tumorigenicity assays

In the identification of TICs, the gold standard is tumor growth of limiting
dilutions of cancer cells in vivo; in theory every single cell of a stringently fractionated,
pure TIC population will have the ability to establish a complete and heterogeneously
populated tumor (50). Researchers use dilutions of cells of different signatures (e.g. 104 ,
103, 102 , 10 1 CD44+ cells versus CD44- cells) and observe whether fewer cells of a
particular signature are required for tumor growth. This implies that selecting for that
signature enriches for CSCs.
For the study of CSC-targeting drugs, two main approaches have been described
(193-195). The first is pretreatment of cancer cells with the experimental drug ex vivo
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followed by transplantation to mice. The rationale is that treatment will deplete the TIC
sub population and that tumor growth will require a greater number of total cancer cells.
This requires that the bulk tumor cells are not greatly affected by treatment with the
experimental drug. The pretreatment approach may also employ the limiting dilution
concept; pretreated and untreated cells may be implanted in varying numbers. The second
approach is more powerful, involving establishing tumors in mice and then treating them
with the experimental drug, alone or perhaps in combination with currently used
chemotherapy. A TIC targeting drug should inhibit tumor growth, an effect that may be
rapidly evident or may require a longer period of time in order for the bulk tumor cells to
senesce and the tumor to regress. These models may be used in combination, and for this
project we performed both the pretreated and long-term models.

Rationale for this project

Our hypothesis is that ASI411, a G-rich, quadruplex-forming aptamer that was
studied in Phase II clinical trial as treatment for cancer, is effective at eliminating TICs.
To test this, we used an established prostate cancer cell line and investigated whether
AS 1411 is capable of eliminating the TIC sub-population within these cancer cells. As
discussed in Chapter 1, our hypothesis involving the effect of AS 1411 on TICs arose
from the clinical observation that treatment with the aptamer resulted in markedly
delayed (rather than immediate) but durable tumor regression in a number of patients. A
study of the scientific literature at the time revealed further correlates between aptamers
and CSCs that suggest aptamers may be especially appropriate in the targeting of CSCs;
aptamers may be more effective than other chemotherapy types at targeting quiescent
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cells, drug-resistant cells, cells able to repair DNA damage, and cells protected by their
microenvironment (Chapter 1). Additionally, in our own laboratory, gene expression
microarrays were performed on DU145 prostate cancer cells treated with ASI411 for 2
and 18 hours. This study found that, of the genes with the greatest difference in
expression, a large number of those downregulated were implicated in stem cell biology.
(unpublished data, Appendix C). This is consistent with our hypothesis.
Despite the uncertainties and controversial nature of the field, we undertook this
high-risk project because the potential implications for aptamers, CSCs, and clinical
oncology are great. Not only would this work shed light on the target of AS 1411, but a
clear corollary between AS 1411 and CSCs could help elucidate the mechanism of action
of AS 1411, contribute to the rapidly growing knowledge of CSC biology, and further
validate the field of aptamers, especially in the field of clinical oncology. It was decided
that the possibility of high impact results validated the discovery-driven efforts that we
describe in this chapter.
The question of studying primary prostate cancer samples versus established
prostate cancer cell lines was considered. While primary specimens are clearly more
representative of clinically relevant prostate cancer, much of the literature supports the
concept of a TIC popUlation existing (albeit in questionable percentages) in virtually all
the established cancer cell lines studied. Many of the reports of TICs from a variety of
cancer types employ cancer cell lines for their studies. For this preliminary project, we
decided that use of established cancer cell lines is appropriate. As discussed in the
previous section, DU145 TICs in particular have been relatively well characterized in
vitro and in vivo. We therefore felt justified in utilizing this cell line for our experiments.
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We acknowledge the difficulty in definitively proving that a drug targets

CSCs/TICs given the dearth of well-established methodology and rampant controversy in
the field. For this reason, we employ a wide variety of methods and assays, each of which
has been reported to distinguish TIC-targeting agents from non-TIC agents. While each
assay will imperfectly overlap the TIC compartment, we propose that the accumulation of
a large body of data exhibiting decrease in a purported TIC-enriched population in a
multitude of ways will strengthen our hypothesis thatAS1411 acts by targeting TICs.

MATERIALS AND METHODS
Oligodeoxyn ucleotides

Oligomers were purchased from Integrated DNA Technologies, Inc. (Coralville, IA) or
from Invitrogen (Carlsbad, CA). Lyophilized oligomers were resuspended in filteredsterilized water, then heated at 65°C for 10 minutes and vortexed vigorously to dissolve.
For in vivo studies, AS1411 was ordered in large-scale batches and resuspended in 10
mM potassium phosphate buffer (pH 7.4).

Cells and monolayer culture conditions

Three cell lines were studied: DU145 and PC3 prostate adenocarcinoma, and MCF7
breast adenocarcinoma. All cell lines were acquired from ATCC. Cells were grown in
complete cell culture medium of DMEM (DU145 and MCF7) or F-12K (PC3)
supplemented with 10% heat-inactivated FBS (15 minutes at 65°C) and 1%
penicillin/streptomycin. The MCF7 cell line alone was grown with insulin (0.01 mg I
mL). All cells were cultured at 37°C in 5% CO2 •
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MTT anti-proliferative assay

AS 1411 and the chemotherapy drug doxorubicin were tested in triplicate at a range of
concentrations in DU145 prostate cancer cells for 72 hours. We modified previously
published MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay
protocol. Briefly, cells were seeded in 96-well tissue culture plates and incubated
overnight. Cells were plated at 1000 cells per well. Drug stock solutions were then added
to each well to yield the desired final concentration. Plates were incubated with the
oligomer for three days, during which the cell culture medium was not changed. On day
3, cell viability was determined and the background corresponding to medium alone (no
cells) was subtracted. For each concentration, the average of the three wells was
calculated and plotted.

Stem cell marker staining

Antibodies against human surface antigens along with coordinating isotype
control antibodies were purchased from BD Biosciences (San Jose, CA) or Miltenyi
Biotech (Auburn, CA). All antibodies were directly conjugated to fluorophores save the
antibody against Trop2. For this antibody, appropriate secondary antibodies conjugated to
fluorophores were used, and the secondary alone was used as the negative control.
For antibody staining of surface epitopes, cells were resuspended with TrypLE
Express (GIBCO). The cell suspension was washed twice with cold staining buffer (1 %
FBS in sterile PBS), then resuspended in 100 J.lL of staining buffer at a final
concentration of approximately 5 x 105 cells / mL. Appropriate antibodies were added
directly to cells at concentrations recommended by the manufacturers. Samples were
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protected from light and incubated on ice (4°C) for 30 minutes, and mixed occasionally
by tapping during the incubation. Samples were then washed twice and resuspended in
cold stain buffer for analysis. Samples requiring a secondary antibody were washed once
incubated and with the secondary antibody for 30 minutes more, then washed and
resuspended for analysis. Propidium iodide (2 Ilg per sample) was added as a marker of
viability. Cells were kept on ice and protected from light until analysis. Flow cytometry
was performed using a FACScan flow cytometer.
For staining of internal stem cell markers, we used the BD Human and Mouse
Pluripotent Stem Cell Analysis Kit with additional antibodies (Nanog, SOX 2) from BD
6

Biosciences. We modified the manufacturer's protocol slightly as follows: up to 10 cells
were resuspended in 100 /-lL of BD Fix buffer, then incubated at room temperature for 20
minutes. Cells were washed once with Ix Perm/Wash buffer, then resuspended in 100 /-lL
Ix Perm/Wash buffer and incubated for 10 min at room temperature. Appropriate
antibodies were added directly to cells in stain buffer in volumes recommended by the
manufacturer. Samples were protected from light and incubated at room temperature for
30 minutes. Samples were mixed occasionally by tapping during the incubation. After
staining the samples were spun down, washed once with Ix Perm/Wash buffer, then
resuspended in approximately 500 /-lL stain buffer (1 % FBS). As we could not use
propidium iodide as a marker of viability, we counted cells with Trypan blue before
fixing and permeabilizing cells. Cells were protected from light until analysis. Flow
cytometry was performed using a FACScan flow cytometer (BD Biosciences).
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Side population assay (Rhodamine 123 dye exclusion assay)

MCF7 breast cancer cells were grown to approximately 80% confluence in the
appropriate cell culture medium, washed, and harvested with TrypLE Express. Cells were
spun down and resuspended in prewarmed (37°C) OMEM + 2% FBS + 10 mM HEPES
to make a final concentration of 106 cells / mL. One to two mL of cell suspension were
placed in darkened 15 mL tubes. The inhibitor verapamil was added to the control
samples (10 f.lM final concentration) followed by 0.1 f.lg / mL of Rho 123 added to each
sample. Samples were placed in a 37°C water bath for 30 minutes with regular mixing by
inversion of the tubes. Cells were spun down at 4°C and resuspended in 500 f.lL ice cold
HBSS + 2% FBS + 10 mM HEPES. Propidium iodide (2 Ilg per sample) was added as a
marker of viability. Cells were kept on ice and protected from light until analysis. Flow
cytometry was performed using a LSR II flow cytometer (BO Biosciences).
To study the effect of ASI411 treatment on the size of the side population (e.g.
percentage of cells that remained unstained in treated versus untreated cells), MCF7 cells
were treated with 10 f.lM AS 1411 or negative vehicle for 24 hours. Cells were washed,
harvested, and stained with Rho 123 as above.

ALDEFLUOR assay

The aldehyde dehydrogenase (ALDH)-positive population was assayed using a
commercial kit (ALOEFLUOR, Stem Cell Technologies) according to manufacturer's
directions. OU145 cells were grown to approximately 80% confluence in the appropriate
cell culture medium, washed, and harvested with TrypLE non-trypsin enzyme
(Invitrogen). Cells were spun down, then resuspended in room temperature Aldefluor
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Assay Buffer to make a final cell concentration of 106 cells / mL. Aldefluor reagent was
added to the cell suspension at a ratio of 5 IlL per mL. Without delay, the sample was
mixed and a portion of this sample added to a fresh tube containing the DEAB inhibitor.
Another portion was placed in a fresh tube for staining with propidium iodide. Samples
were incubated in 37°C water bath for 30 minutes, mixing occasionally by inversion.
Cells were spun down and resuspended in ice-cold Assay Buffer to make a final
concentration of 106 cells / mL. Propidium iodide (2 /lg per sample) was added as a
marker of viability. Cells were kept on ice and protected from light until analysis. Flow
cytometry was performed using a FACScan flow cytometer.
To study the effect of AS 1411 treatment on the size of the ALDHbr population
(defined as cells negative for ALDH in the presence of ALDEFLUOR and DEAB, but
positive with ALDEFLUOR alone) cells were treated with ASI411 at a range of
concentrations and time points (0-20 /lM ASl411 for 24-72 hours). Cells were washed,
harvested, and stained with ALDEFLUOR as above. Experiments were performed thrice
to ensure reproducibility.

Soft agar colony formation
DU145 cells were plated in soft agar as follows: a lower, cell-free layer of noble
agar and cell culture medium (0.6% agar and 70% complete cell culture medium final
concentrations) was plated in 60 mm tissue culture plates and allowed to solidify at room
temperature. DU145 cells were resuspended with trypsin. An upper layer of agar (0.3%
agar and 86% complete cell culture medium final concentrations) containing 2000
DUl45 cells plus 10 /lM AS1411, 2 /lM doxorubicin, or no drug was plated over the
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solid lower layer. Plates were incubated at 37°C and 5% CO2 for 10-18 days until
colonies grew to an appropriate size. Feeder layers of agar (including fresh drug) were
applied weekly. Plates were stained with 500 ilL of MTT [3-(4,5-Dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide] (1 mg / mL) solution, then photographed and scanned
(EPSO Expression 1680 scanner at 1000 dpi). Average colony size and total colony area
for each sample was analyzed using Image-J software (National Institute of Health).
Experiment was repeated thrice to ensure reproducibility.

Prostate cancer sphere (prostasphere) culture

DU145 prostate cancer cells were sorted for a subpopulation held to be enriched
in TICs (CD24 1o/CD44 hi ), then grown in non-adherent conditions supplemented with
growth factors to promote sphere formation and enrichment of stem-like cells. Serumfree sphere culture media was made fresh on the day of sorting consisting of: DMEIF-12
(Thermo Scientific), Ix B27 (Invitrogen), insulin (4 Ilg/mL, Millipore), bFGF (20 ng/mL,
Millipore), and EGF (20 ng/mL, Millipore). DU145 cells were stained for CD24 and
I

h"

CD44 as described above, and the top 2.5% of CD24 o/CD44 I cells were sorted at the
University of Louisville cell sorting core facility using a MoFIo flow cytometer
(Beckman Coulter). These cells were spun down, washed twice with 50% sphere culture
media (diluted 1:1 with DMEMIF-12), and plated in T75 low-adherence flasks (Coming).
The media was changed weekly. Cells were additionally supplemented with bFGF and
EGF weekly.
To harvest spheres, the cell culture medium containing spheres in suspension was
passed through a 70 micron nylon filter (BD Biosciences) to remove single cells and
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small cell clumps. Spheres were washed with PBS. The filter containing retained spheres
was inverted over a clean 6-well dish and the spheres washed out with PBS. The spheres
in PBS were spun down, resuspended in 1 mL TrypLE, and mixed by pipetting for 10-20
seconds to dissociate them into single cells. An equal volume of complete sphere media
was added to neutralize the enzyme. Samples were counted with trypan blue; typical
viability for primary spherocytes harvested and resuspended in this way was on the order
of80%.
To study the effect of AS 1411 treatment on spherocytes, DU145 CD241o/CD44 hi
cells were sorted and plated as described with the addition of 10 /-1M AS 1411 or negative
vehicle for up to three weeks. For spheres grown in the presence of drug, fresh AS 1411
was added at the time that the media was changed.

Sphere survival assay
To study the effect of AS 1411 treatment on prostasphere survival, freshly sorted
CD24 1o/CD44 hi DU145 cells were plated in complete sphere culture media in 6-well ultra
low attachment plates (Stem Cell Technologies, 2000 cells per well). Wells were treated
with 10 /-1M AS 1411, 1 /-1M doxorubicin, or negative vehicle. The media was changed
weekly with fresh drug added at that time. Cells were additionally supplemented with
bFGF and EGF weekly. Cells were cultured until an effect on sphere survival was seen,
generally three weeks. Spheres were photographed in these plates. For quantification, the
media and cells from each well were passed through a 70 micron nylon filter to remove
any spheres/cells smaller than that diameter. Spheres washed into fresh wells with PBS
and counted under the microscope.
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Ex vivo pretreatment of cells followed by tumor growth in vivo
This experiment was performed four times with slight variations in cell number and
technique. Data are clearly marked with the variations. In general, DU 145 prostate cancer
cells were grown to approximately 50% confluence. Fresh medium was added, and
AS 1411 was added to a final concentration of 10 )lM versus negative vehicle. Cells were
incubated for 72 hours. Cells were washed, trypsinized, and counted, then resuspended in
PBS at a concentration of 1 or 2 x 106 per mL. Just prior to injection, the cells were
mixed at a ratio of 1: 1 with Matrigel (growth factor reduced, without phenol red (BD
Biosciences)). Two hundred microliters of this suspension (containing 0.5 - 1 x 106 cells)
were implanted subcutaneously to the right flank or the midline back of 5-8 female
athymic nude mice (DU145 cells do not require androgen for growth, and therefore
female mice may be used for in vivo experiments). Tumor size was monitored thrice
weekly until animals were euthanized due to tumor burden. Tumor volume was
determined by measuring the greatest linear dimensions in length and width (calculated
by the equation V

=

1 x w2

x

(n / 6)). The tumors were allowed to grow until tumor

volume reached 10% of the total body mass of the animal, approximately 2 cm3 (2000
mm 3) for a 20 gram animal, at which point the animal was euthanized. Approval of this
protocol was granted by the University of Louisville Institutional Animal Care and Use
Committee.

Long-term growth in vivo

DU145 prostate cancer cells were grown to 90-100% confluence. Cells were
washed, trypsinized, and counted, then resuspended in PBS at a concentration of 107 per
108

mL. One hundred ilL of this suspension (containing one million cells) were implanted
subcutaneously to the right flank of twenty female athymic nude mice. Tumors were
allowed to grow until palpable, then measured, and mice stratified into two equivalent
groups.
The test group received intraperitoneal injections of AS 1411 (10 mg/kg/day) in 10
mM potassium phosphate buffer (pH 7.4) while the control group received intraperitoneal
injections of negative vehicle. Injections were given once daily for 21 days. Tumor size
was monitored twice weekly from the start of the injections until animals were sacrificed
due to tumor burden. Tumor volume was determined by measuring the greatest linear
dimensions in height, width and length (calculated by the equation V

=

I x w x h x (n /

6)). The tumors were allowed to grow until tumor volume reached 10% of the total body
mass of the animal, approximately 2 cm 3 (2000 mm 3) for a 20 g animal, at which point
the animal was euthanized. Approval of this protocol was granted by the University of
Louisville Institutional Animal Care and Use Committee.

RESULTS AND DISCUSSION
MTT assay used to assess test doses for AS1411 and doxorubicin
The purpose of this project is to study the effect of AS 1411 on TICs. As a
negative control, we also tested the chemotherapy drug doxorubicin which is used as
second line treatment for CRPC, widely used in other cancer types, and has been reported
to have little effect on TICs (196-198). To minimize confounding effects on bulk tumor
cells with doxorubicin treatment, we decided to select doses of doxorubicin that have
only modest effects on the proliferation ofDU145 cells for the timeframe we intended to
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study. In order to select an appropriate dose, we performed the MTT assay on DU145
cells at 72 hours using different concentrations of both AS 1411 and doxorubicin (Figure
1).

In the majority of our TIC assays, the dose of AS1411 used is 10 /-lM. This dose
was determined empirically, and was selected to illustrate the maximum effect of the
aptamers on TICs. According to this MTT assay, at 72 hours As 1411 inhibits the growth
ofDU145 cells by about 30%. From these data, we also decided upon the dose of2 /-lM
doxorubicin, which inhibits the growth of DU145 cells by about 15%. This range of
doses is also supported by the literature in the study of CSC/TICs. (193, 198-200) We
decided that these doses of doxorubicin and AS 1411 were comparable in terms of
anti proliferative effect on bulk tumor cells, and could thus be used to illustrate
differences in efficacy against TICs.

AS1411 treatment induces cell cycle arrest but is not toxic to DU145 monolayer cells
As a preliminary experiment to study the effects of AS 1411 in our hands, we
treated DU 145 cells with 5 or 10 /-lM AS 1411 for 24 hours, prepared cells for flow
cytometric analysis, and stained them with 7-AAD or propidium iodide. (Figure 2) We
observed that AS 1411 treatment results in modest accumulation of cells in the S phase of
the cell cycle. (Figure 2A) This datum is consistent with previous reports (H.,.2.l). We
also observed, again consistent with previous reports, that AS 1411 causes only a minimal
increase in cell death under these conditions. (Figure 2B) While previous studies have
reported GIso values of about 3 /-lM, those data were generated under different conditions,
namely longer incubation times (6 versus 1 day) (ll). This information generated under
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our experimental conditions validates our methodology in preparing our samples, as well
as aids in the interpretation of subsequent assays that study the effects of AS 1411 on the
TIC compartment. Because "the bulk tumor cells are only marginally affected by AS 1411
under these conditions, we can better determine whether or not any changes in cell
growth and/or survival we see with our later assays are particularly targeting TICs.
Though the data are reassuring, we did routinely stain samples with propidium iodide
and/or trypan blue as a marker for viability for all subsequent experiments.

CD2410/CD44 hi sorted cells and spherocytes are enriched for prostate TIC markers
As discussed previously in this chapter, CD24 1o/CD44 hi prostate cancer cells are
believed to overlap the TIC compartment. A similar argument has been made for prostate
cancer cells that have been grown in non-adherent sphere culture conditions. To establish
and validate the methodology in our hands, we analyzed three classes ofDU145 cells: 1)
unsorted monolayer cells, harvested by a trypsin analogue to make a single cell
suspension (" monolayer" cells) 2) freshly sorted CD241o/CD44 hi DU145 cells ("sorted"
cells), and 3) cells from DU145 spheres that have been digested to form a single cell
suspension ("spherocytes"). Our results are summarized in Figure 3.
We observed that a much greater percentage of sorted cells were CD24-/CD44+
compared to unsorted cells (86.0% versus 15.4%). As this is the cell surface marker
signature for which we sorted, these data support the validity of our sorting procedure.
We also observed that a greater number of sorted cells are ALDH br than seen in
monolayer DU145 cells (20.1% versus 7.51%, P < 0.05). To our knowledge, this is a
previously unpublished finding that provides additional evidence that prostate TICs are
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Figure 4: Heterogeneity of DU145 monolayer versus spherocytes cells
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contained within the CD24 10/CD44 hi compartment. As another assessment, we sorted the
CD24 1o/CD44 1o double negative subpopulation at the same time as the CD24-ICD44+
cells. When stained with ALDEFLUOR, these double-negative cells had fewer ALDHbr
cells (4.21 %) than not only the sorted cells, but also the unsorted monolayer cells.
Though not statistically significant, this finding was not unexpected; if the CD24-ICD44+
subpopulation is enriched in stem-like cells, it follows that at least some other
subpopulations are depleted. We studied both sorted and monolayer cells for several other
reported TIC markers (Trop2, CD133, Nanog, Oct3/4, Sox2) but did not find detectable
levels by flow cytometry.
Spherocytes were found to be enriched in CD24-ICD44+ compared to monolayer
cells (62.5% versus 15.4%), but not compared to sorted cells. We reasoned that the sorted
cells are most enriched in this surface marker signature because they are sorted based on
these markers, and that once in sphere culture conditions some of the cells lose this
signature via cell division and differentiation. We did find positive subpopulations of both
Trop2 (12.4%) and Nanog (41.5%) in spherocytes versus undetectable levels in
monolayer and sorted cells by flow cytometry. Taken together the data suggest that of the
three prostate cancer cell types studied, it is the spherocytes that are most enriched in
TICs. CD133 was once again undetectable.
Spherocytes were more challenging to assess due to limited viability and
heterogeneity. The viability of freshly harvested spherocytes was typically around 80% as
measured by trypan blue. Upon flow cytometric analysis, we observed a large degree of
heterogeneity as seen by widely diffuse forward and side scatter clusters, and even clear
subpopulations with different markers. For example, with ALDEFLUOR staining we
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observed two distinct groups of cells in spherocyte samples, while monolayer samples
had a much more uniform population (Figure 4). We suggest that these phenomena are
due to the physical structure of the prostasphere. Our spheres routinely grew to several
hundred microns in diameter. It is therefore likely that cells embedded deep within the
sphere are less able to receive nutrients, oxygen, and growth factors, and that cells in
different positions within the sphere receive different growth signals that affect their
protein expression. Because of these issues, we decided not to use the ALDH assay for
these cells.
Our rationale for plating sorted cells was that a greater number of sorted cells
would have the ability to form a sphere, and that we could perform our assays involving
spheres more quickly by plating sorted cells rather than unsorted monolayer cells. The
question has been raised whether or not unsorted DU145 cells would form spheres as
robustly as those from sorted cells, and whether spheres grown from unsorted cells would
show a similar enrichment of stem cell markers. We plan to undertake experiments to
assess these questions in the near future. Nevertheless, these data show that, consistent
with the literature, many markers for TICs are enriched in both the CD241o/CD44 hi
subpopulation of DU145 cells and in cells grown in non-adherent sphere culture
conditions. We therefore utilized the sphere culture method to assess the effect of AS 1411
on the TIC subpopulation.

Treatment with AS1411 decreases surface and internal markers believed to be
associated with TICs
Data from the functional markers (SP and ALDH) are discussed
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In

separate

sections below. We studied the effect of AS1411 on TICs by generating dose and time
curves of on DU145 monolayer cells. Cells were treated at 24, 48, and 72 hours with 5
and 10 /lM AS I 411, then stained for CD24 and CD44. The data are summarized in Figure
5. We quantified the percentage ofDU145 cells that lay in the CD24-ICD44+ quadrant as
well as a subpopulation (about 5%) that was negative for CD24 and brightest for CD44
(CD24 10/CD44 hi ). The flow cytometry graphs for 10 /lM AS1411 at the three time points
is shown in Figure 5A to illustrate the populations of interest. The smaller subpopulation
demarked with a rectangle within the upper left quadrant is believed to be most enriched
in TICs. In all cases, we found that ASI411 decreased the percentage of cells in both the
whole quadrant of interest and the subpopulation (Figure 5B). The difference between
untreated and treated samples was statistically significant, while the difference between
the lower and higher dose was not. We concluded from this that the 5 /lM dose is
sufficient to achieve maximal effect on the TICs at these time points. We repeated this
experiment using lower doses of AS 1411 (Figure 5C) at 72 hours and found that the
decrease in these populations was in general dose dependent and can be seen with as little
as 4 /lM AS 1411.
Due to the resources and time required to generate prostaspheres, we limited our
studies of the effect of AS 1411 on prostaspheres to a single dose of 10 /lM. To assess this
effect, we developed an assay whereby freshly sorted CD24 1o/CD44 hi cells were plated in
sphere culture conditions with or without AS 1411. Media was changed and fresh drug
added weekly until any signs of senescence (less dense, less well-defined borders, more
single cells) were seen. At this time all samples were harvested and analyzed. With this
method, we found that AS 1411 decreased the level of all measurable TIC markers: CD24117
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/CD44+, Trop2, and Nanog (Figure 6). Due to the time required for prostaspheres to
mature, replicate experiments are ongoing. In addition, we plan to repeat certain key
experiments with additional controls. We will repeat the treatment of DU145 monolayer
cells for 72 hours and of spherocytes for approximately three weeks with 10 /lM AS 1411
using doxorubicin as a non-TIC targeting control and a cytosine-rich analogue of AS 1411
(CRO) as a control oligomer.

Treatment with AS1411 eliminates the side population of breast cancer cells
We attempted the SP assay using DU145 cells, but found that this cell line did not
have a measurable side population either by Hoechst 33342 or by Rho123 staining. These
data are consistent with reports from other researchers (201). We therefore employed the
MCF7 breast cancer cell line to study the effect of AS 1411 on this TIC-enriched
subpopulation. Cells were treated with and without 10 /lM AS 1411 for 24 hours,
harvested and stained with Rho123. (Figure 7) Upon analysis, untreated MCF7 cells had
a small SP (0.406%) which did not stain with Rho123 and disappeared (i.e. became
fluorescent) in the presence of the pump-inhibitor verapamil (0.007% SP). MCF7 cells
treated with ASI411 for 24 hours had virtually no cells in the side population (0.004%).
AS 1411 had minimal effect on overall cell viability as measured by PI staining (data not
shown).
As discussed previously in this chapter, SP cells have been shown to be enriched
III

TICs in a number of different cancer types. These data therefore support our

hypothesis that AS 1411 is an inhibitor of TICs. One caveat is that we cannot conclude
from our data whether or not AS 1411 is inhibiting the survival SP cells, and it is possible
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that AS 1411 is not frankly decreasing the number of cells in the population, but rather
inhibiting the pumps that efflux the fluorescent dye. These pumps are known to act upon
chemotherapeutic molecules of many types and have been implicated as the mechanism
of drug resistance in cancer cell subpopulations (52, 160, 163, 171 ). Therefore, if AS 1411
acts by inhibiting the ABC pumps it could decrease drug resistance and potentiate the
effects classic cytotoxic chemotherapies as combination therapy. Regardless of which
case is true in actuality, we argue that both cases (decrease in cell survival and inhibition
of ABC pumps) support the utility of AS 1411 in the targeting of TICs.

Treatment with AS1411 decreases the size of ALDH br populations
We assessed ALDH activity in DU145 prostate cancer cells treated with different
doses of ASI411 or negative vehicle. (Figure 8) Untreated cells had a small and
br

consistent ALDH population of 7.51 % ± 0.81 %. Treatment with 10 11M ASI411 for 24
hours decreased the ALDH br population to 1.34% ± 0.68% (P < 0.001). We also studied
the effect of a smaller dose of AS 1411. After 24 hours of treatment with 5 11M AS 1411,
we found that the ALDH br population decreased to 0.43% ± 0.29%, a value even smaller
than seen with 10 11M AS 1411. Although the difference between 5 11M and control treated
DU145 cells was statistically significant (P < 0.01), the difference between 5 and 10 11M
AS 1411 was not. We conclude from this that 5 11M at 24 hours is sufficient to
significantly inhibit the ALDH br population, and that the higher dose of AS 1411 has no
additional effect. Unlike classic cytotoxic chemotherapies, for which higher doses
translates into higher efficacy and doses are limited only by the patient's ability to
tolerate the nonspecific toxicities, newer classes of targeted and biologically active
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chemotherapies may be most efficacious at moderate doses. Possible further experiments
include the study of lower doses of AS 1411 (e.g. 1-5 J...lM) for different time points.

Treatment with AS1411 decreases the formation of DU145 colonies in soft agar
Predating the emergence of the CSC field, the ability of cancer cells to proliferate
and survive in soft agar culture is a classic model for tumorigenicity (202). We plated
DU 145 cells in soft agar with no treatment, AS 1411, or the classic chemotherapy
doxorubicin which has been reported not to inhibit the growth of TICs (196-198). Cells
were cultured for three weeks with new top layers of agar with cell culture medium and
additional drug added weekly. (Figure 9A) Cells grown in the presence of ASI411
developed significantly fewer colonies than untreated cells (366 ± 92 versus 1371 ± 68,
P<O.OO 1). (Figure 9B) The average size of colonies grown with AS 1411 was also

significantly smaller than with no treatment (0.23 ± 0.03 mm 2 versus 1.00 ± 0.17 mm 2 ,
P<O.OI). (Figure 9C) Additionally, doxorubicin had a markedly smaller effect on colony

number as compared to untreated cells (793 colonies ± 84, P<0.05). Colonies with
doxorubicin and with no treatment were the same size (1.00 ± 0.13 mm 2) while the
difference in colony size between AS 1411 and doxorubicin was statistically significant,
(P<0.005 compared toASI411).

The soft agar assay has not yet been as clearly linked to the TIC subpopulation as
other assays (such as sphere formation/survival). Despite this lack of association, this
assay does illustrate the effect of treatment upon cells that do not require adhesion to
matrix to proliferate. The soft agar assay may thus be considered as a functional marker
for a more tumorigenic, invasive, and prone to metastasis cancer cell subpopulation. The
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data we have generated, that AS 1411 strongly inhibits the growth of colonies in soft agar
while doxorubicin modestly inhibits their growth, is therefore noteworthy and supports
our hypothesis that AS 1411 is targeting a TIC compartment.

Treatment with AS1411 inhibits prostasphere survival
Freshly sorted CD241o/CD44 hi DU145 cells were plated in sphere culture media
with no treatment, AS 1411, or doxorubicin. At the end of the experiment, all spheres
greater than 70 microns were counted for each sample. (Figure 10) We found a decrease
in the number of spheres that survived AS1411 treatment versus no treatment (5.7 ± 4.3
versus 42.7 ± 12.3 spheres, respectively per 2000 cells plated). Even more exciting, as
with the soft agar assay we found that doxorubicin had a much more attenuated effect on
sphere survival (34.7 ± 14.8 spheres). These data approached statistical significance, but
additional replicates with our refined sphere culture techniques will be required.
Other putative TIC-targeting drugs have been reported to inhibit sphere formation
(193,194). We observe that AS1411 did not inhibit the formation of cancer spheres, but
rather promoted their demise. This is in contrast to the soft agar assay where colonies are
inhibited from forming by AS 1411 treatment. A decrease in sphere survival may more
accurately model the common clinical scenario in which an existing tumor must be
treated, i.e. a newly diagnosed cancer patient with frank disease. As CSCs are a subclass
of TICs, so other subclasses may exist, such as primary TICs that are responsible for the
growth and maintenance of the primary tumor and metastatic TICs that are responsible
for tumor growth at distant sites. It is possible that these two assays (colony formation
and sphere survival) distinguish different types of TICs. It may be that different classes of
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TIC-targeting drugs will ultimately prove necessary to both cure the initial malignancy
and prevent recurrence. AS 1411 appears to be effective against both the malignant
subpopulation that can grow in soft agar and the subpopulation that can maintain a
prostate cancer sphere.
For this assay we used I f.lM doxorubicin. When this assay was performed we had
not yet assessed the effect of doxorubicin on the bulk tumor cells. As discussed
previously, a higher dose (2 f.lM) would give us a fairer comparison with this dose of
AS 1411. We plan to repeat this assay in order to achieve statistical significance. At that
time we plan to study the higher dose of doxorubicin. We also plan to test oligomer
libraries and candidate anti-prostate cancer aptamers from our previous work: N 26mer,
N cap, GT 26mer, GT cap, GA 26mer, GC 26mer, and a C-rich analogue of AS 1411 in
which all guanines are replaced by cytosines (CRO: 5'- CCT CCT CCT CCT TCT CCT
CCT CCT CC -3 ').

Pretreatment of cancer cells with AS1411 before implantation to mice results in
slowed or delayed tumor growth
We performed an in vivo experiment in which DU 145 prostate cancer cells were
treated ex vivo for 72 hours with AS 1411, washed, and equal numbers of viable cells
implanted subcutaneously to nude mice. This pretreatment model has been described in a
number of different reports that study the potential TIC-targeting ability of
pharmaceuticals (193-195). While certainly less clinically pertinent than the treatment of
established tumors with long term follow up, we undertook this method to see if the
molecular results we have generated thus far in vitro would translate into an effect in the
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complexity of the murine physiologic environment. In essence, the mouse acts as a more
physiologically relevant cell culture system. We felt comfortable employing this model
because it is known that cells treated with AS 1411 for up to 72-96 hours will recover if
the drug is removed (34).
The tumor growth curves from the pretreatment model experiments are shown in
Figure 11. We performed this experiment four times, and each time experienced technical
difficulties with the injections which resulted in different artifacts in tumor growth for
some mice. A number of mice of the first two experiments developed tumors that grew
within the peritoneal cavity rather than subcutaneously (Figure llA and B). Some of the
mice of the second experiment developed ascites, likely due to inadvertent direct
injection of tumor cells into the liver (Figure II C). We then switched the location of the
injections to the skin of the midline back (Figure lID) which avoided the abdominal
cavity altogether, but found that the shapes of the tumors were much more irregular;
several mice had very elongated and narrow tumors, while others grew two distinct
masses instead of one.
For analysis, we eliminated data for any mouse with tumor growth that was
clearly not limited to the subcutaneous area as we reasoned there must be tumor present
that was not measurable by calipers. Because of these issues, the experiments finished
with fewer mice than we intended and we did not achieve the significance that we hoped.
However, for every data point that was statistically significant, tumors from the
pretreated cells were smaller than the control treated cells (marked with asterisks), and in
general all the curves indicate that pretreatment with AS 1411 inhibits the growth of
tumor, either by blocking tumor take or slowing tumor growth. We conclude that
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pretreatment of prostate cancer cells with AS 1411 inhibits tumor growth in vivo. With
better in vivo injection technique, we feel confident that this difference will be
statistically significant for most if not all time points.

Long-term treatment with AS1411 in vivo showed no difference in tumor growth or
outcome
We attempted to mimic the delayed tumor regression seen in the AS 1411 Phase I
clinical trial by establishing DU 145 subcutaneous tumors in nude mice and, once
palpable, treating mice with daily intraperitoneal injections of AS 1411 (10 mg/kglday) or
negative vehicle for three weeks. We observed no significant difference in tumor volume
between treated versus untreated mice (data not shown). We also analyzed survival in the
two groups and again found no difference.
AS 1411, as well as other aptamers, is known to be rapidly cleared from systemic
circulation via the kidneys with a half-life on the order of minutes. Due to this
pharmacokinetic feature, in clinical trials AS 1411 was given by continuous infusion for
seven days. The daily intraperitoneal injection model that we used for this experiment
may thus not be an effective method to study aptamer pharmaceuticals. An experiment
using an infusion method of drug delivery would likely be more appropriate, and we are
planning to pursue this in the near future. Once a modified research protocol is approved,
we will use implantable intraperitoneal pumps to deliver appropriate amounts of AS 1411
over the course of 7 days.

CONCLUSIONS
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Cancer research in recent years has seen the advent of numerous new therapies
with efficacy in decreasing tumor volume, yet there have been relatively few
breakthroughs leading to improvement in survival. This quandary may be due to CSCs.
CSCs and TICs comprise an exciting new field of study experiencing exponential growth
with far reaching implications in clinical oncology and cancer research. Tumor
heterogeneity in general is an increasingly relevant concept. The field of oncology has
moved historically from considering cancer to be a single disease, to believing every
cancer within an organ to be the same, to realizing different cancer types exist within a
given tissue type. Now the dawning realization is that the differences between cancer
cells within a single malignancy must also be addressed. It is likely that in the near future
there will be even more refined medical subdivisions in cancer histology and diagnosis
that guide clinical treatment.
Given the growth in the study of TICs, a steady increase in the identification and
development of TIC-targeting therapies is likely to follow. At present, only a handful of
agents have been reported to deplete TICs. They include small molecule inhibitors of
certain signaling pathways (e.g.

Hedgehog, Akt, NF-KB, Notch), salinomycin,

aurothiomalate, temozolamide, and a few oncolytic viruses. Our preliminary data suggest
that AS 1411 is effective in targeting and inhibiting TICs in prostate cancer cells. We have
generated in vitro and in vivo data supporting our hypothesis. We have studied baseline
levels of prostate TIC surface markers in DU145 prostate cancer cells and shown that
AS 1411 decreases them. Using the SP and ALDH assays we have shown that AS 1411
also decreases functional markers. We have provided evidence that AS 1411 decreases the
clonogenicity of DU 145 cells via demonstrating decreased colony formation in soft agar
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and decrease sphere survival in non-adherent culture. These markers and functional
assays have all been described in the study of prostate TICs. Although the precise
definitions of TIC versus CSC are still being shaped, cancer cells with these signatures
have been shown repeatedly to be more tumorigenic, more invasive, and more drug
resistant than other prostate cancer cells. Therefore, regardless if AS 1411 only targets
TICs rather than the true CSC compartment, or inhibits only a subtype of TICs, or, with
changing definitions, does not target "TICs" at all, we are still providing evidence that
AS 1411 inhibits particularly clinically important and malignant subpopulations of
prostate cancer cells.
The ex vivo pretreatment of cancer cells followed by subcutaneous implantation is
a model that has recently been reported by a number of groups in the study of TICs. This
model does not attempt to mimic the clinical scenario, but illustrates the effect of drugs
on cancer cell growth under the complexities of mammalian physiology. Our data suggest
that treatment with AS 1411 slows the growth of prostate cancer cells in vivo. The longterm in vivo experiments that we performed (which are a truer model for clinical
oncology) did not show a difference with AS 1411 treatment in the growth of established
subcutaneous prostate cancer tumors. As discussed, we feel the lack of effect is due to
insufficiency with administration of the drug and intend to repeat this experiment with
implantable drug delivery pumps to achieve sustained levels of the drug and to more
accurately mimic the clinical trial protocols.
Although we have shown that AS 1411 decreases signatures and markers
associated with TICs, we realize that we are not able to conclude the fate of AS 1411treated TICs from our data. As discussed in the introduction of this chapter, many
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possible fates exist for TICs including cell death, blocking of proliferation (cytostasis),
and differentiation. To shed some light on the mechanism of downregulation of the
CD24 lo

/

CD44 hi stem cell signature with 72 hour treatment of ASI411 on monolayer

DU145 cells, one planned experiment is to plate freshly sorted CD24 lo / CD44 hi cells in
monolayer cell culture conditions with or without 10 J.!M AS 1411, then harvest after 72
hours and stain for CD24, CD44, and with propidium iodide. The experiment will also be
performed plating the sorted cells in non-adherent sphere culture conditions. Although
sphere culture conditions less accurately mimic the conditions under which our assays
were performed, at this time we are uncertain of general effects of monolayer culture
conditions on the sorted cells. According to the literature, both serum and adhesion tend
to induce differentiation of stem-like cells, therefore we will examine the cells under both
monolayer and sphere culture conditions. We hope that investigations such as these using
AS1411 on TICs will provide some insight on the fate ofthese cells.
One technical issue that needs to be addressed is appropriate controls. Most of
these assays have never before been performed in our laboratory. Designing and
optimizing these protocols required a great deal of time and resources, and thus in most
cases we restricted our experiments to AS 141 I-treated and -untreated samples. Additional
important controls to add to our study are classic, non-TIC targeting drugs and other
oligomers at comparable doses. The question of appropriate doses of the classic
chemotherapy doxorubicin has been discussed. An even more relevant chemotherapy
control would be docetaxel, the first-line chemotherapy for CRPC (Petrioli, 2008) which
is also used for other cancer types and has been reported not to target CSCITIC
subpopulations. In terms of oligomer controls, experts in the field opine a lack of true
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relevant control molecules. It is not possible to use a scrambled version of AS 1411 as this
ODN is comprised solely of guanines and thymines, and scrambling the order of these
bases does not provide sufficient variation from the original sequence. The standard
oligomer control that our group has used in many other publications to contrast with
ASI411 is "CRO," a C-rich 26-base oligomer which replaces the guanines of ASI411
with cytosines. Although CRO is limited in relevance because it is not a G-quaduplex, we
use this molecule because it is an ODN of the same length as AS 1411 that is known to
have no biological activity in any assay our laboratory has performed. Plans are
underway to repeat key experiments with CRO.
The field of CSCffICs, though exciting and rapidly expanding, is still only on the
order of a decade old. Even younger is the field of solid tumor CSCs; the establishment
of benign solid organ stem cells was many decades behind hematopoietic stem cells, and
solid tumor CSCs have naturally lagged behind their leukemic counterparts as well. As in
any new field of research, there is a high degree of controversy over virtually every
aspect of CSCs, even their very existence. The validity of methods used to study stemlike cancer cell populations, including the SP and ALDH assays that we describe here,
have been proposed, questioned, and refuted in tum. We have attempted to select
signatures and assays for which the greatest consensus has been built, but it will take time
before the methodology in the study of TICs is universally accepted. Even more
fundamentally, questions such as whether or not all tumors have CSCs and if neutralizing
or destroying CSCs actually translates into clinical benefit have yet to be answered.
In this project, we performed proof-of-principle studies to examine the effect of a
known anticancer aptamer on TIC subpopulations. We do not attempt to prove the CSC
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hypothesis, to answer fundamental questions in the field, or to validate the signatures that
have been reported to identifY prostate TICs. Although we have been as rigorous as
possible in our study of TICs, we acknowledge that we are necessarily utilizing unproven
assays. To compensate for this issue, we tested our hypothesis that ASI411 is a TICtargeting drug by several different methods, each of which in actuality is likely to assess a
slightly different yet overlapping cancer cell subset. While not conclusive, taken together
our data support our hypothesis and provide a strong argument that AS 1411 affects TICs.
This does not preclude effects on non-TIC cells, and indeed previous data from our group
indicate a strong anticancer effect on bulk tumor cells for a number of different cancer
types.
In the future, we would like examine the effect of AS 1411 on the gene expression
of spherocytes to see if these data provide any insight to the mechanism of action of
AS 1411 on TICs. We have plans to perform a qPCR stem cell gene array with cDNA
created from spherocytes that have been treated with AS 1411 versus negative vehicle. We
plan to study the mechanism of action of this inhibition on TICs to see if it differs from
that of the bulk tumor cells, to repeat and refine our assays to achieve statistical
significance using appropriate controls, and to prepare a manuscript for publication.
Ideally we would also like to repeat key experiments using clinical specimens. Our work
will be among the very first articles to combine the fields of aptamers and TICs, and the
first to present data that an anticancer aptamer inhibits the TIC class of cancer cells.
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CHAPTER 6
FINAL REMARKS

Summary of major findings and their significance

G-rich oligodeoxynucleotide libraries
The properties of a molecular solution of any kind that contains a mixture of
species are, most logically, a summative function of the individual molecules that
comprise it. Thus, the properties of the solution may be argued to be representative of the
predominance of molecules. We found that GT and GC ODN 26mer libraries, each
containing millions of different G-rich sequences, exhibit selective anticancer activity as
a whole. This implies that rather than being a rare occurrence, this feature is a common
property for the different individual sequences within these particular libraries. Ours is
the first report of a large, complex library of ODNs, rather than a single sequence or a
few known sequences in combination, exhibiting cancer-selective antiproliferative
activity (Chapter 2, Appendix A).
We found that the selective antiproliferative activity against cancer cells was only
seen in G-rich libraries (though not all G-rich libraries) and generally corresponded with
formation of G-quadruplexes, molecular stability against nucleases, and increased
cellular uptake. The causative relationship between the different biophysical and
biological properties we assayed was not determined, although we suggest that protein
binding may be required for molecular stability. Along this line of reasoning, a follow up
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study could verify that the band "B 1" identified most strongly in the GT libraries is
indeed nucleolin as we suspect, and that the protein is the same across the different ODN
libraries (i.e. that B 1 contains the same protein in all samples). Although nucleolin is a
required factor for AS 1411-mediated anticancer activity, these results suggest that factors
other than nucleolin binding playa role in determining activity; future research could
help us understand why some libraries exhibited this band but did not have
anti proliferative activity against cancer cells. One method to assess the relative binding
affinities is the competitive EMSA using radiolabeled TEL (telomerase sequence) as a
competitor for nucleolin binding. Caveats include the possibility that different ODN
species may bind to different sites or to different forms of nucleolin. As TEL is a known
G-quadruplex-forming sequence, it is logical that libraries with high levels of Gquadruplex formation would compete with TEL, but others would not. This could provide
information about the relative importance of G-quadruplex formation versus G-richness
to anticancer activity.

GC library and poly-dC binding targets
Both GC and C-rich nucleic acid sequences have important roles in cellular biology
(discussed fully in Chapter 3). Arising from the protein binding assay of the ODN
libraries chapter, we identified a handful of proteins that are bound by the GC 26mer
library and the poly-dC oligomer. Some of these have been previously reported while
some were newly identified by us. A number of the identified proteins have known effects
in cancer biology in general and prostate cancer in particular. As discussed in the chapter,
important follow-up experiments include foremost the verification of the protein targets
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and a study of their biological relevance. Many other follow up projects, particularly
involving the GC library, could stem from these data. The mechanism of the GC library's
cancer-selective anti proliferative activity is likely different from the GT-library; this is a
novel finding and could be an important development. Like the GT libraries, the GC
library had potent anti proliferative activity against lung and prostate cancer cells and little
effect on benign fibroblasts. In contrast, the GC library had markedly attenuated activity
against the MCF7 breast cancer cells, while these cells were the most vulnerable cancer
type to the GT libraries. Discovery of the basis of this difference in antiproliferative
activity could be a complete research project in and of itself with implications not only in
oncology but also basic cellular biology. Further studies with the GC library may lead to
new strategies in the advancement of cancer-selective therapies.

Identification of a new anti-prostate cancer aptamer via SELEX
Despite technical hurdles, we identified a candidate aptamer evolved via SELEX
from the GT library that has enhanced cancer-selective antiproliferative activity and
increased nuclease resistance relative to its parent library (Chapter 4). Although our
SELEX protocol was designed to select for sequences with efficient cellular uptake, we
were unable to exhibit an increase in uptake by the GTcap sequence despite employing a
variety of methods. ODN uptake is a challenging phenomenon to study, and at this time
the mechanism of the cellular uptake of G-quadruplex ODNs is poorly understood by the
scientific community as a whole. One technical difficulty that we encountered is intrinsic
variation of fluorescence of ODN samples. Some of this variation may be due to
difference in manufacturing conditions, but this issue is particularly associated with
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quenching of the fluorophore by G-quadruplexes. Fluorescent ODNs can only be used in
comparison if measured fluorescence is proportional to ODN concentration across
samples. We found inconsistent fluorescence among our fluorophore-Iabeled ODN
stocks. Though we attempted to compensate for this difference both mathematically and
experimentally, this incongruity makes any experiment comparing these ODNs
questionable.
More recently, a new paradigm for AS 1411 cellular uptake has developed from
our laboratory (92). In short, evidence suggests that it is not the degree of cellular uptake
that is the key to the cancer-selective anti proliferative activity of AS 1411, but the method
of cellular uptake. The major mechanism of uptake for cancer cells is macropinocytosis
while the predominant mechanism for benign cells is non-macropinocytic endocytosis.
AS 1411 triggers hyperstimulation of macropinocytosis only in the cancer cells, and this
hyperstimulation appears to require nucleolin though the mechanism of this interaction is
incompletely understood at this time. In accordance with the literature, we saw increased
cellular uptake with our "active" G-rich samples in our study of ODN libraries, and the
degree of uptake appeared to correlate with antiproliferative activity (Chapter 2).
Although we were unable to demonstrate increased cellular uptake with the GTcap
sequence, enhanced cellular uptake is a known general characteristic of GROs. Higher
uptake is a valuable pharmacokinetic property that may have many clinical and
experimental applications, but the new data regarding macropinocytosis and AS 1411
suggests that the paradigm of higher intracellular uptake corresponding with higher
efficacy is overly simplistic. We now believe that both the specific mechanism of uptake
as well as high intracellular concentration play important roles in the selective anticancer
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activity of AS 1411 and perhaps GROs in general.
Of note, our newly evolved aptamer (GTcap) is G-rich and does appear to form a
G-quadruplex, have enhanced resistance to nuclease degradation relative to its parent
library, and exhibit greater complexity of protein binding. This finding is in agreement
with our previous results using ODN libraries, namely that selective anti proliferative
activity against cancer cells may correspond with and require all these features.
Therefore, it is possible that we have inadvertently selected the GTcap sequence based on
its superior nuclease-resistance, rather than increased cellular uptake.

AS 1411 inhibits prostate cancer tumor initiating cells
We studied the effect of AS 1411, a known G-rich, G-quadruplex-forming aptamer,
on subpopulations of prostate cancer cells reported to have enhanced tumorigenicity (i.e.
TICs; Chapter 5). By all assays tested, AS 1411 decreased prostate TIC signatures. Most
excitingly, prostaspheres treated with AS 1411 had shorter survival than both negative
vehicle and the classic chemotherapy doxorubicin. This trend also translated to the in vivo
realm; preliminary studies showed that cancer cells pretreated with AS 1411 exhibited
slowed tumor growth compared to control treated samples.
We acknowledge the limitations of the field, for CSCITICs in general and solid
tumor and prostate TICs in particular, but believe that our data collectively support the
hypothesis that one of the ways by which AS 1411 acts against cancer is by inhibiting
TICs. We are interested to study whether or not this effect is exclusive to ASI411, or
rather a general property of other GROs as well. Experiments to test the effect of other Grich samples including ODN libraries (GA, GC, and GT 26mers) and well as our selected
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GTcap aptamer on prostasphere survival are underway. We are also testing some non-Grich libraries and ODN s in parallel. We know that some of these samples form Gquadruplexes and some do not; we may thus be able to correlate G-richness versus Gquadruplex formation with inhibition of prostasphere survival.

Overall conclusions and future directions

Our hypothesis is that guanine-rich oligonucleotides are optimal for the
development of new aptamers for use in the treatment of cancer. We have performed
experiments using GRO libraries correlating G-quadruplex formation with cancerselective antiproliferative activity. Following from this study we undertook and identified
unique GC library-binding proteins. We performed SELEX and managed to evolve a Grich aptamer with more potent anticancer activity and greater nuclease resistance than its
G-rich parent library. And lastly, we generated evidence that a first in class G-rich
anticancer aptamer inhibits TICs. Taken as a whole, this body of work supports the
hypothesis that GROs have great potential in the development of cancer therapies.
For context, we have discussed specific possible future studies for each subproject
(ODN libraries, protein target identification, SELEX, and TIC) in depth within each
chapter. Clearly much more work could be done in every aspect of this project. Our
immediate plans are to strengthen our data involving AS1411 and prostate TICs to
prepare a manuscript for submission. We also plan to study the effect of other G-rich and
non-G-rich libraries and ODNs via the sphere survival assay. The results may have
implications on the anticancer activity of the libraries, and if sphere survival correlates
with the previous anticancer acti vity seen, further study will be warranted.
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As previously discussed, according to the literature, GROs have distinct
properties, namely nuclease resistance and enhanced cellular uptake that appear to be
related to G-quadruplex formation. These properties may be accountable for the cancerselective anti proliferative activity seen with AS 1411, GRO libraries, and the GTcap
sequence, and could perhaps be a common feature of sequences that form Gquadruplexes. The causative relationship between these GRO-associated properties has
not been fully determined. It is widely held that G-quadruplexes are resistant to nucleases
due to the intrinsic stability of their secondary structure, and that this stability affords Gquadruplexes the opportunity to reach a protein target (e.g. nucleolin) and bind it. Our
data suggest that it is in fact protein binding that confers molecular stability rather than
vice versa (Chapter 2, Appendix A). We propose a new model by which GROs are more
likely to bind to a protein such as nucleolin which provides stability against serum and
intracellular nucleases. This protein binding mayor may not depend on G-quaduplex
formation. Regardless, with this stability, GROs survive and are able to be taken up by
the cell and reach other targets.
Although the determinants of the mechanism of cellular uptake of G-quadruplex
ODNs are unclear, it is known that GROs may be taken up by a variety of ways and have
a number of effects, including cell death, cytostasis, and antiviral activity (li). In
accordance with Dr. Reyes-Reyes' recent work, cancer cells take up G-quadruplexes by
macropinocytosis, a process which may then become dysregulated by a nucleolindependent mechanism and lead to a novel kind of cell death. Clearly there is more
information to be discovered, for example why the GC 26mer library was only active
against certain cancer cell types while GT 26mer libraries were active against all cancer
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types tested, and whether cancer-selective hyperstimulation of macropinocytosis is
specific to AS 1411 or a general property of GROs.

The future of anticancer aptamers
Aptamers as pharmaceuticals, especially in the context of oncology, are a worthy
field of study. Aptamers have many features that make them desirable for drug
development and commercial manufacture. The cost of drug development is notoriously
high, and of the total potential pharmaceuticals that enter the research and development
process, less than 1% will ever reach market. Aptamers are inexpensive and easy to
manufacture which is important not only in the context of providing drug to patients, but
also in the scientific study of these molecules. Aptamers typically have low side effects as
evidenced by the lack of dose-limiting toxicities in the clinical trials of AS 1411. Features
that makes GROs good candidates against cancer in general also makes them good
candidates for treatments against CSCs, and there are additional features (previously
discussed in Chapter 1) that may make them particularly well-suited to anti-CSC therapy.
To date, there is a single report of an RNA anti-EpCAM aptamer which may
prove to inhibit CSCs. However, no one has yet reported using SELEX to target whole
CSCITICs. In conclusion, we suggest that in the future it will become technically
possible to employ SELEX using a G-rich library to deliberately develop aptamers that
target CSCITICs. As the field of CSCs and TICs matures, the subpopulations of cancer
cells that are enriched in tumorigenic capabilities will become better characterized. It will
then be possible to use these clinically important subpopulations as targets of whole cell
SELEX using a G-rich starting library as we have described here. TICs may be sorted out
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from clinical tumor samples based on functional or surface markers and if necessary
established as primary cultures at the time of surgical resection. Cancer patients typically
require a post-surgical recovery period before beginning a chemotherapy regimen. During
this time, automated SELEX could be performed upon each individual patient's cancer
cells. Although automation for cell-SELEX is undoubtedly further away than for SELEX
using a molecular target, we believe cell-SELEX would be preferable for tailored therapy
as the SELEX could be performed without knowledge of a target on the molecular level
which mayor may not be relevant for that particular patient. As aptamers are remarkably
safe and non-toxic pharmaceuticals, the issue of dangerous side effects is less concerning.
At this time, tailored oncology therapies are limited to determining which patients will
benefit most from the available chemotherapies (e.g. giving anti-estrogen medication
only to those breast cancer patients whose cancers are ER+). We describe a scenario of the
future, which will involve custom made cancer therapies for each individual and their
unique cancer.
The overall aim of our project is to identify aptamers for use as oncology
therapeutics (i.e. chemotherapy, drug-delivery vehicle, imaging) and to study the
mechanisms of the unusual and potentially useful properties of GROs. A better
understanding of how GROs work may lead to the development of specific and selective
anticancer drugs, both vehicles (for targeted delivery of small molecules or siRNAs) and
frank aptamer pharmaceuticals. In this body of work, we have generated and discussed a
diverse collection of data related to GROs and their effects on cancer cells. Our work has
contributed to the fields of G-rich oligonucleotides, aptamers, cancer therapeutics, and
tumor initiating cells in overlapping and sometimes wholly novel ways. A number of our
146

findings have previously been unreported, and comprise a small yet significant
contribution to the literature.
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ABSTRACT

INTRODUCTION

Oligodeoxynucleotide libraries containing randomly
incorporated bases are used to generate DNA
aptamers by systematic evolution of ligands by
exponential enrichment (SELEX). We predicted that
combinatorial libraries with alternative base compositions might have innate properties different
from the standard library containing equimolar
A + C + G + T bases. In particular, we hypothesized
that G-rich libraries would contain a higher proportion of quadruplex-forming sequences, which may
impart desirable qualities, such as increased
nuclease resistance and enhanced cellular uptake.
Here, we report on 11 synthetic oligodeoxynucleotide libraries of various base combinations
and lengths, with regard to their circular dichroism,
stability in serum-containing medium, cellular
uptake, protein binding and anti proliferative
activity. Unexpectedly, we found that some G-rich
libraries (composed of G + T or G + C nucleotides)
strongly inhibited cancer cell growth while sparing
non-malignant cells. These libraries had spectral
features consistent with G-quadruplex formation,
were significantly more stable in serum than
inactive libraries and showed enhanced cellular
uptake. Active libraries generally had strong
protein binding, while the pattern of protein
binding suggested that GIT and G/C libraries have
distinct mechanisms of action. In conclusion,
cancer-selective anti proliferative activity may be a
general feature of certain G-rich oligodeoxynucleotides and is associated with quadruplex
formation, nuclease resistance, efficient cellular
uptake and protein binding.

Cancer is a leading cause of death throughout the
world. Although many drugs have been developed to
treat cancer, the majority of the oncology pharmacopeia
causes serious, dose-limiting side effects due to damage to
healthy cells. There exists a clear need for better, more
specific cancer therapies, not only to increase efficacy
against cancer cells but also to decrease the suffering of
patients who are subjected to these drug regimens.
Nucleic acid aptamers are emerging as a new class
of targeted therapeutic agents and are the focus of a
rapidly growing field of medical research (1-4). These
small synthetic oligomers of DNA or RNA form stable three-dimensional structures and bind to defined
molecular targets via shape-specific recognition. Thus, in
essence, their mechanism of action is similar to that of
protein-based monoclonal antibodies. However, due to
their smaller size and different chemical composition,
aptamers have a number of potential advantages over
antibodies. These include ease of manufacture and
storage, facile conjugation, better tumor penetration,
more rapid systemic clearance and non-immunogenicity.
In recent years, aptamers have been identified as potential
treatments for a variety of diseases, including macular
degeneration (5,6), autoimmune disease (7), disseminated
intravascular coagulation (8,9) and prion diseases (10).
In the oncology field, the most clinically advanced
aptamer, and the first anticancer aptamer to be tested
in humans, is a 26-nt G-rich DNA known as ASI411
(formerly, AGROIOO). This nucleolin-targeted aptamer,
which was discovered by our group, has shown promising
clinical activity without any major side effects in Phase I
and ongoing Phase II clinical trials (11).
New aptamers against specific targets are most often
engineered via systematic evolution of ligands by exponential enrichment (SELEX) (1,12,13), an iterative methodology designed to create target-specific aptamers from a
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Figure I. Overview of SELEX procedure and oligonucleotide libraries. (A) Schematic of SELEX procedure. (B) Diagram of N library.
Primer-binding regions (PBR) flank a length of random sequence, for which eacb base has equal likelihood of being an A , C, a or T . In theory,
the library contains 4" different sequences, wbere II is the length of the random sequence (in this example 11 = 26). (C) Example of a guanine-ricb
aT library. The random sequence is restricted sucb that each base may be either a a or a T . This library should contain 2" different sequences
(in this example II = 26).

com binatoria l library (Figure IA). For DNA aptamers, a
si ngle-stranded oligodeoxynucleotide library consisting of
two known primer-binding sequences flanking a random
sequence of usually 20--40 nt in length (N library, where
N = A, C, G, or T; Figure IB) is applied to the target of
interest. The molecules that do not bind are washed away,
and the remainder are harvested and amplified by
polymerase chain reaction (PCR). The aptamer-enriched
pool of single-stranded molecules is then isolated from the
PCR product, reapplied to the target and the process is
repeated. In this manner, highly specific aptamer
seq uences are usually evolved after 10-20 cycles. For
RNA aptamers, a similar procedure with additional
steps for transcription and reverse transcription can be
utilized . Typically, the target of interest for SELEX is a
purified protein or small molecule, but the development of
aptamers against intact cells or organisms can be also
achieved (1,14).
One shortcoming of traditional SELEX is the high
number of iterations required, which consumes time and
resources, and increases the likelihood of artifacts (since
every round of SELEX requires PCR and must be carefully protected from contamination). Moreover, for in vivo
use, evolved sequences must typically be modified to
enhance their pharmacokinetic properties and to increase
resistance to serum nucleases. This can be achieved
post-SELEX, or by incorporating modified bases or backbones during the SELEX procedure (1,15). However,
these approaches have some drawbacks: post-SELEX
modification can reduce aptamer activity or increase
toxicity, and not all modified nucleotides are compatible
with the polymerases used during SELEX. An additional
shortcoming of aptamers (which is also shared by
anti bodies) is their inefficient cellular internalization,
which generally limits their clinical targets to extracellular
or cell surface molecules.
176

In an attempt to address some of these limitations, we
have considered the use of alternative starting libraries for
SELEX. Rather than the random N library containing
billions of sequences, the vast majority of which will not
turn out to be clinically useful aptamers, we propose
beginning with smaller libraries, especially those which
may be enriched in molecules that contain secondary
structure motifs, such as hairpins or G-quartets. In particular, we hypothesized that libraries enriched in guanine
(G) residues (for example, see Figure IC) would contain
a higher proportion of quadruplex-forming sequences,
which may impart increased functionality, nuclease resista nce and cellular uptake compared to the N library. An
additional driving force for this study was the realization
that very G-rich sequences such as ASI411 (5'-d[GGTGG
TGGTGGTTGTGGTGGTGGTGG)), which was discovered by chance, would rarely occur in the standard N
library, making it unlikely to have been discovered by
standard SELEX. Furthermore, our previous work
involving the ' bench-to-bedside' development of ASI411
and the preclinical research of several other groups who
are researching a variety of different G/T-containing
oligonucleotides (II) led us to focus on GfT DNA
libraries for our studies on the effect of oligonucleotide
length .
As a prelude to SELEX studies using alternative
oligodeoxynucleotide libraries, we have sought to establish the baseline characteristics of various libraries and to
test our hypothesis that G-rich libraries will be enriched
in quadruplex-forming sequences with improved nuclease
resistance and cellular uptake. In this project, we have
examined II oligodeoxynucleotide libraries of varying
base compositions and lengths, as well as three monobasic
oligomers (Figure 2). We have performed studies to
evaluate various characteristics of the libraries, including
a well-established colorimetric assay to determine their
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Figure 2. Oligonucleotides and libraries used in this study. Singlestranded DNA oligonucleotide libraries and monobasic oligomers
used in this study. Libraries with >25% guanines are considered
'G-rich·.

intrinsic antiproliferative activities in three different cancer
cell lines compared to non-malignant cells. As far as we
know, we are the first to perform such a comprehensive
screen of oligonucleotide libraries. In addition, we report
here the unexpected discovery that certain G-rich libraries
have high levels of intrinsic, cancer-selective anti proliferative activity.

In the four cells lines, each library/oligomer was tested
in triplicate at eight concentrations of oligonucleotide
(0, 2, 4, 6, 8, 10, 12 and 141lM) using a modified
previously publ ished MTT [3-( 4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide] assay protocol (16).
Briefly, cells were seeded in 96-well tissue culture plates
and incubated overnight. To account for intrinsic differences in growth rate, the A549 and DUI45 lines were
plated at 1000 cells per well, MCF7 at 2000 per well and
Hs27 at 3000 per well. Oligomer library stock solutions
were then added to each well to yield the desired fina l
concentration. Plates were incubated with the oligomer
libraries for 5 days, during ' which the cell culture
medium was not changed . On Day 5, cell viability was
determined and the background corresponding to
medium alone (no cells) was subtracted . For each concentration, the mean and standard error of triplicate wells
was plotted . Assays were repeated at least twice in triplicate to ensure reproducibility of the results.
Circular dichroism spectroscopy

MATERIALS AND METHODS
Oligodeoxynucleotides and libraries
All oligonucleotides and oligonucleotide libraries were
purchased from Integrated DNA Technologies, Inc.
(Coralville, lA, USA) and a re shown in Figure 2. The
relative proportion of bases was specified for libraries,
which can be synthesized by mixing phosphoramidite precursors in the desired ratio. The specified bases are then
ra ndomly incorporated into the sequence. Lyophilized
libraries were resuspended in filter-sterilized water, then
heated at 65°C for 10 min a nd vortexed vigorously to
dissolve. For uptake studies, three thymidine bases
(TIT) were added to the 3'-end of the library sequence
to avoid quenching the 3'-fluorophore, which ca n occur
when it is proximal to a G-quartet (Choi,E., Nayak,L. and
Bates,P . unpublished data). A G 26 oligodeoxynucleotide
was originally proposed for study, but is not commercially
ava ilable due to difficulties in synthesis of oligodeoxyguanosines of this length.
Cell culture
Four cell lines were comprehensively studied: A549
lung adenocarcinoma, DUI45 prostate adenocarcinoma,
MCF7 mammary carcinoma and Hs27 non-malignant
skin fibroblasts . All cell lines were acquired from
American Type Cultu re Collection (ATCC, Manassas,
VA, USA). Cells were grown in complete cell culture
medium of Dulbecco's Modified Eagle Medium
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Oligomer library stocks were diluted to a concentration
of 5 11M (strand concentration) usi ng either water (buffer
was not included in order to be representative of the stock
solutions used to treat cells), or aqueous solutions containing 100mM sodium chloride or 100mM potassium
chloride. Samples were incubated at 95°C for 5 min, then
cooled on ice until analysis. Circular dichroism (CD)
spectra were collected at 20°C using a Jasco J-7 15
spectropolarimeter between 340 and 220 nm wavelengths,
using 200 nm/min scanning speed, 2 s response time, 5 nm
bandwidth and I-cm pathlength . For each set of samples,
the same solution used to prepare the oligomers was used
as the reference. The resulting spectra in millidegrees
(mdeg) were converted to molar CD (~e), referring
to per mole of nucleotide. Methods for analysis of
(dC)26 at various pH can be found in the Supplementary
Data.
Nuclease-resistance in serum-containing medium
Each oligomer library was 5'-end-Iabeled with 32p using
T4 kinase (Invitrogen) and unincorporated y_ 32 p_ATP was
removed from samples using TE-Midi SELECT-D G-25
columns (Shelton Scientific, Shelton , CT, USA), according
to manufacturers' directions. Collection tubes containing
end-labeled libraries were kept on ice, or sto red at -20°C.
The radioactivity of end-labeled libraries was measured
in a scintillation counter on the day of the experiment.
For each library to be tested, four reaction tubes containing complete cell culture medium without antibiotics were
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prepared . One million counts per minute of end-labeled
oligomer was added to each of four tubes. Samples were
incubated at 37°C, and tubes were flash-frozen in a dry
ice/ethanol bath at 0, 1.5, 24 and 72 h. Frozen samples
were stored at -SO°C until all samples had been harvested .
Samples were then thawed on ice and run on 12%
denaturing polyacrylamide gels. Band density was
measured over each lane using the UN-SCAN-IT gel
densitometry application (Silk Scientific, Orem, UT,
USA). The percent sample remaining was calculated
taking the signal of the zero time point lane to be 100% .
Cellular uptake
Uptake experiments were performed using oligomer
libraries labeled at the 3' end with FAM
(6-carboxyfluorescein) for representative libraries that
were inactive (N 26mer and GA 26mer) or active (GC
26mer and GT 26mer) . For each sample, 3 x 10 5 cells
were plated and incubated overnight. The following day,
fresh medium was added to each plate. FAM-Iabeled
libraries were added to make a final concentration of
5-f!M oligonucleotide and plates were incubated for I h.
The medium containing unbound oligo was removed .
Cells were washed twice and treated with trypsin
(Invitrogen) to remove surface-bound oligonucleotides
and harvest cells. Cells were kept on ice and protected
from light unti l analysis. Propidium iodide (PI, 2 ~lg per
sample, BD Biosciences, San Jose, CA, USA) was added
as a marker of viability. Ten thousand cells were counted ,
after gating to exclude PI-positive (non-viable) cells from
analysis. Cells were analyzed using a FACSCalibur
cytometer (BD Biosciences). The relative fluorescence of
cells was determined using the FlowJo software program
(Tree Star, Ashland , OR, USA).
Protein binding using electrophoretic mobility shift assay
Libraries were end-labeled with 32p as described for the
nuclease-resistance assay and then electrophoresed on a
non-denaturing 20% polyacrylamide gel to check
labeling. Who le-cell extracts from A549, DU 145, MCF7
and Hs27 cells were prepared using a modification of a
previously published method (17) as follows: cells were
grown until confluent in 75 cm 2 flasks . The cells
were washed, then scraped with 100 ~I HEDG buffer
[20mM HEPES-NaOH , pH 7.S, 0.5mM EDTA, 0.5mM
dithiothreitol
(DTT)]
containing
10%
glycerol,
I x protease inhibitor cocktail (Sigma, St Louis) , and
0.42 M NaCI. The solution was harvested and subjected
to three freeze-thaw cycles (liquid nitrogen versus room
temperature). Samples were centrifuged at 16000g at 4°C
for 45 min to pellet cell debris. An equal volume of HEDG
with glycerol and protease inhibitor but without NaCi was
added to reach a final concentration of 0.21 M NaCi . An
aliquot (IOOOOOc.p.m.) of radiolabeled oligomer was
combined with 5.0 f!g of cell extract from A549, DU 145
and MCF7 cells, or with 3.2 f!g from Hs27 cells, and 5X
protein binding buffer [IX is 20 mM Tris-HCI, pH 7.4,
140mM K1 , 2.5mM MgCI 2 , I mM dithiothreitol,
0.2mM phenylmethylsulfonyl fluoride (PMSF), S% (v/v)
glycerol]. Samples were incubated at 37°C for 15 min and
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run on a non-denaturing 5% polyacrylamide gel. Gels
were fixed in a solution of 10% (v/v) methanol + 10%
(v/v) glacial acetic acid in water for 10min at room temperature, then exposed to a storage phosphor screen for
2 h at room temperature before scanning. Gels were also
exposed to X-ray film overnight at -SO°C.
RESULTS AND DISCUSSION

GT libraries of all types and the GC 26mer library have
selective antiproliferative activity against cancer cells
The anti proliferative activity of II oligomer libraries and
three monobasic oligomers at various concentrations
against four cell lines was determined using the MTT
assay. The results are summarized in Figure 3A, which
shows the percentage reduction in cell number at 6-f!M
oligonucleotide strand concentration . This format was
selected for clarity of presentation and 6 f!M was chosen
beca use it best illustrated the relative activities of the
various libraries.
Some libraries containing G + T or G + C were found
to strongly inhibit cancer cell proliferation at low
micromolar concentrations, whereas non-G-rich libraries,
including the standard N library, had little effect on the
cancer cells (Figure 3A). All libraries tested had minimal
anti proliferative activity against the non-cancerous Hs27
cells (Figure 3A and B). These novel data provide surprising evidence that some oligomer libraries possess intrinsic
antiprolifera tive activity, even before isolation of individual aptamer sequences.
The GT IS-mer, 26-mer and 34-mer libraries had the
highest level of antiproliferative activity against the three
cancer cell lines (Figure 3A). The GT 10-mer, GT 0.33
26-mer and GT 0.67 26-mer libraries had similar
specificity, but were less effective at inhibiting the cancer
cells (Figure 3A). Figure 3B and C illustrate these results
for A549 cells, and similar patterns of activity were
observed in the other cancer cell lines (Figure 3A
and data not shown) . The GC 26-mer library had
potent anti proliferative activity against A549 and
DU 145 cells, and had a weaker effect on MCF7 cells
(Figure 3E). In contrast to the other G-rich libraries, the
GA 26-mer library had very little antiproliferative activity
against any cell line (Figure 3A and data not shown).
Based on the shape of the dose-dependence curves (for
example, see Figure 3C, which plateaus at a non-zero
value), it appears that active libraries have a cytostatic
rather than cytotoxic effect. This was also observed
previously for individual antipro liferative G-rich
oligonucleotides (J 6).
From these data, we designated all of the GT libraries
and the GC 26-mer library as 'active' against cancer cells.
In the remaining experiments, we compared these active
libraries against the remaining ' inactive' libraries in
order to identify characteristics that were associated with
the unexpected antiproliferative activity. To confirm
the cancer-selectivity of the active libraries, we also
examined all libraries and oligomers in an additional
non-tumorigenic cell line, MCFIOA, which is derived
from benign breast epithelial cells. The results indicated
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is shown for comparison. (E) Growth curves showing the effects of the GC 26-mer library on fo ur cell lines.

that although the MCF IOA cells were slightly more sensitive to anti proliferative effects than the Hs27 skin
fibrobl asts, they were markedly less sensitive than the
cancer cell lines, incl udi ng MCF7 breast cancer cells
(Supplementary Figure S I).
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Libraries with anti proliferative activity share features
of CD spectra

CD of DNA arises from the helical arrangement
of the bases and therefore conformatio nal char acteristics (e.g. A-, B- or Z-forms of duplexes, and C- or
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G-quadruplexes) can often be inferred from CD spectra,
as described in an excellent recent review article (18).
In our experiments, we observed that the CD spectra
of active libraries typically displayed a negative peak
at ~240 nm, a strong positive peak at 260-265 nm and
an additional maximum or shoulder (depending on the
cation present) in the region 285- 290 nm (Figure 4A). In
add ition, the spectra of the active libraries changed
significantly between different salt solutions, with the
largest peaks seen in the 100 mM potassium chloride
solution. While CD data alone cannot be used to absolutely assign structure, it is widely accepted that positive
peaks close to 260 nm or 290 nm are associated with
G-quadruplex formation ( 18, 19). Similarly, the
conformational polymorphism suggested by the differences in CD spectra in the presence of various cations is
typical of G-quadruplexes. Obvio usly, the shape of the

A

spectrum for an oligonucleotide library is derived from
the combined CD spectra from millions of sequences.
Thus, the characteristic spectrum of the active GT
libraries (Figure 4A) presumably represents contributions
from molecules with various arra ngements of G-quartets
(maxima at 260 and 290 nm) and non-quadruplex
single-stranded molecules (maximum at 275- 280 nm).
Somewhat surprisingly, the spectrum of the GC library
(Figure 4A) was quite similar to the GT libraries and
shared features suggestive of G-quadruplex form ation ,
altho ugh the presence of duplexes or hairpins in the
GC-library cannot be excluded .
Most of the inactive libraries showed a negative peak
at ~ 250 nm as well as a single positive peak at ~275 om
(Figure 4B). This is typical of both ordered singlestranded and dou ble-stranded DNA (18) . The spectra
of the inactive libraries changed only minimally with
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different salt solu tions, except for the CT library and
(dAh6, which showed slightly different spectral patterns
in water compared to the salt-containing solu tions.
Interestingly, the (dC)26 oligomer displayed a very large
ellipticity and the peaks were slightly phase-shifted from
the remaining inactive libra ries, with a negative peak at
265 nm and positive at 285 nm. This subtle shift in CD
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spectra may be due to the formation of secondary structures called i-motifs that have been reported in
cytosine-rich molecules (20,21), al beit usually o nly under
slightly acidic conditions. Our theory was supported by
additional experiments in buffered sol utio ns, which
showed that the amp litude and sha pe of the CD
spectrum for (dCh6 was strongly pH-dependent a nd was
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typical of the i-motif (18.21) at pH 5, 6 or 7, but there
was a transition to the standard single-stranded DNA
spectrum at pH 8 (Supplementary Figure S2).
The two exceptions to the general trends were the
GT 0.33 26-mer library and the GA 26-mer library
(Figure 4C); although the GT 0.33 26-mer library is
included in the active libraries, its spectrum resembled
the inactive libraries, consistent with the expected much
smaller proportion of quadruplex-forming seq uences a nd
its lower level of a nti proliferative activity. The spectrum of
the inactive GA 26-mer library varied considerably
between water, NaCl and KCI , but was di sti nct from
any of the other libraries examined, being close to zero
at 240 om , with a positive peak at 260 nm a nd a negative
peak at 285 om. This has been reported to be typical
of G + A containing oligonucleotides and associated
with stacked guanosines, although it is not clear if this
reflects the presence of quadruplexes or other ordered
structures, such as alternatively base-paired duplexes (18).
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To assess nuclease resistance, oligonucleotides and
libraries were radiolabeled at the 51 -end a nd incuba ted
in complete medium (which contains serum-deri ved
exonucleases) for various times. The primary purpose of
this experiment was to determine nuclease sta bility under
the exact conditions used in the MTT as ays. This was
considered essential, beca use if an oligonucleotide
is degraded in the cell culture medium, it is unlikely to
be active whatever other properties it has (unless the
active component is derived from degrad ation of the
oligonucleotide into nucleotides). The results (Figure SA)
showed that libraries tha t did not contain any G bases, as
well as a ll of the monobasic oligomers tested, were highly
susceptible to degradation in serum-containing medium,
with most being fully degraded within 90 min. Libraries
containing guanines in any percentage had at least some
molecules still intact at 72 h, regardless of anti proliferative
activity.
Although all active libraries displayed sta bility in the
presence of serum nUcleases, the degree of stability
did not correlate with antiproliferative activity. For
example, the modera tely active GT lO-mer library was
ma rkedly less stable than the inactive N 26-mer library .
However, although band density did not correspond to
anti proliferative activity for the individual libraries, the
mean band density of the active libraries at 24 a nd 72 h
was significantly greater (P = 0.026 usi ng Students'
two-tailed I-test) than the inactive libra ries (Figure 5B).
Active libraries had increased cellular uptake compared
to inactive libraries as shown by flow cytometry
For this assay, four representative 26-mer libraries
(the active GT a nd GC libra ries, a nd the inactive Nand
GA libraries) were synthesized with a fluorophore a t the
3/-end and used to assess cellular upta ke by flow
cytometry. Cells were washed a nd harvested with trypsin
prior to analysis to remove any surface-bound
oligonucleotides. The relative level of uptake in a given
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Figure S. Nuclease-resistance in serum-containing medium. (A) Autoradiographs showing elcctophoretic migration of radiolaheled oligomers
or libraries following incubation in complete cell culture medium.
which contains serum exonucleases. (8 ) Mean stability of active
versus inactive libraries. The difference in band density between
active and inactive libraries was statistically significant at 24 and 72 h
(0 P < 0.05 using Student's two-tailed I-test).

cell line can be estimated by determining the percent of
cells tha t are ' positive' for the fluorophore (i.e. have a
greater fluorescent intensity than the background signal,
which a rises from a utofluorescence of the cells) after
excluding non-viable cells. This type of analysis is especially useful for comparing the uptake of various libraries
a nd oligonucleotides in a particular cell line (22), although
its use for comparing uptake between different cell lines is
somewhat complicated by differing levels of baseline
autofluorescence between cell lines.
We observed that the active libraries, GT and GC,
consistently yielded a higher proportion of fluorescent
cells compared to inactive libraries in all cell lines
(Figure 6). In general, the inactive N library had the
lowest uptake of any library examined, and the inactive
GA library had a similar or slightly higher uptake than the
N library, but substantially less than the active libraries.
For the GC 26-mer libra ry, whereas its uptake in Hs27,
o U 145 and A549 cells was close to that of the GT library
(albeit a different distribution), its uptake in MCF7 cells
was considerabl y less than the GT library (Figure 60).
This result is noteworthy beca use the GC library also
has reduced anti proliferative activity in this particular
cell line (Figure 3E). Thus, these data suggest a correlation
between relative uptake and antiproliferative activity,
although with the caveat that, as mentioned above, thi s
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technique may not be optimal for compari ng uptake
between different cell lines. We noted the non-uniform
shape of the curve for the GT library compared to other
libraries, which may indicate a non-uniform uptake of the
GT library (some cells take up much more oligomer than
others), but the reason for this is unclear at present.
Active libraries and inactive libraries had quantitative
and qualitative differences in protein binding

The protein binding patterns of S'-radio labeled libraries or
oligonucleotides fo llowing incubation wit h cell extracts
were examined by electrophoretic mobility shift assay
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(EMSA) and are shown in Figure 7. To start, we first
analyzed the libraries and oligomers in the absence of
proteins. The results (Figure 7A) confirmed the labeling
and integrity of each sample and showed a quite marked
dependence of electrophoretic migration on base composition, as expected. A very general observation from the
EMSA experiments was that inactive libraries and
oligomers displayed fewer and less intense shifted bands,
when compared to the active libraries across all samples.
Several shifted bands of interest were noted and are
marked in Figure 7B-F. Appearance of the band
marked 'B " was associated for the most part with
nuclease-resistance libraries, but not nuclease-susceptible
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libraries or oligomers (Figure 5), suggesting it may be a
general DNA-binding protein. However, this was usually
most intense for the most active libraries and was present
at much higher levels in the cancer cell lines compared to
184

the non-cancer cells (Figu re 7F), suggesting it may contribute to the antiproliferative effects. The series of faster
migrating bands indicated by 'B2' were much less intense
than B I, but are of interest because they were present

Nucleic Acids Research, 2009

predominantly for the most active libraries (GT26 and
GT34). However, these bands were observed for Hs27
cell extracts, as well as for cancer cells (Figure 7F).
The band marked 'B3' is particularly interesting because
it is specific for the GC-library, which has strong
antiproliferative activity, and it is present at high levels
in all of the cancer cells, but is undetectable in the
non-malignant cells (Figure 7F). The fastest migrating
band we have highlighted, 'B4', is present only in
the C26 sample. Although this sequence has no
antiproliferative activity, this band is interesting because
oligo--<lC sequences may form unusual structures,
involving the i-motif, and very few proteins that bind specifically to such structures have been previously reported
(20). We plan to follow up these studies in the future by
attempting to identify proteins of interest using mass
spectrometry-based techniques.
Interpretation of the EMSA data in the presence of
protein (Figure 7B-F) has the potential to be somewhat
complicated because the presence of shifted bands
may depend not only on protein binding activity,
but on nuclease-resistance as well. The relative
nuclease-susceptibility under these conditions was
expected to reflect the results from our serum stability
assay (Figure 5), but may not be exactly the same
because cell extracts contain endonucleases, as well as
exonucleases. To further investigate these issues, we performed nuclease-resistance assays in the presence of the
DUI45 cellular extracts that were used in the EMSA
experiments. We examined stability after incubation
for a short time (15min), which mimics the EMSA conditions, and found no significant nuclease degradation
(Supplementary Figure S3A). These results verify that
the absence of a shifted band in the EMSA is due to the
complex not being formed, rather than the oligonucleotides being degraded by nucleases. After longer incubation
(18 h), which we anticipate will reflect the persistence of
oligonucleotides inside cells, we observed (Supplementary
Figure S3B) relative stabilities similar to those reported
above for long-term stability in cell culture medium
(Figure 5). This confirms our conclusions regarding the
relationship between nuclease resistance, protein binding
and anti proliferative activity (i.e. that, while active
libraries are invariably stable and display strong protein
binding, not all libraries that are stable and display strong
protein binding are active). Furthermore, the data also
suggest that protein binding may be responsible for
nuclease resistance and not vice versa.
CONCLUSIONS

In this study, we have examined the biological properties
and CD spectra of oligonucleotide libraries. The purpose
of this exercise was primarily to test our hypothesis that
G-rich libraries would be enriched in quadruplexes, which
might make them useful starting points for the development of new therapeutic aptamers using SELEX or similar
technologies.
The results of our analyses seem to confirm that G-rich
oligodeoxynucleotide libraries do indeed contain large
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numbers of quadruplex-forming sequences, and they are
more nuclease-resistant and efficiently internalized by cells
compared to the standard 'N library' currently used in
SELEX. Experiments are now underway to determine if
G-rich libraries can be used for SELEX and whether they
will allow faster evolution of aptamers for in vivo use.
While many of the observed properties of G-rich
libraries were anticipated, the strong and cancer-selective
growth inhibitory effects of some GT and GC libraries
were unforeseen. When analyzing a library of molecules,
it is important to remember that the results are the
averages of the effects of all the different molecules
within the library. Given our previous work, showing
that several different quadruplex-forming oligonucleotides
have cancer-selective antiproliferative activity (19,23), we
expected that G-rich libraries might contain a small proportion of active molecules. However, while we
anticipated that a G-rich library might contain some
very potent molecules, we presumed that the vast
majority of the estimated 67000000 sequences in such a
library would be ineffective, such that the library as a
whole would display at best a modest growth inhibitory
effect against cancer cells. Thus, the finding that certain
GT and GC libraries have very potent and tumor-selective
antiproliferative effects against a variety of cancer cell
types was somewhat surprising. Remarkably, the
antiproliferative activity of these libraries was comparable
to some individual G-rich oligodeoxynucleotides that are
currently in pre-clinical development or clinical trials (II).
Although a full understanding of the anti proliferative
properties of active libraries will require further efforts,
the work that we have described provides some clues to
the mechanism of action for these effects. The restriction
of the activity to only certain GT and GC libraries indicates that it cannot be a non-specific effect of
phosphodiester oligonucleotides or simply due to the
presence of deoxyguanosine nucleotides (either in the
context of an oligonucleotide or as nucleobases resulting
from oligomer degradation), because some dG-containing
libraries, including the GA and N libraries, had no
activity. In addition, although active libraries are generally
more stable than inactive libraries, nuclease-resistance
alone cannot explain the anti proliferative effects because
some of the inactive libraries displayed comparable
stability.
In view of our observations, we now propose that
antiproliferative activity requires all of the following:
nuclease-resistance, efficient cellular uptake and binding
to a specific protein (or proteins). It is not yet clear if
quadruplex formation, per se, is necessary for activity,
or whether it is simply that quadruplex-forming oligonucleotides generally have the aforementioned properties.
One possible candidate for the complex in the EMSAs that
appears to be most relevant for activity (band 'B I'
in Figure 7) is nucleolin. This protein is highly expressed
in cancer cells and is a general DNA binding protein, but binds particularly strongly to a variety of
quadruplex-forming sequences (24-27). It is also the
molecular target of an existing G/T oligonucleotide
aptamer (11). However, further studies will be required
to verify this possibility and to reconcile why some
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libraries bind to this protein (if it is indeed band B I), yet
do not have enhanced cellular uptake or anti proliferative
activity. Interestingly, the GC library appears to have a
different cancer cell selectivity compared to the GT
libraries and forms a specific protein complex (band 'B3'
in Figure 7), suggesting that its mechanism of action
and molecular target may be distinct from the GT
oligonucleotides.
In summary, the potent intrinsic and selective
anti proliferative activity of the GT and GC libraries is
an unexpected and wholly novel finding. Our results
indicate that cancer-selective anti proliferative activity is
a common characteristic of G-rich DNA oligonucleotides,
which may explain why numerous different G-rich
oligonucleotides have been reported as potential
anticancer agents (II). Although many different mechanisms of action have been proposed for these, our
results suggest there may be common mechanisms
(related to nuclease resistance, protein binding and
cellular uptake) that contribute to the activity of G-rich
oligonucleotides. Further research is warranted to elucidate the mechanism of action for these cancer-selective
effects, as this may lead to insights into basic cancer cell
biology, as well as to the identification of novel molecular
targets and new oligomer-based therapies for cancer.

SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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SUPPLEMENTARY DATA: METHODS
Antiproliferative assay of oligomers on MCFIOA cells
MCF10A non-malignant mammary epithelial cells were cultured in MEBM
supplemented according to ATCC guidelines (BPE l3 mg/ml, 2 ml; hydrocortisone 0.5
mg/ml, 0.5 ml; hEGF 10 ug/ml, 0.5 ml; insulin 5 mg/ml, 0.5 ml). Cells were incubated at
37°C in 5% CO 2 , For the MTT assays, 3000 cells were plated per well and assays were
performed according to methods described in the manuscript.
Circular dichroism at varying pH
The (dCb oligomer was prepared at a concentration of 5 11M (strand concentration) in 50
mM Tris acetate buffer that was pH-adjusted using glacial acetic acid to final values of 5,
6, 7, and 8. Samples were incubated and analyzed according to methods described in the
manuscript.
Nuclease-resistance in DU145 protein extracts
Libraries and oligomers were end-labeled as described in the manuscript. To match the
conditions of the protein-binding assay, 50,000 cpm of oligomer was combined with 2.5
Ilg DU145 whole cell lysate and protein binding buffer, as described for the EMSA in the
manuscript. Samples were incubated at 37°C for 15 min, then electrophoresed on a 12%
denaturing gel as described in the manuscript for the nuclease resistance assay. To
examine nuclease resistance under conditions mimicking the cellular environment,
similar experiments were carried out using 50,000 cpm of oligomer with 2.5 Ilg DU145
whole cell lysate, but without protein-binding buffer, incubated at 37°C for l8h.

SUPPLEMENTARY DATA: FIGURE LEGENDS
Supplementary Figure 1: Antiproliferative activities of libraries and oligomers against
MCFlOA cells.
(a) Growth curves showing the effects of all libraries on non-cancerous breast epithelial
cells (MCF1OA). Relative cell numbers at each concentration are compared to no
treatment. For comparison, the following are also shown: (b) Hs27 non-cancerous
fibroblasts; and (c) MCF7 breast adenocarcinoma cells.
Supplementary Figure 2: Circular dichroism (CD) of C 26-mer oligodeoxynucleotide at
varying pH. Samples containing 5 11M oligomer in Tris-acetate buffer were analyzed and
the results shown are molar circular dichroism (i1E), referring to per mole of nucleotide.
Supplementary Figure 3: Nuclease-resistance in the presence ofDU145 protein extracts.
5' -Radio labeled libraries and oligomers were incubated with protein extracts (prepared as
described for EMSA studies) at 37°C for the time indicated, and then electrophoresed on
a 12% polyacrylamide denaturing gel. "0" indicates the origin of the gel.
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Supplementary Figure 1 (new)
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Supplementary Figure 3 (new)
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APPENDIXB
SELEX sequences from Nand GT library using PC3 prostate cancer cells
PC3, N library

Round 1:
1) AGTAGGACTCGAGTGAGCGTGCGAGA
2) CTATTATGACAGTGCATGTTAGCCAT
3) GACGTGACTTATATAATTATGCATGG
4) ACCTATCTTCTCTAAGCTACTGAAGG
5) CTGGTACTATGGAAGAGATTGGTTCA
6) GGGGTAAGTAGATGGCAGCGTAGGCA
7) AGGAGTGGCACCAAAGTTCTGGCCTG
8) AGAAGGAAATCCGCTATCCAAAGTAC
9) AGGAAACACGGGAGATTACCTCTGCT
10)GAACCCCCGAACAGAAAAACCAGTCA
II)ACATCAAGTGCTGACGGTTGCACGAG
12) ACATCAAGTGCTGACGGTTGCACGAG
Round 2:
1) ACTCGTGAGTATCGTCGTC (GACGACGATACTCACGAG)
2) AAATAAAATCGTACGCAGCAGGGAAC (1+1)
3) TGGGAAATCCGATAGGCACTCAATGG
4) GACGAAGAAATGCACATGCAAAACTG
5) AACATTGGTAGACACAGTATTTTCCA
6) TAAAATGCGGAAAATAAGGGAACCGT
7) GATTGTGAAAAACAAATGACGTCGCG
8) TCGTTATGGACGGTGCGGAGGCGCAG
9) GTGTGGTTTGTGTGGGGGGTGGTGTT
10) GCACTACGTAAATCGGTGCGCGAAGC
II)ATAAAAAGAGGTGTCGGATCACGGAT
12)ATGGACTTCATGCCAAAAGCAAGTCG
13)TACGGAATAATGAGATTGTCAACGGA
14)GGTTGAGAAAAACCGATGGTCAGT
15)AGGTACATAACAATCTGACAAAGCAA
16)GGGGGATAGACAGTG
17)CGGACAAGAAATGTGTACTAGTGGTG
192

18)AAAGGATCACGTAGATGGATACGCAC
19)ATGGAGGAAAACTCAGCCCCAGAT
Round 3:
1) GCTGAGATGACTCATCCTCCCAGGCACAGCAAGAAGAAACAGGCAGCATGCCCATTG
CTTGTTTATTCCTTGTTTTAATTTTCATTATTACGTTTCTCAGGAAATGCACGCCTT
AGCTAACAGTTACTGGCAAAAAAATAAATAAATAAATAAGGTGTTTGAGTTCTTGCC
AACATTTGGGGAAGCTGAATGAGATGCCTAGAGGAGGGTTGGCCCATCCTTTGCTTA
AAGTTTTCTTTCCTTTTTTCTTTTTTGTTTTTTTTCTGTCCTTTAGCCCATGAAGAG
CATCATGCTTTTGAAGGTGGACGTGGAAAACACTAATTGCACTCTGTAAAGAATTCT
TTGTCCTTTGCTGATTGGTTTTGGAAACGGTCTTAACAGGAGGGAGAGTGAAGAGAA
GACTTGCCG (3+21)
2) ACTACGGAGGGGCTAGAGCAACAAGT (6+58)
3) GTTTTGGTTGGGGGTGGGGGTTGGGT
4) *GCTGAGATGACTCATCCTCCCAGGCACAGCAAGAAGAAACAGGCAGCATGCCCATT
GCTTGTTTATTCCTTGTTTTAATTTTCATTATTACGTTTCTCAGGAAATGCACGCCT
TAGCTAACAGTTACTGGCAAAAAAATAAATAAATAAATAAGGTGTTTGAGTTCTTGC
CAACATTTGGGGAAGCTGAATGAGATGCCTAGAGGAGGGTTGGCCCATCCTTTGCTT
AAAGTTTTCTTTCCTTTTTTTCTTTTTTGTTTTTTTTCTGTCCTTTGGCCCATGAAG
AGCATCATGCTTTTGAAGGTGGACGTGGAAAACACTAATTGCACTCTGTAAAGAATT
CTTTGTCCTTTGCTGATTGGTTTTGGAAACGGTCTTAACAGGAGGGAGAGTGAAGAG
AAGACTTGCCG (3+21)
5) CGGCAAGTCTTCTCTTCACTCTCCCTCCTGTTAAGACCGTTTCCAAAACCAATCAGC
AAAGGACAAAGAATTCTTTACAGAGTGCAATTAGTGTTTTCCACGTCCACCTTCAAA
AGCATGATGCTCTTCATGGGCCAAAGGACAGAAAAAAAACAAAAAAGAAAAAAAGGA
AAGAAAACTTTAAGCAAAGGATGGGCCAACCCTCCTCTAGGCATCTCATTCAGCTTC
CCCAAATGTTGGCAAGAACTCAAACACCTTATTTATTTATTTATTTTTTTGCCAGTA
ACTGTTAGCTAAGGCGTGCATTTCCTGAGAAACGTAATAATGAAAATTAAAACAAGG
AATAAACAAGCAATGGGCATGCTGCCTGTTTCTTCTTGCTGTGCCTGGGAGGATGAG
TCATCTCAGC (2+18)
6) ACTACGGAGGGGCTAGAGCAACAAGT (6+58)
7) GTTGCACTTCTGAATTCAACTCTCGG
8) ACTACGGAGGGGCTAGAGCAACAAGT (6+58)
9) ACTACGGAGGGGCTAGAGCAACAAGT (6+58)
10)ACTACGGAGGGGCTAGAGCAACAAGT (6+58)
11) GCTGAGATGACTCATCCTCCCAGGCACAGCAAGAAGAAACAGGCAGCATGCCCATTG
CTTGTTTATTCCTTGTTTTAATTTTCATTATTACGTTTCTCAGAAAATGCACGCCTT
AGCTAACAGTTACTGGCAAAAAAATAAATAAATAAATAAGGTGTTTGAGTTCTTGCC
AACATTTGGGGAAGCTGAATGAGATGCCTAGAGGAGGGTTGGCCCATCCTTTGCTTA
AAGTTTTCTTTCCTTTTTTTCTTTTTTGTTTTTTTTCTGTCCTTTAGCCCATGAAGA
GCATCATGCTTTTGAAGGTGGACGCGGAAAACACTAATTGCACTCTGTAAAGAATTC
TTTGTCCTTTGCTGATTGGTTTTGGAAACGGTCTTAACAGGAGGGAGAGTGAAGAGA
AGACTTGCCG (3+21)
12)CGGCAAGTCTTCTCTTCACTCTCCCTCCTGTTAAGACCGTTTCCAAAACCAATCAGC
AAAGGACAAAGAATTCTTTACAGAGTGCAATTAGTGTTTTCCACGTCCACCTTCAAA
AGCATGATGCTCTTCATGGGCCAAAGGACAGAAAAAAAACAAAAAAGAAAAAAAGGA
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AAGAAAACTTTAAGCAAAGGATGGGCCAACCCTCCTCTAGGCATCTCATTCAGCTTC
CCCAAATGTTGGCAAGAACTCAAACACCTTATTTATTTATTTATTTTTTTGCCAGTA
ACTGTTAGCTAAGGCGTGCATTTCCTGAGAAACGTAATAATGAAAATTAAAACAAGG
AATAAACAAGCAATGGGCATGCTGCCTGTTTCTTCTTGCTGTGCCTGGGAGGATGAG
TCATCTCAGC (2+18)
13)ACTACGGAGGGGCTAGAGCAACAAGT (6+58)
14)TGTTGTGGTGGGGGGGGGGTTGTTTT

Round 4:
1) ACTACGGAGGGGCTAGAGCAACAAGT (23+41)
2) GCTGAGATGACTCATCCTCCCAGGCACAGCAAGAAGAAACAGGCAGCATGCCCATTG
CTTGTTTATTCCTTGTTTTAATTTTCATTATTACATTTCTCAGGAAATGCACGCCTT
AGCTAACAGTTACTGGCAAAAAAATAAATAAATAAATAAGGTGTTTGAGTTCTTGCC
AACATTTGGGGAAGCTGAATGAGATGCCTAGAGGAGGGTTGGCCCATCCTTTGCTTA
AAGTTTTCTTTCCTTTTTTTCTTTTTTGTTTTTTTTCTGTCCTTTGGCCCATGAAGA
GCATCATGCTTTTGAAGGTGGACGTGGAAAACACTAATTGCACTCTGTAAAGAATTC
TTTGTCCTTTGCTGATTGGTTTTGGAAACGGTCTTAACAGGAGGGAGAGTGAAGAGA
AGACTTGCCG (1+23)
3) ACTACGGAGGGGCTAGAGCAACAAGT (23+41)
4) ACTACGGAGGGGCTAGAGCAACAAGT (23+41)
5) ACTACGGAGGGGCTAGAGCAACAAGT (23+41)
6) ACTACGGAGGGGCTAGAGCAACAAGT (23+41)
7) ACTACGGAGGGGCTAGAGCAACAAGT (23+41)
8) ACTACGGAGGGGCTAGAGCAACAAGT (23+41)
9) ACTACGGAGGGGCTAGAGCAACAAGT (23+41)
10) ACTACGGAGGGGCTAGAGCAACAAGT (23+41)
II)ACTACGGAGGGGCTAGAGCAACAAGT (23+41)
12) ACTACGGAGGGGCTAGAGCAACAAGT (23+41)
13) ACTACGGAGGGGCTAGAGCAACAAGT (23+41)
14) ACTACGGAGGGGCTAGAGCAACAAGT (23+41)
15) ACTACGGAGGGGCTAGAGCAACAAGT (23+41)
16) ACTACGGAGGGGCTAGAGCAACAAGT (23+41)
17) ACTACGGAGGGGCTAGAGCAACAAGT (23+41)
18) ACTACGGAGGGGCTAGTGCAACAAGT
19) ACTACGGAGGGGCTAGAGCAACAAGT (23+41)
20) ACTACGGAGGGGCTAGAGCAACAAGT (23+41)
21) ACTACGGAGGGGCTAGAGCAACAAGT (23+41)
22) ACTACGGAGGGGCTAGAGCAACAAGT (23+41)
23) ACTACGGAGGGGCTAGAGCAACAAGT (23+41)
24) ACTACGGAGGGGCTAGAGCAACAAGT (23+41)
25) ACTACGGAGGGGCTAGAGCAACAAGT (23+41)
Round 5:
1) ACTACGGAGGGGCTAGAGCAACAAGT (35+29)
2) ACTACGGAGGGGCTAGAGCAACAAGT (35+29)
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3) GCTGAGATGACTCATCCTCCCAGGCACAGCAAGAAGAAACAGGCAGCATGCCCATTG
CTTGTTTATTCCTTGTTTTAATTTTCATTATTACGTTTCTCAGGAAATGCACGCCTT
AGCTAACAGTTACTGGCAAAAAAATAAATAAATAAATAAGGTGTTTGAGTTCTTGCC
AACATTTGGGGAAGCTGAATGAGATGCCTAGAGGAGGGTTGGCCCATCCTTTGCTTA
AAGTTTTCTTTCCTTTTTTTCTTTTTTGTTTTTTTTCTGTCCTTTAGCCCATGAAGA
GCATCATGCTTTTGAAGGTGGACGTGGAAAACACTAATTGCACTCTGTAAAGAATTC
TTTGTCCTTTGCTGATTGGTTTTGGAAACGGTCCTAACAGGAGGGAGAGTGAAG~GA

AGACTTGCCG (11+13)
4) GCTGAGATGACTCATCCTCCCAGGCACAGCAAGAAGAAACAGGCAGCATGCCCATTG
CTTGTTTATTCCTTGTTTTAATTTTCATTATTACGTTTCTCAGGAAATGCACGCCTT
AGCTAACAGTTACTGGCAAAAAAATAAATAAATAAATAAGGTGTTTGAGTTCTTGCC
AACATTTGGGGAAGCTGAATGAGATGCCTAGAGGAGGGTTGGCCCATCCTTTGCTTA
AAGTTTTCTTTCCTTTTTTTCTTTTTTGTTTTTTTTCTGTCCTTTAGCCCATGAAGA
GCATCATGCTTTTGAAGGTGGACGTGGAAAACACTAATTGCACTCTGTAAAGAATTC
TTTGTCCTTTGCTGATTGGTTTTGGAAACGGTCTTAACAGGAGGGAGAGTGAAGAGA
AGACTTGCCG (11+13)
5) GCTGAGATGACTCATCCTCCCAGGCACAGCAAGAAGAAACAGGCAGCATGCCCATTG
CTTGTTTATTCCTTGTTTTAATTTTCATTATTACGTTTCTCAGGAAATGCACGCCTT
AGCTAACAGTTACTGGCAAAAAAATAAATAAATAAATAAGGTGTTTGAGTTCTTGCC
AACATCTGGGGAAGCTGAATGAGATGCCTAGAGGAGGGTTGGCCCATCCTTTGCTTA
AAGTTTTCTTTCCTTTTTTTCTTTTTTGTTTTTTTTCTGTCCTTTGGCCCATGAAGA
GCATCATGCTTTTGAAGGTGGACGTGGAAAACACTAATTGCACTCTGTAAAGAATTC
TTTGCCCTTTGCTGATTGATTTAGGAAACGGTTTTAACTG (9+15)
6) ACTACGGAGGGGCTAGAGCAACAAGT (35+29)
7) ACTACGGAGGGGCTAGAGCAACAAGT (35+29)
8) ACTACGGAGGGGCTAGAGCAACAAGT (35+29)
9) GCTGAGACGACTCATCCTCCCAGGCACAGCAAGAAGAAACAGGGCAGCAGGCCCATT
GCTTGTTTATTCCTTGTTTTAATTTTTATTATTACGTTTCTCAGGAAATGCACGCCT
TAGCTAACAGTTACTGGCAAAAAAATAAATAAATAAATAAGGTGTTTGAGTTCTTGC
CAACATTTGGGGAAGCTGAATGAGATGCCTAGAGGAGGGTTGGCCCATCCTTTGCTT
AAAGTTTTCTTTCCTTTTTTTCTTTTTTGTTTTTTTTCTGTCCTTTGGCCCATGAAG
AGCATCATGCTTTTGAAGGTGGACGTGGAAAACACTAATTGCACTCTGTAAAGAATT
CTTTGTCCTTTGCTGATTGGTTTTGGAAACGGTCTTAACAGGAGGGGGAGTGAAGAG
AAGACTTGCCG (11+13)
10)ACTACGGAGGGGCTAGAGCAACAAGT (35+29)
11)GCTGAGATGACTCATCCTCCCAGGCACAGCAAGAAGAAACAGGCAGCATGCCCATTG
CTTGTTTATTCCTTGTTTTAATTTTCATTATTACGTTTCTCAGGAAATGCACGCCTT
AGCTAACAGTTACTGGCAAAAAAATAAATAAATAAATAAGGTGTTTGAGTTCTTGCC
AACATTTGGGGAAGCTGAATGAGATGCCTAGAGGAGGGTTGGCCCATCCTTTGCTTA
AAGTTTTCTTTCCTTTTTTTCTTTTTTGTTTTTTTTCTGTCCTTTGGCCCATGAAGA
GCATCATGCTTTTGAAGGTGGACGTGGAAAACACTAATTGCACTCTGTAAAGAATTC
TTTGTCCTTTGCTGATTGGTTTTGGAAACGGTCTTAACAGGAGGGAGAGTGAAGAGA
AGACTTGCCG (11+13)
12)ACTACGGAGGGGCTAGAGCAACAAGT (35+29)
13)ACTACGGAGGGGCTAGAGCAACAAGT (35+29)
14)ACTACGGAGGGGCTAGAGCAACAAGT (35+29)
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15)ACTACGGAGGGGCTAGAGCAACAAGT (35+29)
16)ACTACGGAGGGGCTAGAGCAACAAGT (35+29)
17)CGGCAAGTCTTCTCTTCACTCTCCCTCCTGTTAAGACCGTTTCCAAAACCAATCAGC
AAAGGACAAAGAATTCTTTACAGAGTGCAATTAGTGTTTTCCACGTCCACCTTCAAA
AGCATGATGCTCTTCATGGGCCAAAGGACAGAAAAAAAACAAAAAAGAAAAAAAGGA
AAGAAAACTTTAAGCAAAGGATGGGCCAACCCTCCTCTAGGCATCTCATTCAGCTTC
CCCAAATGTTGGCAAGAACTCAAACACCTTATTTATTTATTTATTTTTTTGCCAGTA
ACTGTTAGCTAAGGCGTGCATTTCCTGAGAAACGTAATAATGAAAATTAAAACAAGG
AATAAACAAGCAATGGGCATGCTGCCTGTCTCTTCTTGCTGTGCCTGGGAGGATGAG
TCATCTCAGC (5+15)
18)ACTACGGAGGGGCTAGAGCAACAAGT (35+29)
19)ACTACGGAGGGGCTAGAGCAACAAGT (35+29)
20)ACTACGGAGGGGCTAGAGCAACAAGT (35+29)
21)ACTACGGAGGGGCTAGAGCAACAAGT (35+29)
22)ACTACGGAGGGGCTAGAGCAACAAGT (35+29)
23) GCTGAGATGACTCATCCTCCCAGGTACAGCAAGAAGAAATAGGCAGCATGCCCATTG
CTTGTTTATTCCTTGTTTTAATTTTCATTATTACGTTTCTCAGGAAATGCACGCCTT
AGCTAACAGTTACTGGCAAAAAAATAAATAAATAAATAAGGTGTTTGAGTTCTTGCC
AACATTTGGGGAAGCTGAATGAGATGCCTAGAGGAGGGTTGGCCCATCCTTTGCTTA
AAGTTTTCTTTCCTTTTTTTCTTTTTTGTTTTTTTTCTGTCCTTTGGCCCATGAAGA
GCATCATGCTTTTGAAGGTGGACGTGGAAAACACTAATTGCACTCTGTAAAGAATTC
TTTGTCCTTTGCTGATTGGTTTTGGAAACGGTCTTAACAGGAGGGAGAGTGAAGAGA
AGACTTGCCG(ll+13)
24)CGGCAAGTCTTCTCTTCACTCTCCCTCCTGTTAAGATCGTTTCCAAAACCAATCAGC
AAAGGACAAAGAATTCTTTACAGAGTGCAATTAGTGTTTTCCACGTCCACCTTCAAA
AGCATGATGCTCTTCATGGGCCAAAGGACAGAAAAAAAACAAAAAAGAAAAAAAGGA
AAGAAAACTTTAAGCAAAGGATGGGCCAACCCTCCTCTAGGCATCTCATTCAGCTTC
CCCAAATGTTGGCAAGAACTCAAACACCTTATTTATTTATTTATTTTTTTGCCAGTA
ACTGTTAGCTAAGGCGTGCATTTCCTGAGAAACGTAATAATGAAAATTAAAACAAGG
AATAAACAAGCAATGGGCGTGCTGCCTGTTTCTTCTTGCTGTGCCTGGGAGGATGAG
TCATCTCAGC (11+13)
25) ACTACGGAGGGGCTAGAGCAACAGGT
26)CGGCAAGTCTTCTCTTCACTCTCCCTCCTGTTAAGACCGTTTCCAAAACCAATCAGC
AAAGGACAAAGAATTCTTTACAGAGTGCAATTAGTGTTTTCCACGTCCACCTTCAAA
AGCATGATGCTCTTCATGGGCCAAAGGACAGAAAAAAAACAAAAAAGAAAAAAAGGA
AAGAAAACTTTAAGCAAAGGATGGGCCAACCCTCCTCTAGGCATCCCATTCAGCTTC
CCCAAATGTTGGCAAGAACTCAAACACCTTATTTATTTATTTATTTTTTTGCCAGTA
ACTGTTAGCTAAGGCGCGCATTTCCTGAGAAACGTAATAATGAAAATTAAAACAAGG
AATAAACAAGCAATGGGCATGCTGCCTGTTTCTTCTTGCTGTGCCCGGGAGGATGAG
TCATCTCAGC (5+15)
27)ACTACGGAGGGGCTAGAGCAACAAGT (35+29)
28) GCTGAGATGACTCATCCTCCCAGGCACAGCAAGAAGAAACAGGCAGCATGCCCATTG
CTTGTTTATTCCTTGTTTTAATTTTCATTATTACGTTTCTCAGGAAATGCACGCCTT
AGCTAACAGTTACTGGCAAAAAAATAAATAAATAAATAAGGTGTTTGAGTTCTTGCC
AACATTTGGGGAAGCTGAATGAGATGCCTAGAGGAGGGTTGGCCCATCCTTTGCTTA
AAGTTTTCTTTCCTTTTTTTCTTTTTTGTTTTTTTTCTGTCCTTTAGCCCATGAAGA
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GCATCATGCTTTTGAAGGTGGACGTGGAAAACACTAATTGCACTCTGTAAAGAATTC
TTTGTCCTTTGCTGATTGGTTTTGGAAACGGTCTTAACAGGAGGGAGAGTGAAGAGA
AGACTTGCCG(11+13)
29) GCTGAGATGACTCATCCTCCCAGGCACAGCAAGAAGAAACAGGCAGCATGCCCATTG
CTTGTTTATTCCTTGTTTTAATTTTCATTATTACGTTTCTCAGGAAATGCACGCCTT
AGCTAACAGTTACTGGCAAAAAATAAATAAATAAATAAGGTGTTTGAGTTCTTGCCA
ACATTTGGGGAAGCTGAATGAGATGCCTAGAGGAGGGTTGGCCCATCCTTTGCTTAA
AGTTTTCTTTCCTTTTTTCCTTTTTGTTTTTTTTCTGTCCTTTGGCCCATGAAGAGC
ATCATGCTTTTGAAGGTGGACGTGGAAAACACTAATTGCACTCTGTAAAGAATTCTT
TGTCCTTTGCTGATTGGTTTTGGAAACGGTCTTAACAGGAGGGAGAGTGAAGAGAAG
ACTTGCCG(11+13)
30)ACTACGGAGGGGCTAGAGCAACAAGT (35+29)
31)ACTACGGAGGGGCTAGAGCAACAAGT (35+29)
32) GCTGAGATGACTCATCCTCCCAGGCACAGCAAGAAGAAACAGGCAGCATGCCCATTG
CTTGTTTATTCCTTGTTTTAATTTTCATTATTACGTTTCTCAGGAAATGCACGCCTT
AGCTAACAGTTACTGGCAAAAAAATAAATAAATAAATAAGGTGTTTGAGTTCTTGCC
AACATTTGGGGAAGCTGAATGAGATGCCTAGAGGAGGGTTGGCCCATCCTTTGCTTA
AAGTTTTCTTTCCTTTTTTTCTTTTTTGTTTTTTTTCTGTCCTTTAGCCCATGAAGA
GCATCATGCTTTTGAAGGTGGACGTGGAAAACACTAATTGCACTCTGTAAAGAATTC
TTTGTCCTTTGCTGATTGGTTTTGGAAACGGTCTTAACAGGAGGGAGAGTGAAGAGA
AGACTTGCCG (11+13)
33)TGTGGTTTTGTTGTTGGGGGGGGGTG
34)ACTACGGAGGGGCTAGAGCAACAAGT (35+29)
35)ACTACGGAGGGGCTAGAGCAACAAGT (35+29)
36)ACTACGGAGGGGCTAGAGCAACAAGT (35+29)
37)ACTACGGAGGGGCTAGAGCAACAAGT (35+29)
38)ACTACGGAGGGGCTAGAGCAACAAGT (35+29)
39)ACTACGGAGGGGCTAGAGCAACAAGT (35+29)
40)ACTACGGAGGGGCTAGAGCAACAAGT (35+29)
41)TGGGGGGTGTTGTTGTTGTGGTTGTT
42)ACTACGGAGGGGCTAGAGCAACAAGT (35+29)
43)ACTACGGAGGGGCTAGAGCAACAAGT (35+29)
44)CGGCAAGTCTTCTCTTCACTCTCCCTCCTGTTAAGACCGTTTCCAAAACCAATCAGC
AAAGGACAAAGAATTCTTTACAGAGTGCAATTAGTGTTTTCCACGTCCACCTTCAAA
AGCATGATGCTCTTCATGGGCTAAAGGACAGAAAAAAAACAAAAAAGAAAAAAAGGA
AAGAAAACTTTAAGCAAAGGATGGGCCAACCCTCCTCTAGGCATCTCATACAGCTTC
CCCAAATGTTGGCAAGAACTCAAACACCTTATTTATTTATTTATTTTTTTGCCAGTA
ACTGTTAGCTAAGGCGTGCATTTCCTGAGAAACGTAATAATGAAAATTAAAACAAGG
AATAAACAAGCAATGGGCATGCTGCCTGTTTCTTCTTGCTGTGCCTGGGAGGATGAG
TCATCTCAGC
(5+15)
45)ACTACGGAGGGGCTAGAGCAACAAGT (35+29)
46) GCTGAGATGACTCATCCTCCCAGGTACAGCAAGAAGAAATAGGCAGCATGCCCATTG
CTTGTTTATTCCTTGTTTTAATTTTCATTATTACGTTTCTCAGGAAATGCACGCCTT
AGCTAACAGTTACTGGCAAAAAAATAAATAAATAAATAAGGTGTTTGAGTTCTTGCC
AACATTTGGGGAAGCTGAATGAGATGCCTAGAGGAGGGTTGGCCCATCCTTTGCTTA
AAGTTTTCTTTCCTTTTTTTCTTTTTTGTTTTTTTTCTGTCCTTTGGCCCATGAAGA
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GCATCATGCTTTTGAAGGTGGACGTGGAAAACACTAATTGCACTCTGTAAAGAATTC
TTTGTCCTTTGCTGATTGGTTTTGGAAACGGTCTTAACAGGAGGGAGAGTGAAGAGA
AGACTTGCCG (11+13)
47)CGGCAAGTCTTCTCTTCACTCTCCCTCCTGTTAAGACCGTTTCCAAAACCAATCAGC
AAAGGACAAAGAATTCTTTACAGAGTGCAATTAGTGTTTTCCACGTCCACCTTCAAA
AGCATGATGCTCTTCATGGGCTAAAGGACAGAAAAAAACAAAAAAGAAAAAAAGGAA
AGAAAACTTTAAGCAAAGGATGGGCCAACCCTCCTCTAGGCATCTCATTCAGCTTCC
CCAAATGTTGGCAAGAACTCAAACACCTTATTTATTTATCTATTTTTTTGCCAGTAA
CTGTTAGCTAAGGCGTGCATTTCCTGAGAAACGTAATAATGAAAATTATTACAAGGA
ATAAACAAGCAATGGGCATGCTGCCTGTTTCTTCTTGCTGTGCCTGGGAGGATGAGT
CATCTCAGC (5+15)
48)TGGTTTTGTGTGGGGGGTTGGGTTTG
49)ACTACGGAGGGGCTAGAGCAACAAGT (35+29)
50)ACTACGGAGGGGCTAGAGCAACAAGT (35+29)
51)ACTACGGAGGGGCTAGAGCAACAAGT (35+29)
52)ACTACGGAGGGGCTAGAGCAACAAGT (35+29)
53) * GCTGAGATGACTCATCCTCCCAGGCACAGCAAGAAGAAACAGGCAGCATGCCCATT
GCTTGTTTATTCCTTGTTTTAATTTTCATTATTACGTTTCTCAGGAAATGCACGCCT
TAGCTAACAGTTACTGGCAAAAAAATAAATAAATAAATAAGGTGTTTGAGTTCTTGC
CAACATTTGGGGAAGCTGAATGAGATGCCTAGAGGAGGGTTGGCCCATCCTTTGCTT
AAAGTTTTCTTTCCTTTTTTTCTTTTTTGTTTTATTTCTGTCCTTTAGCCCATGAAG
AGCATCATGCTTTTGAAGGTGGACGTGGAAAACACTAATTGCACTCTGTAAAGAATT
CTTTGTCCTTTGCTGATTGGTTTTGGAAACGGTCTTAACAGGAGGGAGAGTGAAGAG
AAGACTTGCCG (11+13)
54)ACTACGGAGGGGCTAGAGCAACAAGT (35+29)
55)ACTACGGAGGGGCTAGAGCAACAAGT (35+29)
56) ACTACGGAGGGGCTAGAGCAACAAGT
57) ACTACGGAGGGGCTAGAGCAACAAGT
58) GCTGAGACGACTCATCCTCCCAGGCACAGCAAGAAGAAACAGGGCAGCAGGCCCATT
GCTTGTTTATTCCTTGTTTTAATTTTTATTATTACGTTTCTCAGGAAATGCACGCCT
TAGCTAACAGTTACTGGCAAAAAAATAAATAAATAAATAAGGTGTTTGAGTTCTTGC
CAACATTTGGGGAAGCTGAATGAGATGCCTAGAGGAGGGTTGGCCCATCCTTTGCTT
AAAGTTTTCTTTCCTTTTTTTCTTTTTTGTTTTTTTTCTGTCCTTTGGCCCATGAAG
AGCATCATGCTTTTGAAGGTGGACGTGGAAAACACTAATTGCACTCTGTAAAGAATT
CTTTGTCCTTTGCTGATTGGTTTTGGAAACGGTCTTAACAGGAGGGGGAGTGAAGAG
AAGACTTGCCG
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PC3, GT60mer
Round 1
1) GGGTTGTTTGGTGTGTTTTTATTGGG
2) GTGGTTGGGGGGGGTGGGGTTTGTTG
3) TTGTGGGTTTGGGTTGGGGGTTTTGG
4) GGTGTGTGTTGGGTTGGGGTGGTGTT
5) TTTGGGGGGGTTGGGGTTTTTTGGGG
6) GGGGTGTTTGGGGTTTGTTGGTGTGG
7) GTTTTTTTTTGGGGTGGTGGGGGGGG
8) GTGTTTTTTGGGGGTGGTGGGGGGGG
9) GTTGTGGGTGTGGTGTTTGTTTGGGT
10)GGGTTGTTGGTTTGTGTTGGGGGTGG
11)*GGGGTGTTTGGGGCTCGTTGGTGTGG
·12) GTTTTTGGTTTGGTGGGGTGTGTTGT
Round 2
1) TGGTGGTGTGTGTGTGTTGGGGGGTG
2) GGGTTTTGTGTGGGGGGGGGGGGTGG
3) GGGTGGGTTTGGGTGTTTGTGTGGGG
4) GGGTTGTGTTGGGGTGGTGTGGGGTT
5) GGGTTGGTTGGTGTGGGAGGTTGTGG
6) TGGTTTTGTGGTTGGTGGTGTGTTGG
7) GTGTGGTTGGGGGGGTGGGTGTGTGT
8) GGGTTTTGGGGGTGGGGTGGTGTTGG
9) TGGTTGGGGGTGGTGGGTGTGGGTTG
10)GGGTGGTGTTTTGGTTGGTGGGTTGT
II)TGGTTTTGGTGTGGTTTGTGGTGTTG
12)TGGGTTTGTGTGGGGGTTGTGTGTTG
13)GGTTGGGGTGGTTGTTGGTTTTGGGT
14)GTTGGTGTTTGGGGGTTTGGGGTGTG
Round 3
1) GGTGTGTGTGGGGTGGTGTTGGGTGT
2) CAAAAACAGCTTACTTCAGGGACATTTTGGAGCACTGAAATGAACTTATTTGAAAAT
TGCAAGAACCACATGAAAATACGGTGACATTTAATGATAAAGTTTATGGATTCGAAG
CAAAAACGTCACCTTTAGAAAAGCGAAATCAGAAGCCGCTCACCAGTGGTGTTTAGA
GGGGGTTATCATTTGAATCCTACAGAAGAATCATTAAGGTTCTGGGAGGAACATCTG
CGGATGTGAGGAAAAAGTCATCGTTATTTTGAAATATTTGATATAAAAAGTTCAATT
AGATTCAAAATCCATTTGCATTATCACAAAAAATTCTAACATTATATTTGTCAACGA
AAGAAAAAGACGGTTGTTAGATTAGAAGAATGAGTTCAATTCAGAGCAACTGGATTA
TTCGAATTCTGGTTTATGGAGAGAAAGGAGGTTTTACCAGGCTGAAACGCAGCCACC
ATACTCTCCAGCCATTTGTTCTCAGCTCTTGCTAGAGTTTCTTATCCTCAATCTGGG
AAGATTAACCCAGAAATTACCCCAGGCCATTTCACGTAT (1+7)
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3) GCTGAGATGACTCATCCTCCCAGGCACAGCAAGAAGAAACAGGCAGCATGCCCATTG
CTTGTTTATTCCTTGTTTTAATTTTCATTATTACGTTTCTCAGGAAATGCACGCCTT
AGCTAACAGTTACTGGCAAAAAAATAAATAAATAAATAAGGTGTTTGAGTTCTTGCC
AACATTTGGGGAAGCTGAATGAGATGCCTAGAGGAGGGTTGGCCCATCCTTTGCTTA
AAGTTTTCTTTCCTTTTTTTCTTTTTTGTTTTTTTTCTGTCCTTTAGCCCATGAAGA
GCATCATGCTTTTGAAGGTGGACGTGGAAAACACTAATTGCACTCTGTAAAGAATTC
TTTGTCCTTTGCTGATTGGTTTTGGAAACGGTCTTAACAGGAGGGAGAGTGAAGAGA
AGACTTGCCG (1+28)
4) GGGGTTGGTGTGGTGGTTTAGTGTTG
5) GGTTGGGGGGGGGTTGTTGTGGGGGG
6) GGTGGGTGTTGTTGTTTGTGGTGTTG*

Round 4
1) GGGGTGTGGGGTTTGGGGGGGTGTTT
2) GTTGGGGGGGGTTTGTGGGGTTGTTT (2)
3) CTAAAACAGCTTACTTCAGGGACATTTTGGGCACTGAAATGAACTTATTTGAAAATT
GCAAGAACCACATGAAAATACCGTGACATTTAATGATAAAGTTTATGGATTCCAACC
AGAAACATCCCCTTTTCAAAACCGAAATCAGAAGCCGCTCACCACTGGTGTTTAGAG
GGGGTTATCATTTGAATCCTACACAACAATCATTATCGTTCTGGGAGGAACATCTGC
GGATGTGGGGAAGAAGTCATCGTTATTTTGAAATATTTGATATAAAAAGTTCAATTA
GATTCAAAATCCAGTTGCATTATCACAAAAAATTCTAACATTAAATTTGTCCCCGAA
ACAAAAAGACGGTTGCTAGATTATAAGAATGAGTTCAATTCACAGCAACTGGATTAT
TCGAATTCTGGTTTATGGAGAGAAAGGAGGTTTTACCATTCTGAAACACACCCACCA
TACTCTCCTGCCAGTTGTTCTCATCTCTTGCGAGAGTTTCTTATCCTCAATCTGTGA
AGATTAACCCTCAAATTACCCCCCTGCCATTTCACGTAT* (5+3)
4) GGTGTTTTTGGGGTTGTGGGGTTGGG*
5) TGGGTGTGGGTGTTGTTTGTTGTGTG (2)
6) GGTTGGTTTGTTTGTGGGGGGGTTTG
7) GTTGGGGGGGGTTTGTGGGGTTGTTT (2)
8) CAAAAACAGCTTACTTCAGGGACATTTTGGAGCACTGAAATGAACTTATTTGAAAAT
TGCAAGAACCACATGAAAATACGGTGACATrTAATGATAAAGTTTATGGATTCGAAG
CAAAAACGTCACCTTTAGAAAAGCGAAATCAGAAGCCGCTCACCAGTGGTGTTTAGA
GGGGGTTATCATTTGAATCCTACAGAAGAATCATTAAGGTTCTGGGAGGAACATCTG
CGGATGTGAGGAAGAAGTCATCGTTATTTTGAAATATTTGATATAAAAAGTTCAATT
AGATTCAAAATCCATTTGCATTATCACAAAAAATTCTAACATTATATTTGTCAACGA
AAGAAAGAGACGGTTGTTAGATTAGAAGAATGAGTTCAATTCAGAGCAACTGGATTA
TTCGAATTCTGGTTTATGGAGAGAAAGGAGGTTTTACCAGGCTGAAACGCAGCCACC
ATACTCTCCAGCCATTTGTTCTCAGCTCTTGCTAGAGTTTCTTATCCTCAATCTGGG
AAGATTAACCCAGAAATTACCCCAGGCCATTTCACGTAT(5+3)
9) CAAAAACAGCTTACTTCAGGGACATTTTGGAGCACTGAAATGAACTTATTTGAAAAT
TGCAAGAACCACATGAAAATACGGTGACATTTAATGATAAAGTTTATGGATTCGAAG
CAAAAACGTCACCTTTAGAAAAGCGAAATCAGAAGCCGCTCACCAGTGGTGTTTAGA
GGGGGTTATCATTTGAATCCTACAGAAGAATCATTAAGGTTCTGGGAGGAACATCTG
CGGATGTGAGGAAGAAGTCATCGTTATTTTGAAATATTTGATATAAAAAGTTCAATT
AGATTCAAAATCCATTTGCATTATCACAAAAAATTCTAACATTATATTTGTCAACGA
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AAGAAAGAGACGGTTGTTAGATTAGAAGAATGAGTTCAATTCAGAGCAACTGGATTA
TTCGAATTCTGGTTTATGGAGAGAAAGGAGGTTTTACCAGGCTGAAACGCAGCCACC
ATACTCTCCAGCCATTTGTTCTCAGCTCTTGCTAGAGTTTCTTATCCTCAATCTGGG
AAGATTAACCCAGAAATTACCCCAGGCCATTTCACGTAT(5+3)
10)TGGGTGTGTTTGTGGTTTGGGTGGGG
11)CAAAAACAGCTTACTTCAGGGACATTTTGGAGCACTGAAATGAACTTATTTGAAAAT
TGCAAGAACCACATGAAAATACGGTGACATTTAATGATAAAGTTTATGGATTCGAAG
CAAAAACGTCACCCTTAGAAAAGCGAAATCAGAAGCCGCTCACCAGTGGTGTTTAGA
GGGGGTTATCATTTGAATCCTACAGAAGAATCATTAAGGTTCTGGGAGGAACATCTG
CGGATGTGAGGAAAAAGTCATCGTTATTTTGAAATATTTGATATAAAAAGTTCAATT
AGATTCAAAATCCATTTGCATTATCACAAGAAATTCTAACATTATATTTGTCAACGA
AAGAAAAAGACGGTTGTTAGATTAGAAGAATGAGTTCAATTCAGAGCAACTGGATTA
TTCGAATTCTGGTTTATGGAGAGAAAGGAGGTTTTACCAGGCTGAAACGCAGCCACC
ATACTCTCCAGCCATTTGTTCTCAGCTCTTGCTAGAGTTTCTTATCCTCAATCTGGG
AAGATTAACCCAGAAATTACCCCAGGCCATTTCACGTAT(5+3)
12)GAAAAACAGCTTACTTCGGGGACATTTTGGAGCACTGAAATGAACTTATTTGAAAAT
TGCAAGAACCACATGAAAATACGGTGACATTTAATGATAAAGTTTATGGATTCGAAG
CAAAAACGTCACCCTTAGAAAAGCGAAATCGAAGCCGCTCACCAGTGGTGTTTAGAG
GGGGTTATCATTTGAATCCTACAGAAGAATCATTAAGGTTCTGGGAGGAACATCTGC
GGATGTGAGGAAAAAGTCATCGTTATTTTGAAATATTTGATATAAAAAGTTCAATTA
GATTCAAAATCCATTTGCATTATCACAAGAAATTCTAACATTATATTTGTCAACGAA
AGAAAAAGACGGTTGTTAGATTAGAAGAATGAGTTCAATTCAGAGCAACTGGATTAT
TCGAATTCTGGTTTATGGAGAGAAAGGAGGTTTTACCAGGCTGAGACGCAGCCACCA
TACTCTCCAGCCATTTGTGCTCAGCTCTTGCTAGAGTTTCTTATCCTCAATCTGGGA
TGATTATCCCACATATTACCCCACGCCATGTCAAGTAT*(5+3)
13)TTGTTGTTGTGTGTGGTTTGGGGTGT
14) GCTGAGATGACTCATCCTCCCAGGCACAGCAAGAAGAAACAGGCAGCATGCCCATTG
CTTGTTTATTCCTTGTTTTAATTTTCATTATTACGTTTCTCAGGAAATGCACGCCTT
AGCTAACAGTTACTGGCAAAAAAATAAATAAATAAATAAGGTGTTTGAGTTCTTGCC
AACATTTGGGGAAGCTGAATGAGATGCCTAGAGGAGGGTTGGCCCATCCTTTGCTTA
AAGTTTTCTTTCCTTTTTTTCTTTTTTGTTTTTTTTCTGTACTTTACCCATGAAGAG
CATCATGCTTTTGAAGGTGGACGTGGAAAACACTAAATGCCTTTGTAAAGAATTTTT
GTCCTTTGCTGATTGGTTTTTGGAAACGGTCCTTAACAC (2+26)
15)GTGTTGGTGGGTTTTTTTGGTGTTTT (2)
16)GTGTTGGTGGGTTTTTTTGGTGTTTT (2)
17)TGGGTGTGGGTGTTGTTTGTTGTGTG (2)
18) GCTGAGATGACTCATCCTCCCAGGCACAGCAAGAAGAAACAGGCAGCATGCCCATTG
CTTGTTTATTCCTTGTTTTAATTTTCATTATTACGTTTCTCAGGAAATGCACGCCTT
AGCTAACAGTTACTGGCAAAAAAATAAATAAATAAATAAGGTGTTTGAGTTCTTGCC
AACATTTGGGGAAGCTGAATGAGATGCCTAGAGGAGGGTTGGCCCATCCTTTGCTTA
AAGTTTTCTTTCCTTTTTTTCTTTTTTGTTTTTTTTCTGTCCTTTAGCCCATGAAGA
GCATCATGCTTTTGAAGGTGGACGTGGAAAACACTAATTGCACTCTGTAAAGAATTC
TTTGTCCTTTGCTGATTGGTTTTGGAAACGGTCTTAACAGGAGGGAGAGTGAAGAGA
AGACTTGCCG (2+26)
19)GGGTGGTGGGGGTGTGTTGGGGGGTG
20)GTTGAGATGAGTGTTTTGGTTGTTTT*
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21)GGTGGGTGGGTGGTTTTTGTTGTTTT
22)GTTGAGATGAGTGTTTTGGTTTTTTT*
23)TTGGGGTTGGGTGTTTTTTTTGGTGG
24) GCTGAGATGACTCATCCTCCCAGGCACAGCAAGAAGAAACAGGCAGCATGCCCATTG
CTTGTTTATTCCTTGTTTTAATTTTCATTATTACGTTTCTCAGGAAATGCACGCCTT
AGCTAACAGTTACTGGCAAAAAAATAAATAAATAAATAAGGTGTTTGAGTTCTTGCC
AACATTTGGGGAAGCTGAATGAGATGCCTAGAGGAGGGTTGGCCCATCCTTTGCTTA
AAGTTTTCTTTCCTTTTTTTCTTTTTTGTTTTTTTTCTGTCCTTTAGCCCATGAAGA
GCATCATGTTTTTTATTGTGGACGTGGAAAACACTAATTGCACTCTGTAAAGAATTC
TTTGTCCTTTGCTGATTGGTTTTGGAAACGGTCTTAACAGGAGGGAGAGTGAAGAGA
AGACTTGCCA
25)GTTGGGTGTGTTGTTTTTGTGGGTTT

Round 5
I) ATACGTGAAATGGCCTGGGGTAATTTCTGGGTTAATCTTCCCAGATTGAGGATAAGA
AACTCTAGCAAGAGCTGAGAACAAATGGCTGGAGAGTATGGTGGCTGCGTTTCAGCC
TGGTAAAACCTCCTTTCTCTCCATAAACCAGAATTCGAATAATCCAGTTGCTCTGAA
TTGAACTCATTCTTCTAATCTAACAACCGTCTTTTTCTTTCGTTGACAAATATAATG
TTAGAATTTTTTGTGATAATGCAAATGGATTTTGAATCTAATTGAACTTTTTATATC
AAATATTTCAAAATAACGATGACTTTTTCCTCACATCCGCAGATGTTCCTCCCAGAA
CCTTAATGATTCTTCTGTAGGATTCAAATGATAACCCCCTCTAAACACCACTGGTGA
GCGGCTTCTGATTTCGCTTTTCTAAAGGTGACGTTTTTGCTTCGAATCCATAAACTT
TATCATTAAATGTCACCGTATTTTCATGTGGTTCTTGCAATTTTCAAATAAGTTCAT
TTCAGTGCTCCAAAATGTCCCTGAAGTAAGCTGTTTTTG (2)
2) CGGCAAGTCTTCTCTTCACTCTCCCTCCTGTTAAGACCGTTTCCAAAACCAATCAGC
AAAGGACAAAGAATTCTTTACAGAGTGCAATTACTGTTTTCCACGTCCACCTTCAAA
AGCATGATGCTCTTCATGGGCTAAAGGACAGAAAAAAAACAAAAAAGAAAAAAAGGA
AAGAAAACTTTAAGCAAAGGATGGGCCAACCCTCCTCTAGGCATCTCATTCAGCTTC
CCCAAATGTTGGCAAGAACTCAAACACCTTATTTATTTATTTATTTTTTTGCCAGTA
ACTGTTAGCTAAGGCGTGCATTTCCTGAGAAACGTAATAATGAAAATTAAAACAAGG
AATAAACAAGCAATGGGCATGCTGCCTGTTTCTTCTTGCTGTGCCTGGGAGGATGAG
TCATCTCAGC (2+19)
3) CAAAAACAGCTTACTTCAGGGACATTTTGGAGCACTGAAATGAACTTATTTGAAAAT
TGCAAGAACCACATGAAAATACGGTGACATTTAATGATAAAGTTTATGGATTCGAAG
CAAAAACGTCACCTTTAGAAAAGCGAAATCAGAAGCCGCTCACCAGTGGTGTTTAGA
GGGGGTTATCATTTGAATCCTACAGAAGAATCATTAAGGTTCTGGGAGGAACATCTG
CGGATGTGAGGAAAAAGTCATCGTTATTTTGAAATATTTGATATAAAAAGTTCAATT
AGATTCAAAATCCATTTGCATTATCACAAAAAATTCTAACATTATATTTGTCAACGA
AAGAAAAAGACGGTTGTTAGATTAGAAGAATGAGTTCAATTCAGAGCAACTGGATTA
TTCGAATTCTGGTTTATGGAGAGAAAGGAGGTTTTACCAGGCTGAAACGCAGCCACC
ATACTCTCCAGCCATTTGTTCTCAGCTCTTGCTAGAGTTTCTTATCCTCAATCTGGG
AAGATTAACCCAGAAATTACCCCAGGCCATTTCACGTAT (2+6)
4) CAAAAACAGCTTACTTCAGGGACATTTTGGAGCACTGAAATGAACTTATTTGAAAAT
TGCAAGAACCACATGAAAATACGGTGACATTTAATGATAAAGTTTATGGATTCGAAG
CAAAAACGTCACCTTTAGAAAAGCGAAATCAGAAGCCGCTCACCAGTGGTGTTTAGA
GGGGGTTATCATTTGAATCCTACAGAAGAATCATTAAGGTTCTGGGAGGAACATCTG
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CGGATGTGAGGAAAAAGTCATCGTTATTTTGAAATATTTGATATAAAAAGTTCAATT
AGATTCAAAATCCATTTGCATTATCACAAAAAATTCTAACATTATATTTGTCAACGA
AAGAAAAAGACGGTTGTTAGATTAGAAGAATGAGTTCAATTCAGAGCAACTGGATTA
TTCGAATTCTGGTTTATGGAGAGAAAGGAGGTTTTACCAGGCTGAAACGCAGCCACC
ATACTCTCCAGCCATTTGTTCTCAGCTCTTGCTAGAGTTTCTTATCCTCAATCTGGG
AAGATTAACCCAGAAATTACCCCAGGCCATTTCACGTAT (2+6)
5) CGGCAAGTCTTCTCATCACTCTCCCTCCTGTTAAAACCGTTTCCAAAACCAATCAGT
TAAGGACAAAGAATTCTTTACAAAGTGCAATTAGTGTTTTCCACGTCCACCTTCTTA
ATGATGATGCTCTTCATGGGCTAAAGGACACAAAAAAAACAAAAAACAAAAAAAGGA
AAGAAAACTTTAATCAAAGGATGGGCCAACCCTCCTCTAGGCATCTCATTCATCTTC
CCCAAATGTTGGCAAGAACTCAAACACCTTATTTATTTATTTATTTTTTTGCCACTA
ACTGTTAGCTAAGGCATGCATTTCCTGAAAAGCGTAATAATGAAAATTAAAACAAGG
AATAAACAAGCAATGGGCATGCTGCCTGTTTCTTCTTGCTGTGCCTGGGAGGATGAC
TCATCTCAGC (2+19)
6) CAAGAAACGT
7) GGTGTGTTTGGGGTGGTGGGTGTTGT
8) GCTGAGATGACTCATCCTCCCAGGCACAGCACGAAGAACCAGGCCGCAGGCCCATTG
CTTGTTTATTCCTCGTTTTAATTTTCATTATTACGTTTCTCCCGAAATGCACGCCTT
AACTAACATTTACGGTTCCAGAAATAAATAAATAAATAAGGTGTTTGACTTCTTGCC
AACATTTGGGAAACCTGAATGAGATGCCTAGAGGAGGGTTGGCCCATCCTTTGCTTA
ATTTTTCCTTCCTTTTTTTCTTTTTTGTTTTTTTTCTGTCCTTTAGCCCAGGAAGAT
GATCTTGCTTTTGAAGGTGGACGTGGAAAACACTAATTGCACTCTGTAAAGAATTCT
TTGTCCTTTGCTGATTGGTTTTGGAAATCGTCTTATCAGGAGGGACAATGAATATAA
GATCTGTCG* (1+27)
9) ATCACGGCATCATC
10)ATACGTGAAATGGCCTGGGGTAATTTCTGGGTTAATCTTCCCAGATTGAGGATAAGA
AACTCTAGCAAGAGCTGAGAACAAATGGCTGGAGAGTATGGTGGCTGCGTTTCAGCC
TGGTAAAACCTCCTTTCTCTCCATAAACCAGAATTCGAATAATCCAGTTGCTCTGAA
TTGAACTCATTCTTCTAATCTAACAACCGTCTTTTTCTTTCGTTGACAAATATAATG
TTAGAATTTTTTGTGATAATGCAAATGGATTTTGAATCTAATTGAACTTTTTATATC
AAATATTTCAAAATAACGATGACTTTTTCCTCACATCCGCACATGTACTTCCCAGAA
CCTTAATGATTCTTCTGTAGGATTCAAATGATAACCCCCTCTAAACACCACTGGTGA
GCGGCTTCTGATTTCGCTTTTCTAAAGGTGACGTTTTTGCTTCGAATCCATAGACTT
TATCATTAGATGTCAGCGTATATTCATGTGATTCTTGCAATTTTCACATAAGTTCAT
TTCTCTGCTCCCAAATGTCGCTGCACTAAGCTGTTTTTG* (2)
11)GTTGGGTGTGTTGGGTGTTTGTGTGG
12)TGGTGATGTGTGGTTGGGTGGTGTGG
13) GCTGAGATGACTCATCCTCCCAGGCACAGCAAGAAGAAACAGGCAGCAGGCCCAT TG
CTTGTTTATTCCTCGTTTTAATTTTCATTATTACGTTTCTCCCGAAATGCACGCCTT
AACTAACATTTACGGTTCCAGAAATAAATAAATAAATAAGGTGTTTGACTTCTTGCC
AACATTTGGGAAAGCTGAATGAGATGCCTAGAGGAGGGTTGGCCCATCCTTTGCTTA
ATTTTTCCTTCCTTTTTTTCTTTTTTGTTTTTTTTCTGTCCTTTAGCCCAGGAAGAT
GATCTTGCTTTTGAAGGTGGACGTGGAAAACACTAATTGCACTCTGTAAAGAATTCT
TTGTCCTTTGCTGATTGGTTTTGGAAATCGTCTTATCAGGAGGGACAATGAATATAA
GATCTGTCG*
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APPENDIXC
Microarray Analysis of Changes in Gene Expression in
DU145 Cells Treated with AS1411
(A) GENES WHOSE EXPRESSION DECREASED AFTER 2 HOURS
Fold change
-12.0
-8.9
-6.8
-5.1
-4.7
-4.5

-3.6
-2.8
-2.7
-2.7
-2.4
-2.3
-2.3

-2.2
-2.2

-2.2
-2.2

-2.1
-2.1
-2.1

-2.1
-2.1

-2.1
-2.1

-2.0
-2.0

Gene Description
calponin homology (CH) domain containing 1
acetyl-Coenzyme A carboxylase alpha
S-cell ClL/lymphoma 7C
chromosome 6 open reading frame 11
protein kinase C and casein kinase substrate in neurons 3
chromosome 14 open reading frame 34
peptidylprolyl isomerase (cyclophilin)-like 2
autoantigen
cholinergic receptor, nicotinic, epsilon polypeptide
keratin 15
hypothetical protein MGC5178
hypothetical protein 24432
transmembrane 4 superfamily member 7
hypothetical protein FLJ22341
host cell factor C1 regulator 1 (XP01 dependant)
7-dehydrocholesterol reductase
transmembrane 7 superfamily member 2
pleiomorphic adenoma gene-like 1
proline dehydrogenase (oxidase) 1
PISC domain containing hypothetical protein
inhibitor of DNA binding 2, dominant negative helix-loop-helix protein
jagged 2
hepatitis delta antigen-interacting protein A
stearoyl-CoA desaturase (delta-9-desaturase)
filamin S, beta (actin binding protein 278)
hypothetical protein FLJ21347
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(B) GENES WHOSE EXPRESSION INCREASED AFTER 2 HOURS
Fold change Gene Description
17.4
11.7
8.3
7.0
6.1
4.9
4.9
4.0
4.0
3.2
2.9
2.8
2.8
2.8
2.6
2.6
2.6
2.5
2.5
2.4
2.3
2.3
2.3
2.3
2.2
2.2
2.2
2.2
2.2
2.1
2.1
2.1
2.1
2.1
2.1
2.0
2.0

Homo sapiens clone 24540 mRNA sequence
RAB9, member RAS oncogene family, pseudogene 1
nuclear antigen Sp100
EGF-like repeats and discoidin I-like domains 3
KIM 1068 protein
Homo sapiens mRNA; cDNA DKFZp434J193 (from clone DKFZp434J193); partial
cds
thymus high mobility group box protein TOX
HIV-1 inducer of short transcripts binding protein
ADP-ribosylation factor interacting protein 1 (arfaptin 1)
likely ortholog of mouse and zebrafish forebrain embryonic zinc finger-like
I factor (complement)
TAF6-like RNA polymerase II, p300/CBP-associated factor (PCAF)-associated
factor, 65kDa
21383_at
hypothetical protein MGC11266
hypothetical protein FLJ 11142
macrophage stimulating, pseudogene 9
hypothetical protein FLJ32389
leukocyte Ig-like receptor 9
216688_at
zinc finger protein, V-linked
hypothetical protein FLJ 13646
eukaryotic translation initiation factor 4E
APG12 autophagy 12-like (S. cerevisiae)
zinc finger protein 45 (a Kruppel-associated box (KRAB) domain polypeptide)
polymerase delta interacting protein 46
F-box and WD-40 domain protein 1B
amiloride binding protein 1 (amine oxidase (copper-containing))
RNA binding motif protein 3
CD34 antigen
nescient helix loop helix 2
211074_at
211506_s_at
transient receptor potential cation channel, subfamily A, member 1
protein tyrosine phosphatase type IVA, member 2
hypothetical protein MGC3067
solute carrier family 35 (UDP-N-acetylglucosamine (UDP-GlcNAc) transporter),
memberA3
superoxide dismutase 2, mitochondrial
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(C) GENES WHOSE EXPRESSION DECREASED AFTER 18 HOURS
Fold change

Gene Description

-78.8
-62.2
-27.3
-27.1
-20.5
-15.5

T-box 1
semenogelin II
achaete-scute complex-like 2 (Drosophila)
hypothetical protein LOC 157697
tumor-associated calcium signal transducer 2
Homo sapiens similar to dJ309K20.1.1 (novel protein similar to dysferlin, isoform
1) (LOC375095), mRNA
208278_s_at
216737_at
single-minded homolog 2 (Drosophila)
217451_at
EphA5
Homo sapiens transcribed sequence with weak similarity to protein
ref:NP _060219.1 (H.sapiens) hypothetical protein FLJ20294 [Homo sapiens]
217093_at
superoxide dismutase 2, mitochondrial
insulin-like growth factor 1 (somatomedin C)
Homo sapiens transcribed sequence with moderate similarity to protein
ref:NP _060219.1 (H.sapiens) hypothetical protein FLJ20294 [Homo sapiens]
Homo sapiens transcribed sequences
histamine receptor H3
alkaline phosphatase, placental-like 2
G protein-coupled receptor 17
cardiac ankyrin repeat kinase
dachshund homolog (Drosophila)
A kinase (PRKA) anchor protein 5
ankyrin repeat domain 1 (cardiac muscle)
estrogen receptor 1
tight junction protein 3 (zona occludens 3)
transmembrane protease, serine 4
cold autoinflammatory syndrome 1
glutathione S-transferase theta 2
glutamate receptor, ionotropic, N-methyl D-aspartate 1
hypothetical protein FLJ 10786
CD1E antigen, e polypeptide
zinc finger protein 157 (HZF22)
Homo sapiens cDNA: FLJ21911 fis, clone HEP03855
hypothetical protein FLJ22688
tissue inhibitor of metalloproteinase 3 (Sorsby fundus dystrophy,
pseudoinflammatory)
major histocompatibility complex, class II, DO beta
gasdermin-like
inversin
KlAA0685
small muscle protein, X-linked
zinc finger protein 254
cadherin, EGF LAG seven-pass G-type receptor 1 (flamingo homolog,
Drosophila)
telomerase reverse transcriptase
Nef associated protein 1
glycoprotein Ib (platelet), beta polypeptide
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-15.2
-13.5
-12.4
-12.3
-12.0
-11.6
-11.6
-11.1
-11.0
-10.8
-10.1
-9.8
-9.5
-9.4
-9.4
-8.6
-8.4
-8.3
-8.1
-8.0
-7.6
-7.6
-7.5
-7.2
-7.1
-6.8
-6.6
-6.6
-6.5
-6.5
-6.4
-6.4
-6.3
-6.0
-5.9
-5.8
-5.7
-5.7
-5.5
-5.4

-5.1
-4.9
-4.9
-4.8
-4.7
-4.6
-4.5
-4.4
-4.4
-4.4
-4.1
-4.1
-3.9
-3.8
-3.7
-3.7
-3.7
-3.7
-3.6
-3.5
-3.4
-3.4
-3.4
-3.3
-3.3
-3.3
-3.2
-3.0
-3.0
-2.9
-2.8
-2.8
-2.8
-2.8
-2.8
-2.7
-2.7
-2.7
-2.7
-2.6
-2.6
-2.6
-2.6
-2.6
-2.5
-2.5
-2.5
-2.5

a disintegrin and metalloproteinase domain 28
high density lipoprotein binding protein (vigilin)
NADH:ubiquinone oxidoreductase MLRQ subunit homolog
5-hydroxytryptamine (serotonin) receptor 2C
family with sequence similarity 12, member B (epididymal)
butyrobetaine (gamma), 2-oxoglutarate dioxygenase (gamma-butyrobetaine
hydroxylase) 1
tripartite motif-containing 3
sema domain, immunoglobulin domain (Ig), short basic domain, secreted,
(semaphorin) 3F
211218_at
cathepsin S
homeo box D3
FK506 binding protein 12-rapamycin associated protein 1
217311_at
ubiquitin protein ligase E3A (human papilloma virus E6-associated protein,
Angelman syndrome)
dystrophin (muscular dystrophy, Duchenne and Becker types)
SWI/SNF related, matrix associated, actin dependent regulator of chromatin,
subfamily a, member 4
tyrosine kinase with immunoglobulin and epidermal growth factor homology
domains
aquaporin 4
forkhead box D3
homeo boxA6
adipose specific 2
T-cell leukemia, homeobox 2
caspase recruitment domain family, member 10
ribosomal protein S11
agouti signaling protein, nonagouti homolog (mouse)
arginine vasopressin receptor 2 (nephrogenic diabetes insipidus)
diacylglycerol kinase, epsilon 64kDa
eukaryotic translation initiation factor 3, subunit 5 epsilon, 47kDa
Homo sapiens transcribed sequences
granzyme A (granzyme 1, cytotoxic T-Iymphocyte-associated serine esterase 3)
erythrocyte membrane protein band 4.1 (elliptocytosis 1, RH-linked)
G protein-coupled receptor 8
potassium inwardly-rectifying channel, subfamily J, member 12
histone 1, H4f
leukocyte immunoglobulin-like receptor, subfamily A (without TM domain),
member 5
Homo sapiens transcribed sequences
chromodomain helicase DNA binding protein 3
solute carrier family 22 (organic anion/cation transporter), member 11
221018_s_at
ATPase, H+ transporting, lysosomal 9kDa, VO subunit e
fibroblast growth factor 18
LOC92346
Homo sapiens transcribed sequences
prostaglandin D2 synthase 21 kDa (brain)
KIM 1922 protein
hypothetical protein LOC339047
IMP (inosine monophosphate) dehydrogenase 2
Homo sapiens mRNA; cDNA DKFZp564P142 (from clone DKFZp564P142)
207

-2.4
-2.4
-2.3
-2.3
-2.3
-2.3

-2.2
-2.2

-2.2
-2.2

-2.2
-2.2

-2.2
-2.2
-2.1
-2.1
-2.1
-2.1
-2.1
-2.1
-2.1
-2.0
-2.0
-2.0
-2.0
-2.0
-2.0

transient receptor potential cation channel, subfamily C, member 3
zinc finger protein 165
carnitine palmitoyltransferase 1B (muscle)
tripartite motif-containing 31
221720_s_at
leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM
domains), member 1
mitogen-activated protein kinase 8 interacting protein 3
cholinergic receptor, nicotinic, epsilon polypeptide
chorionic somatomammotropin hormone-like 1
UDP glycosyltransferase 2 family, polypeptide B17
viperin
hypothetical protein FLJ 12443
calponin homology (CH) domain containing 1
growth differentiation factor 11
calcium channel, voltage-dependent, L type, alpha 1B subunit
CD84 antigen (leukocyte antigen)
cysteine knot superfamily 1, BMP antagonist 1
NAD synthetase 1
growth arrest and DNA-damage-inducible, beta
ribosomal protein L 17
hypothetical protein HSPC 109
chromosome 12 open reading frame 6
CDC28 protein kinase regulatory subunit 1B
interleukin 24
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 11 (CHL 1-like helicase homolog,
S. cerevisiae)
E4F transcription factor 1
protocadherin beta 8
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(0) GENES WHOSE EXPRESSION INCREASED AFTER 18 HOURS

Fold change
15.6
14.5
13.5
13.2
10.9
10.1
8.0
6.5
6.2
5.9
5.5
5.5

5.4
5.2
5.2
5.1
5.0
4.9
4.9

4.4
4.3
4.1
4.0
3.8
3.7
3.6
3.5

3.4
3.3

3.3
3.2
3.1
3.1
3.1
3.1
3.0
3.0
3.0
3.0
2.9
2.9
2.8
2.8
2.8
2.8
2.8
2.7

Gene Description
HUS1 checkpoint homolog (S. pombe)
hypothetical protein FLJ 10849
hypothetical protein FLJ 10970
DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked
EGF-like repeats and discoidin I-like domains 3
SWI/SNF related, matrix associated, actin dependent regulator of chromatin,
subfamily a, member 2
hypothetical protein PRO 1853
PTB domain adaptor protein CED-6
SEC10-like 1 (S. cerevisiae)
v-rei reticuloendotheliosis viral oncogene homolog (avian)
glucosamine (N-acetyl)-6-sulfatase (Sanfilippo disease 1110)
RAB3B, member RAS oncogene family
golgi SNAP receptor complex member 2
zinc finger protein 37a (KOX 21)
hypothetical protein FLJ 12994
prenylcysteine oxidase 1
ATPase, Ca++ transporting, cardiac muscle, slow twitch 2
actin filament associated protein
wingless-type MMTV integration site family, member 7B
DEAD (Asp-Glu-Ala-Asp) box polypeptide 17
zinc finger RNA binding protein
paraneoplastic antigen
PTK9 protein tyrosine kinase 9
211506_s_at
216383_at
similar to Caenorhabditis elegans protein C42C1.9
guanine nucleotide binding protein (G protein), alpha activating activity
polypeptide, olfactory type
suppression of tumorigenicity
Homo sapiens cONA FLJ31439 fis, clone NT2NE2000707.
tumor necrosis factor receptor superfamily, member 10d, decoy with truncated
death domain
ring finger protein 125
fumarate hydratase
stress-induced-phosphoprotein 1 (Hsp70/Hsp90-organizing protein)
zinc finger RNA binding protein
NGFI-A binding protein 1 (EGR1 binding protein 1)
paternally expressed 10
poly(A) polymerase alpha
steroid sulfatase (microsomal), arylsulfatase C, isozyme S
Homo sapiens, clone IMAGE:5294815, mRNA
secretory carrier membrane protein 1
endothelial and smooth muscle cell-derived neuropilin-like protein
aryl hydrocarbon receptor nuclear translocator-like 2
208844_at
met proto-oncogene (hepatocyte growth factor receptor)
SOCS box-containing WD protein SWiP-1
PCTAIRE protein kinase 2
vesicle-associated membrane protein 3 (cellubrevin)
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2.7
2.7
2.7
2.6
2.6
2.6
2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.4
2.4
2.4
2.4
2.4
2.4
2.4
2.4
2.3
2.3
2.3
2.3
2.3
2.3
2.3
2.3
2.3
2.3
2.3
2.2

2.2
2.2

2.2
2.2

2.2
2.2

2.2
2.2

2.2
2.2
2.1
2.1
2.1
2.1
2.1
2.1
2.1
2.1

BcI-2-associated transcription factor
cyclin E2
hypothetical protein H41
cell division cycle 27
solute carrier family 7, (cationic amino acid transporter, y+ system) member 11
NDRG family member 3
progesterone receptor membrane component 1
mitogen-activated protein kinase kinase kinase kinase 5
zinc finger protein 426
secretory carrier membrane protein 1
heat shock 70kDa protein 4
APG12 autophagy 12-like (S. cerevisiae)
CD164 antigen, sialomucin
AFFX-r2-Hs 18SrRNA-M_x_at
REV3-like, catalytic subunit of DNA polymerase zeta (yeast)
SWI/SNF related, matrix associated, actin dependent regulator of chromatin,
subfamily a, member 2
zinc finger protein 45 (a Kruppel-associated box (KRAB) domain polypeptide)
septin 10
Homo sapiens hypothetical LOC133993 (LOC133993), mRNA
Sec23 homolog A (S. cerevisiae)
polymerase (RNA) III (DNA directed) (32kD)
hypothetical protein KIM 1164
histone 1, H3h
Ras-GTPase activating protein SH3 domain-binding protein 2
RIO kinase 3 (yeast)
interleukin 6 signal transducer (gp130, oncostatin M receptor)
HIV-1 Rev binding protein
hypothetical protein MGC3067
calumenin
SEC24 related gene family, member D (S. cerevisiae)
core-binding factor, beta subunit
insulin-like 5
AFFX-HUMRGE/M 10098_5_at
erythrocyte membrane protein band 4.1-like 1
calumenin
butyrate-induced transcript 1
hypothetical protein MGC11061
lectin, mannose-binding, 1
NCK-associated protein 1
RecQ protein-like (DNA helicase Q1-like)
chromosome 20 open reading frame 30
secretory carrier membrane protein 1
chromosome 6 open reading frame 62
AFFX-HUMISGF3A1M97935_MA_at
calnexin
muscleblind-like (Drosophila)
SBBI26 protein
sphingosine-1-phosphate phosphatase 1
GM2 ganglioside activator protein
oculocerebrorenal syndrome of Lowe
catalase
nucleolar and spindle associated protein 1
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2.1
2.1
2.1
2.1
2.1
2.1
2.1
2.1
2.1
2.1
2.1
2.1
2.1
2.1
2.1
2.0
2.0
2.0
2.0
2.0
2.0
2.0

2.0
2.0
2.0

Homo sapiens cDNA FLJ35853 fis, clone TEST12007078, highly similar to
MEMBRANE COMPONENT, CHROMOSOME 17, SURFACE MARKER 2.
DKFZP586N0721 protein
cleavage and polyadenylation specific factor 5, 25 kDa
leukocyte-derived arginine aminopeptidase
transducin (beta)-like 1X-linked
hypothetical protein MGC14799
ROD1 regulator of differentiation 1 (S. pombe)
promethin
phosphoglycerate kinase 1
M-phase phosphoprotein, mpp8
RIO kinase 3 (yeast)
thioredoxin domain containing
UDP-Gal:betaGlcNAc beta 1 ,3-galactosyltransferase, polypeptide 3
tumor rejection antigen (gp96) 1
PTD016 protein
Homo sapiens transcribed sequence with weak similarity to protein
ref:NP _060312.1 (H.sapiens) hypothetical protein FLJ20489 [Homo sapiens]
216899_s_at
AFFX-HUMRGE/M10098_M_at
solute carrier family 35 (UDP-N-acetylglucosamine (UDP-GlcNAc) transporter),
memberA3
lamina-associated polypeptide 1B
hypothetical protein FLJ12806
Homo sapiens transcribed sequence with strong similarity to protein
ref:NP _055485.1 (H.sapiens) basic leucine-zipper protein BZAP45; KlAA0005
gene product [Homo sapiens]
adenovirus 5 E1A binding protein
solute carrier family 16 (monocarboxylic acid transporters), member 1
serum/glucocorticoid regulated kinase-like
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APPENDIXD
Abbreviations and Symbols

AML

Acute myelocytic leukemia

AS1411

Anticancer aptamer discovered by P. Bates et. al

CD

Circular dichroism

CSC

Cancer stem cells

CRPC

Castration resistant prostate cander

DNA

Deoxyribonucleic acid

ELISA

Enzyme-linked immunosorbent assay

EMSA

Electromotility shift assay

FACS

Fluorescent activated cell sorting

GRO

G-rich oligonucleotide

MTT

dye for antiproliferation assay

MRCC

Metastatic renal cell carcinoma

NCI

National Cancer Institute

NED

No evidence of disease

NMR

Nuclear magnetic resonance

PCBP

Poly-cytosine binding protein

PrCa

Prostate cancer

PrCSC

Prostate cancer stem cells
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PCR

Polymerase chain reaction

RNA

Ribonucleic acid

SELEX

Systematic Evolution of Ligands by Exponential Enrichment

SP

Side population

TIC

Tumor initiating cell

UV

Ultraviolet

VSELS

Very small embryonic-like cells
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